<SEC-DOCUMENT>0001104659-20-028589.txt : 20200303
<SEC-HEADER>0001104659-20-028589.hdr.sgml : 20200303
<ACCEPTANCE-DATETIME>20200303164134
ACCESSION NUMBER:		0001104659-20-028589
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20200303
DATE AS OF CHANGE:		20200303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-232122
		FILM NUMBER:		20683043

	BUSINESS ADDRESS:	
		STREET 1:		3200 SOUTHWEST FREEWAY
		STREET 2:		SUITE 2240
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		3200 SOUTHWEST FREEWAY
		STREET 2:		SUITE 2240
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2011417d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="text-align: right; vertical-align: top"><B>Filed Pursuant to Rule 424(b)(5)<BR>
 &nbsp;</B>&nbsp; <B>Registration No. 333-232122</B>&nbsp;</TD>
</TR>
<TR>
<TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: justify; vertical-align: top"><B>PROSPECTUS&nbsp;SUPPLEMENT</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>(To Prospectus dated June
25, 2019) </B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2011417d1_424b5img001.jpg" ALT="" STYLE="height: 51pt; width: 227.25pt"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$30,000,000 of Common Stock</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>plus 345,357 Commitment Shares</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to this prospectus
supplement and the accompanying prospectus, we are offering up to $30,000,000 aggregate amount plus 345,357 shares of our common
stock, par value $0.001 per share, or Common Stock, to Aspire Capital Fund, LLC, or Aspire Capital, under a Common Stock Purchase
Agreement entered into on February 28, 2020, or the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The shares offered include
(i) 345,357 shares of Common Stock to be issued to Aspire Capital in consideration for entering into the Common Stock Purchase
Agreement, or the Commitment Shares, and (ii) additional shares of Common Stock in an aggregate offering price of up to $30,000,000
which may be sold from time to time to Aspire Capital over the 30-month term of the Purchase Agreement, or the Purchase Shares.
The purchase price for the Purchase Shares will be based upon one of two formulas set forth in the Purchase Agreement depending
on the type of purchase notice we submit to Aspire Capital from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Common Stock is listed
on The Nasdaq Global Market under the symbol &ldquo;MRKR.&rdquo; On February 28, 2020, the last reported sale price of our Common
Stock was $2.47 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our business and an investment in
our Common Stock involve significant risks. See &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus
supplement and page 5 of the accompanying prospectus to read about factors that you should consider before making an
investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement
or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
February 28, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 90%; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">About this Prospectus Supplement </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prospectus Supplement Summary </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-2</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#b_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#b_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-6</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#b_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Special Note Regarding Forward-Looking Statements </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#b_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-8</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#b_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#b_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-9</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#b_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dilution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#b_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-10</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#b_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Aspire Transaction</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#b_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-11</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#c_01"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plan of Distribution </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#c_01"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-15</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#c_02"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Matters </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#c_02"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-16</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#c_03"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#c_03"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-16</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#c_04"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporation of Certain Information by Reference </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#c_04"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-16</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Prospectus</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 8pt; width: 90%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 8pt; width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">About this Prospectus </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">i</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Summary </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description of Capital Stock </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description of Debt Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description of Warrants</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Ownership of Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plan of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Matters </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Experts </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-bottom: 8pt; padding-left: 10pt; text-indent: -10pt"><A HREF="#h_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporation of Certain Information by Reference </FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt; text-align: right"><A HREF="#h_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0000EE">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document is in two parts. The first
part is this prospectus supplement, which describes the specific terms of the Common Stock we are offering. The second part, the
accompanying prospectus dated June 25, 2019, gives more general information about our Common Stock. You should read this prospectus
supplement and the accompanying prospectus, including the information incorporated by reference and any free writing prospectuses
we have authorized for use in connection with this offering, in their entirety before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not authorized anyone to provide
any information other than that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus
or in any free writing prospectus that we have authorized for use in connection with this offering. We take no responsibility for,
and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement
and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered
by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it
is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information contained in this prospectus supplement,
the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering, including
the documents incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of the
time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our Common Stock. It is important
for you to read and consider all information contained in this prospectus supplement, the accompanying prospectus and any free
writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference
herein and therein, in making your investment decision. You should also read and consider the information in the documents to which
we have referred you in the sections entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain
Information by Reference&rdquo; in this prospectus supplement and in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the context requires otherwise, references
to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;the company&rdquo; and &ldquo;Marker Therapeutics&rdquo; refer
to Marker Therapeutics,&nbsp;Inc., formerly known as TapImmune, Inc., and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe that these sources are reliable, we do not
guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we
are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement and the accompanying
prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject
to change based on various factors, including those discussed under the heading &ldquo;Risk Factors&rdquo; in this prospectus supplement
and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into
this prospectus supplement and the accompanying prospectus. Accordingly, you should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made
to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits
to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the section entitled &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit or incorporated by reference to the registration
statement of which this prospectus supplement and accompanying prospectus form a part were made solely for the benefit of the parties
to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should
not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were
accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as
accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus, including the information incorporated by reference into this prospectus supplement and the accompanying prospectus,
include trademarks, service marks and trade names owned by us or others. All trademarks used herein are the property of their respective
owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: center">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>This summary
highlights certain information about us, this offering and information appearing elsewhere in this prospectus supplement, in
the accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not
contain all of the information that you should consider before making an investment decision. To fully understand this
offering and its consequences to you, you should read this entire prospectus supplement and the accompanying prospectus
carefully, including the factors described under the heading &ldquo;Risk Factors&rdquo; in this prospectus supplement
beginning on page S-6 and page 5 of the accompanying prospectus, together with any free writing prospectus we have authorized
for use in connection with this offering and the financial statements and all other information incorporated by reference in
this prospectus supplement and the accompanying prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a clinical-stage
immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative
peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product
candidates from our MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific
T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those
targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing
two pipelines of product candidates as part of our MultiTAA-specific T cell program: the autologous T cells for the treatment of
lymphoma, multiple myeloma, or MM, and selected solid tumors and the allogeneic T cells for the treatment of acute myeloid leukemia,
or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically engineer the MultiTAA-specific T cell therapies,
we believe that our product candidates are easier and less expensive to manufacture, with reduced toxicities, than current engineered
chimeric antigen receptor, or CAR-T, and T cell receptor-based therapies and may provide patients with meaningful clinical benefit.
We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are pursuing post-transplant
AML as the lead indication for our first company-sponsored MultiTAA-specific T cell program. The MultiTAA-specific T cell therapy
has been well tolerated in an ongoing Phase 1/2 clinical trial conducted by our strategic partner Baylor College of Medicine, or
BCM. As reported in March 2019, eleven of the thirteen patients in the adjuvant disease setting dosed with the MultiTAA-specific
T cell therapy after receiving an allogeneic stem cell transplant survived, ranging from 6 weeks to 2.5 years post-infusion, with
nine of these remaining patients in continuing complete remission. Survival of the six patients with active disease ranged from
4 to 21 months, as compared to a historical survival rate of approximately 4.5 months for patients who receive the standard of
care post-transplant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We submitted an investigational
new drug application to the United States Food and Drug Administration, or the FDA, to initiate a Phase 2 clinical trial of MultiTAA-specific
T cell therapy, which we refer to as MT-401, in post-allogeneic hematopoietic stem cell transplant patients with AML in both the
adjuvant and active disease setting, which may become pivotal pending the results of the interim analysis. The dose administered
in this multicenter trial is the current maximum tolerated dose from the ongoing Phase 1/2 trial. In the adjuvant setting, patients
will be randomized to either MultiTAA-specific T cell therapy at approximately 90 days post-transplant versus standard of care
observation, while the active disease patients will receive MT-401 following relapse post-transplant as part of a single-arm group.
In February 2020, we announced that the FDA has permitted us to initiate our Phase 2 clinical trial beginning with a safety lead-in
portion of the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We recently reported
interim data for an ongoing Phase 1/2 clinical trial of the MultiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma
being conducted by BCM. In this trial, we have observed a clinical benefit correlated with the post-infusion detection of tumor-reactive
T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of the trial. These
T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To
date, we have not observed any drug-related systemic or neurotoxicity in this trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are also
evaluating the MultiTAA-specific T cell therapies in a Phase 2 clinical trial for the treatment of breast cancer and in Phase
1 clinical trials for the treatment of ALL, lymphoma, MM and sarcoma, all of which are being conducted by BCM. As of December
2019, the MultiTAA-specific T cell therapies have been generally well tolerated by all of the patients enrolled in clinical
trials in hematological and solid tumor indications with no incidents of cytokine release syndrome or neurotoxicity, which
are frequently associated with CD19 CAR-T therapies. Based on our observations in clinical trials in AML, pancreatic cancer,
lymphoma, ALL and MM, we believe that the MultiTAA-specific T cell therapies have the potential to mediate a meaningful
anti-tumor effect, as well as significant&nbsp;in vivo&nbsp;expansion of T cells. We may initiate additional Phase 2 clinical
trials investigating other indications in 2020 in addition to our planned Phase 2 trial in post-transplant AML patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We believe that our
therapies present promising innovations in immuno-oncology. We developed the MultiTAA-specific T cell therapy in collaboration
with the Cell and Gene Therapy Center at BCM, which was founded by Dr. Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in
immuno-oncology. BCM remains an important strategic partner and conducts early-stage clinical trials of the MultiTAA-specific T
cell therapies pursuant to a sponsored research agreement. Our cell therapy founders include Drs. Brenner, Ann Leen, Ph.D., Juan
Vera, M.D., Helen Heslop, M.D., DSc (Hon) and Cliona Rooney, Ph.D., who all have significant experience in this field. Drs. Brenner,
Heslop, Rooney, James P. Allison and Padmanee Sharma serve on our Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our clinical-stage pipeline, including clinical
trials being conducted by BCM and other partners, is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="tm2011417d1_424b5img002.jpg" ALT="" STYLE="height: 164.25pt; width: 392.25pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated under the laws of the
State of Nevada in 1991 under the name &ldquo;TapImmune, Inc.&rdquo; and reincorporated in Delaware in October 2018 under the name
 &ldquo;Marker Therapeutics, Inc.&rdquo; On October 17, 2018, we completed a business combination with a Delaware corporation that
was then known as &ldquo;Marker Therapeutics,&nbsp;Inc.,&rdquo; or Private&nbsp;Marker, in accordance with the terms of the Agreement
and Plan of Merger and Reorganization dated as of May 15, 2018, or the Merger Agreement, by and among us, Private Marker and Timberwolf
Merger Sub,&nbsp;Inc., a Delaware corporation and a wholly owned subsidiary of TapImmune, or Merger Sub, pursuant to which, among
other matters, Merger Sub merged with and into Private Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune
and the surviving corporation of the merger.&nbsp; In connection with the merger, we changed our name from &ldquo;TapImmune, Inc.&rdquo;
to &ldquo;Marker Therapeutics,&nbsp;Inc.&rdquo; and Private Marker changed its name to &ldquo;Marker Cell Therapy, Inc.&rdquo;
and became our wholly owned subsidiary. Our principal executive offices are located at 3200 Southwest Freeway, Suite 2240, Houston,
Texas 77027, and our telephone number is (713) 400-6400. Our website is located at&nbsp;<I>http://www.markertherapeutics.com</I>.
We do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should
not consider it as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">We are a &ldquo;smaller reporting company&rdquo;
(and may continue to qualify as such even after we no longer qualify as an emerging growth company) and accordingly may provide
less public disclosure than larger public companies, including the inclusion of only two years of audited financial statements
and only two years of related selected financial data and management&rsquo;s discussion and analysis of financial condition and
results of operations disclosure. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding-right: 4pt; padding-left: 4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares of Common Stock offered</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Up to $30,000,000 of shares of Common Stock plus 345,357 &nbsp;Commitment Shares</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock to be outstanding after the offering </FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Up to 58,522,320 shares, assuming the issuance of 345,357 Commitment Shares and sales of 12,448,132 shares of Common Stock at an assumed price of $2.41 per share, which was the closing price of our Common Stock on The Nasdaq Global Market on February 27, 2020. The actual number of shares issued will vary depending on the sales prices under this offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Manner of offering</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Issuance of 345,357 Commitment Shares to&nbsp;Aspire Capital&nbsp;in consideration for entering into the Purchase Agreement and additional Purchase Shares to&nbsp;Aspire Capital&nbsp;from time to time, subject to certain minimum stock price requirements, and daily and other caps, for an aggregate offering price of up to $30,000,000. See &ldquo;The Aspire Transaction&rdquo; and &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Use of proceeds </FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We currently expect to use the net proceeds from this offering for general corporate purposes, including working capital. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk factors </FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See &ldquo;Risk Factors&rdquo; beginning on page S-6 for a discussion of factors you should consider before buying shares of our Common Stock. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nasdaq Global Market Symbol </FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;MRKR&rdquo; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-indent: 35.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-indent: 35.25pt">The number of shares of Common Stock
to be outstanding after the offering is based on 45,728,831 shares outstanding as of December 31, 2019 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-indent: 35.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4,983,314 shares of our common stock issuable upon the exercise of
stock options outstanding as of December 31, 2019, at a weighted-average exercise price of $7.79 per share; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">22,664,000 shares of our common stock issuable upon the exercise of
warrants outstanding as of December 31, 2019, at a weighted-average exercise price of $4.71 per share; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2,493,036 shares of our common stock reserved for future issuance
under our 2014 Omnibus Stock Ownership Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-indent: 35.25pt">Unless otherwise noted, the information
in this prospectus supplement reflects and assumes no exercise of outstanding options or warrants subsequent to December 31, 2019.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_001"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><I>Investing in our
Common Stock involves a high degree of risk. This prospectus supplement does not describe all of those risks. You should
consider the risk factors described in this prospectus under the caption &ldquo;Risks Related to This Offering and Our Common
Stock&rdquo; below, as well as the those described under the caption &ldquo;Risk Factors&rdquo; in the documents incorporated
by reference herein, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q as
filed with the Securities and Exchange Commission, or SEC, together with the other information contained or incorporated by
reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have
authorized for use in connection with this offering, before making an investment decision. <FONT STYLE="background-color: white">Each
of the risk factors could adversely affect our business, results of operations, financial condition and cash flows, as well
as adversely affect the value of an investment in our Common Stock, and the occurrence of any of these risks might cause you
to lose all or part of your investment. </FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Risks Related to This
Offering and Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales of our Common Stock to Aspire Capital may
cause substantial dilution to our existing stockholders and the sale of the shares of our Common Stock acquired by Aspire Capital
could cause the price of our Common Stock to decline.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This prospectus supplement
relates to the 345,357 Commitment Shares and the Purchase Shares that we may issue and sell to Aspire Capital from time to time
pursuant to the Purchase Agreement. It is anticipated that the Purchase Shares offered to Aspire Capital in this offering will
be sold over a period of up to <FONT STYLE="font-family: Times New Roman, Times, Serif">30 </FONT>months from the date of this
prospectus supplement. The number of shares ultimately offered for sale to Aspire Capital under this prospectus supplement is dependent
upon the number of shares we elect to sell to Aspire Capital under the Purchase Agreement. Depending upon market liquidity at the
time, sales of shares of our Common Stock under the Purchase Agreement may cause the trading price of our Common Stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Aspire Capital may ultimately
purchase all, some or none of the shares of Common Stock that, together with the Commitment Shares, is the subject of this prospectus
supplement. After Aspire Capital has acquired shares under the Purchase Agreement, it may sell all, some or none of those shares.
Sales to Aspire Capital by us pursuant to the Purchase Agreement under this prospectus supplement may result in substantial dilution
to the interests of other holders of our Common Stock. The sale of a substantial number of shares of our Common Stock to Aspire
Capital in this offering, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities
in the future at a time and at a price that we might otherwise wish to effect sales. However, we have the right to control the
timing and amount of any sales of our shares to Aspire Capital and the Purchase Agreement may be terminated by us at any time at
our discretion without any cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have a right to sell
up to <FONT STYLE="font-family: Times New Roman, Times, Serif">100,000</FONT> Purchase Shares per day under our Purchase Agreement
with Aspire Capital, which total may be increased by mutual agreement up to an additional 2,000,000 Purchase Shares per day. The
extent to which we rely on Aspire Capital as a source of funding will depend on a number of factors, including the prevailing market
price of our Common Stock and the extent to which we are able to secure working capital from other sources. The aggregate number
of shares that we can sell to Aspire Capital under the Purchase Agreement may in no case exceed 9,232,814 shares of our Common
Stock (which is equal to approximately 19.99% of the Common Stock outstanding on the date of the Purchase Agreement), including
the Commitment Shares, or the Exchange Cap, unless stockholder approval is obtained to issue more, in which case the Exchange Cap
will not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future sales of a significant number of shares of
our Common Stock in the public markets, or the perception that such sales could occur, could depress the market price of shares
of our Common Stock.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Sales of a
substantial number of our shares of Common Stock in the public markets, or the perception that such sales could occur, could
depress the market price of our shares of Common Stock and impair our ability to raise capital through the sale of additional
equity securities. A substantial number of shares of Common Stock are being offered by this prospectus supplement, and we
cannot predict if and when Aspire Capital may sell such shares in the public markets. We cannot predict the number of these
shares that might be sold nor the effect that future sales of our shares of Common Stock would have on the market price of
our shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will have broad discretion in the use of proceeds from
this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not yield a return.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will have broad discretion over the use
of proceeds from this offering. You may not agree with our decisions, and our use of the proceeds may not yield any return on your
investment in us. Our failure to apply the net proceeds of this offering effectively could result in financial losses that could
materially impair our ability to pursue our growth strategy, cause the price of our Common Stock to decline, delay development
of our product candidates, or require us to raise additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Terms of subsequent financings may adversely impact our
stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To finance our future business plans and
working capital needs, we will have to raise funds through the issuance of equity or debt securities in addition to sales in the
Aspire transaction. Depending on the type and the terms of any financing we pursue, stockholders&rsquo; rights and the value of
their investment in our Common Stock could be reduced. A financing could involve one or more types of securities including common
stock, convertible debt or warrants to acquire common stock. These securities could be issued at or below the then prevailing market
price for our Common Stock. In addition, if we issue secured debt securities, the holders of the debt would have a claim to our
assets that would be senior to the rights of stockholders until the debt is paid. Interest on these debt securities would increase
costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders of our
Common Stock, the market price of our Common Stock could be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We do not currently intend to
pay dividends on our Common Stock, and any return to investors is expected to come, if at all, only from potential increases in
the price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">At the present
time, we intend to use available funds to finance our operations. Accordingly, while payment of dividends rests within the discretion
of our board of directors, we have no intention of paying any such dividends in the foreseeable future. Any return to investors
is expected to come, if at all, only from potential increases in the price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_002"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement, the accompanying
prospectus and the documents we have filed with the SEC that are incorporated by reference contain &ldquo;forward-looking statements&rdquo;
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of
the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known
and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking
statements may include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">the timing, progress and results of clinical trials of MultiTAA-specific
T cell therapies and our other product candidates, including statements regarding the timing of initiation and completion of preclinical
studies or clinical trials or related preparatory work, the period during which the results of the trials will become available
and our research and development programs;</TD>
</TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">the timing of any submission of filings for regulatory approval
of product candidates and our ability to obtain and maintain regulatory approvals for product candidates for any indication;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our ability to successfully commercialize product candidates;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our expectations regarding the potential benefits, activity,
effectiveness and safety of product candidates;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our expectations regarding the size of the patient populations,
market acceptance and opportunity for and clinical utility of product candidates, if approved for commercial use;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our manufacturing capabilities and strategy, including the
ease, scalability and commercial viability of our manufacturing methods and processes;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our expectations regarding the scope of any approved indications
for product candidates;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">the potential benefits of and our ability to maintain our relationships
and collaborations with the Baylor College of Medicine and other potential collaboration or strategic relationships;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our ability to use the MultiTAA-specific T cell platform to
develop future product candidates;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our estimates of our expenses, ongoing losses, future revenue,
capital requirements and our needs for or ability to obtain additional funding;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our ability to identify, recruit and retain key personnel;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our ability to protect and enforce our intellectual property
position for our product candidates, and the scope of such protection;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our financial performance;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">our competitive position and the development of and projections
relating to our competitors or our industry; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">the impact of laws and regulations.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In some cases, you can identify
forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo;
 &ldquo;would,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
 &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; and similar expressions
intended to identify forward-looking statements. These statements reflect our current views with respect to future events and
are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &ldquo;Risk
Factors,&rdquo; in any free writing prospectuses we may authorize for use in connection with this offering, and in our most
recent Annual Report on Form 10-K and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto
reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus supplement and
accompanying prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions
only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation
to update or revise any forward-looking statements to reflect new information or future events or developments. You should
read this prospectus supplement and the accompanying prospectus, together with the documents we have filed with the SEC that
are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering
completely and with the understanding that our actual future results may be materially different from what we expect. We
qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_003"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will retain broad discretion over the
use of the net proceeds from this offering. We currently expect to use the net proceeds from this offering for working capital
and general corporate purposes. <FONT STYLE="background-color: white">Pending the application of the net proceeds, we expect to
invest the proceeds in investment-grade, interest-bearing instruments or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="b_004"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our net tangible
book value as of December 31, 2019 was $44.1&nbsp;million, or $0.96 per share of Common Stock. Net tangible book value per share
represents the amount of our total tangible assets less total liabilities, divided by the 45,728,831 shares of our common stock
outstanding on December&nbsp;31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">After giving effect
to the issuance of the 345,357 Commitment Shares and the sale of additional shares of our Common Stock in the aggregate amount
of $30,000,000 at an assumed offering price of $2.41 per share, the last reported sale price of our Common Stock on The Nasdaq
Global Market on February 27, 2020, and after deducting estimated offering expenses payable by us, our net tangible book value
as of December 31, 2019, would have been $74.1 million, or $1.27 per share of Common Stock. This represents an immediate increase
in the net tangible book value of $0.31 per share to our existing stockholders and an immediate and substantial dilution in net
tangible book value of $1.14 per share to Aspire Capital. The following table illustrates this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; font-size: 10pt; text-align: left">Assumed offering price per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 10%">2.41</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Net tangible book value per share as of December 31, 2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.96</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; padding-bottom: 1pt; font-size: 10pt; text-align: left">Increase per share attributable to Aspire Capital</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">As adjusted&nbsp;net tangible book value per share after this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">1.27</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">Net dilution per share to Aspire Capital</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.14</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The above discussion
and table are based on 45,728,831 shares of our Common Stock outstanding as of December 31, 2019 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4,983,314 shares of our common stock issuable upon the exercise of
stock options outstanding as of December 31, 2019, at a weighted-average exercise price of $7.79 per share; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">22,664,000 shares of our common stock issuable upon the exercise of
warrants outstanding as of December 31, 2019, at a weighted-average exercise price of $4.71 per share; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2,493,036 shares of our common stock reserved for future issuance
under our 2014 Omnibus Stock Ownership Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in; background-color: white">To the extent that
outstanding options have been or may be exercised or other shares issued, Aspire Capital may experience further dilution. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient
funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_005"></A><B>THE ASPIRE TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On&nbsp;February 28, 2020, we entered into
the Purchase Agreement with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set
forth therein, Aspire Capital is committed to purchase up to an aggregate of $30,000,000 Purchase Shares from time to time over
the 30-month term of the Purchase Agreement. As consideration for entering into the Purchase Agreement, we agreed to issue 345,357
Commitment Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are filing this prospectus supplement
with regard to the offering of our Common Stock consisting of (i) the Commitment Shares and (ii) the Purchase Shares that we may
sell to Aspire Capital pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purchase of Shares under the Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 28, 2020, the conditions necessary
for purchases under the Purchase Agreement to commence were&nbsp;satisfied. On any business day over the 30-month term of the Purchase
Agreement, we have the right, in our sole discretion, to present Aspire Capital with a purchase notice, or a Purchase Notice, directing
Aspire Capital to purchase up to 100,000 Purchase Shares per business day, provided that Aspire Capital will not be required to
buy Purchase Shares pursuant to a Purchase Notice that was received by Aspire Capital on any business day on which the last closing
trade price of our Common Stock on The Nasdaq Global Market (or alternative national exchange in accordance with the Purchase Agreement)
is below $0.25. We and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an
additional 2,000,000 Purchase Shares per business day. The purchase price per Purchase Share pursuant to such Purchase Notice,
or the Purchase Price, is the lower of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(i)</TD>
    <TD>the
lowest sale price for our Common Stock on the date of sale; or</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>the average of the three lowest closing sale prices for our Common Stock during the 10 consecutive business days ending on
the business day immediately preceding the purchase date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The applicable Purchase Price will be determined
prior to delivery of any Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, on any date on which we submit
a Purchase Notice to Aspire Capital for 100,000 Purchase Shares, we also have the right, in our sole discretion, to present Aspire
Capital with a volume-weighted average price purchase notice, or a VWAP Purchase Notice, directing Aspire Capital to purchase an
amount of our Common Stock equal to up to 30% of the aggregate shares of our Common Stock traded on the next business day, or the
VWAP Purchase Date, subject to a maximum number of shares determined by us, or the VWAP Purchase Share Volume Maximum. The purchase
price per Purchase Share pursuant to such VWAP Purchase Notice, or the VWAP Purchase Price, shall be the lesser of the closing
sale on the VWAP Purchase Date or 97% of the volume weighted average price for our Common Stock traded on (i) the VWAP Purchase
Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or (ii) the portion
of such business day until such time as the aggregate shares to be purchased will equal the VWAP Purchase Share Volume Maximum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of Purchase Shares covered
by and timing of each Purchase Notice are determined by us, at our sole discretion. The aggregate number of shares that we
can sell to Aspire Capital under the Purchase Agreement may in no case exceed the Exchange Cap of 9,232,814 shares of our
Common Stock (which is equal to approximately 19.9% of our Common Stock outstanding on the date of the Purchase Agreement),
including the Commitment Shares, unless (i) stockholder approval is obtained to issue more, in which case the Exchange Cap
will not apply, or (ii) stockholder approval has not been obtained and at any time the Exchange Cap is reached and at all
times thereafter the average price paid for all shares issued under the Purchase Agreement (including the Commitment Shares)
is equal to or greater than a price equal to $2.41, which is the closing sale price immediately preceding the execution of
the Purchase Agreement; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more
than 19.99% of our Common Stock. Aspire Capital has no right to require any sales by us, but is obligated to make purchases
from us as we direct in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or
business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated
damages in the Purchase Agreement. We did not pay any additional amounts to reimburse or otherwise compensate Aspire Capital
in connection with the transaction. The Purchase Agreement may be terminated by us at any time, at our discretion, without
any penalty or cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Events of Default</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aspire Capital may terminate the Purchase
Agreement upon the occurrence of any of the following events of default:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the effectiveness of any registration statement that is required to
be maintained effective pursuant to the terms of the registration rights agreement between us and Aspire Capital lapses for any
reason (including, without limitation, the issuance of a stop order) or is unavailable for sale of shares of our Common Stock in
accordance with the terms of the registration rights agreement, and such lapse or unavailability continues for a period of 10 consecutive
business days or for more than an aggregate of 30 business days in any 365-day period, which is not in connection with a post-effective
amendment to any such registration statement or the filing of a new registration statement; provided, however, that in connection
with any post-effective amendment to such registration statement or filing of a new registration statement that is required to
be declared effective by the SEC, such lapse or unavailability may continue for a period of no more than 30 consecutive business
days, which such period shall be extended for an additional 30 business days if we receive a comment letter from the SEC in connection
therewith;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the suspension from trading or failure of our Common Stock to be listed
on our principal market for a period of three consecutive business days;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the delisting of our Common Stock from our principal market, provided
our Common Stock is not immediately thereafter trading on the New York Stock Exchange, the NYSE American, the Nasdaq Global Select
Market, the Nasdaq Global Market, or the Nasdaq Capital Market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our transfer agent&rsquo;s failure to issue to Aspire Capital shares
of our Common Stock which Aspire Capital is entitled to receive under the Purchase Agreement within five business days after an
applicable purchase date;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any breach by us of the representations or warranties or covenants
contained in the Purchase Agreement or any related agreements which could have a material adverse effect, subject to a cure period
of five business days;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if we become insolvent; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if the Exchange Cap is reached unless and until stockholder approval
has been obtained.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">So long as an Event of Default has occurred
and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and
is continuing, or so long as the closing price of our common stock is below the Floor Price, we may not require and Aspire Capital
has no obligation to purchase any shares of our common stock under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Purchase Agreement will be automatically
terminated in the event of any participation in insolvency or bankruptcy proceedings by or against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Termination Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may terminate the Purchase Agreement
at any time, in our discretion, without any cost or penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Short-Selling or Hedging by Aspire Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aspire Capital has agreed that neither it
nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of our Common
Stock during any time prior to the termination of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effect of Performance of the Purchase Agreement on Our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Purchase Agreement does not limit the
ability of Aspire Capital to sell any or all of the shares it currently owns or receives in this offering. It is anticipated that
shares sold to Aspire Capital in this offering will be sold to Aspire Capital over a period of up to 30 months from the date of
the Purchase Agreement. The subsequent resale by Aspire Capital of our Common Stock may cause the market price of our Common Stock
to decline or to be highly volatile. Aspire Capital may ultimately purchase all, some or none of the shares of Common Stock that,
together with the Commitment Shares, is the subject of this prospectus supplement. Aspire Capital may resell all, some or none
of the Commitment Shares and any Purchase Shares it acquires. Therefore, sales to Aspire Capital by us pursuant to the Purchase
Agreement and this prospectus supplement also may result in substantial dilution to the interests of other holders of our Common
Stock. However, we have the right to control the timing and amount of any sales of our shares to Aspire Capital and the Purchase
Agreement may be terminated by us at any time at our discretion without any cost to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amount of Potential Proceeds to be Received under the Purchase
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Purchase Agreement, we may sell
Purchase Shares having an aggregate offering price of up to $30,000,000 to Aspire Capital from time to time. The number of shares
ultimately offered for sale to Aspire Capital in this offering is dependent upon the number of shares we elect to sell to Aspire
Capital under the Purchase Agreement. In addition, Aspire Capital will not be required to buy Purchase Shares pursuant to a Purchase
Notice that was received by Aspire Capital on any business day on which the last closing trade price of our Common Stock on The
Nasdaq Global Market (or alternative national exchange in accordance with the Purchase Agreement) is below $0.25. The following
table sets forth the amount of proceeds we would receive from Aspire Capital from the sale of shares at varying purchase prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assumed Average <BR>
Purchase Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Proceeds from the <BR>
Sale of Shares to <BR>
Aspire Capital Under <BR>
the Purchase <BR>
Agreement <BR>
Registered in this <BR>
Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares to be <BR>
Issued in this Offering at <BR>
the Assumed Average <BR>
Purchase Price (1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percentage of <BR>
Outstanding Shares <BR>
After Giving Effect to the<BR>
 Purchased Shares Issued <BR>
to Aspire Capital (2)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: right">0.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">2,221,864</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">8,887,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right">16.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,887,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,887,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,331,186</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,887,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,418,771</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,887,457</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.52</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Split-Segment; Name: a3 -->
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Includes the total number of Purchase
                                Shares (but not Commitment Shares) which we would have sold under the Purchase Agreement at the
                                corresponding assumed purchase price set forth in the adjacent column, up to an aggregate purchase
                                price of $30,000,000, subject to the Exchange Cap.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The denominator is based on 45,728,831
                                shares outstanding as of December 31, 2019, plus the (i) 345,357 Commitment Shares issued to Aspire
                                Capital and (ii) number of shares set forth in the adjacent column which we would have sold to
                                Aspire Capital. The numerator is based on the number of shares which we may issue to Aspire Capital
                                under the Purchase Agreement (that are the subject of this offering) at the corresponding assumed
                                purchase price set forth in the adjacent column.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Information with Respect to
Aspire Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Aspire Capital
Partners LLC, or the Aspire Partners, is the Managing Member of Aspire Capital Fund LLC, or Aspire Fund. SGM Holdings Corp, or
SGM, is the Managing Member of Aspire Partners. Mr. Steven G. Martin is the president and sole shareholder of SGM, as well as
a principal of Aspire Partners. Mr. Erik J. Brown is the president and sole shareholder of Red Cedar Capital Corp, or Red Cedar,
which is a principal of Aspire Partners. Mr. Christos Komissopoulos is president and sole shareholder of Chrisko Investors Inc.,
or Chrisko, which is a principal of Aspire Partners. Mr. William F. Blank, III is president and sole shareholder of WML Ventures
Corp., or WML Ventures, which is a principal of Aspire Partners. Each of Aspire Partners, SGM, Red Cedar, Chrisko, WML Ventures,
Mr. Martin, Mr. Brown, Mr. Komissopoulos and Mr. Blank may be deemed to be a beneficial owner of our Common Stock held by Aspire
Fund. Each of Aspire Partners, SGM, Red Cedar, Chrisko, WML Ventures, Mr. Martin, Mr. Brown, Mr. Komissopoulos and Mr. Blank disclaims
beneficial ownership of our Common Stock held by Aspire Fund.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="c_01"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Aspire
Capital is an &ldquo;underwriter&rdquo; within the meaning of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Neither
we nor Aspire Capital can presently estimate the amount of compensation that any agent will receive. We know of no existing arrangements
between Aspire Capital, any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the
shares offered by this prospectus supplement. At the time a particular offer of shares is made, a prospectus supplement, if required,
will be distributed that will set forth the names of any agents, underwriters, or dealers and any other required information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
will pay all of the expenses incident to the registration, offering, and sale of the shares to Aspire Capital. We have agreed
to indemnify Aspire Capital and certain other persons against certain liabilities in connection with the offering of shares of
Common Stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute
amounts required to be paid in respect of such liabilities. Aspire Capital has agreed to indemnify us against liabilities under
the Securities Act that may arise from certain written information furnished to us by Aspire Capital specifically for use in this
prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling
persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the
Securities Act and is therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Aspire
Capital and its affiliates have agreed not to engage in any direct or indirect short selling or hedging of our Common Stock during
the term of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
have advised Aspire Capital that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions,
Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates
in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which
is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases
made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing
may affect the marketability of the shares offered hereby this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
may suspend the sale of shares to Aspire Capital pursuant to this prospectus for certain periods of time for certain reasons,
including if the prospectus is required to be supplemented or amended to include additional material information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
offering will terminate on the date that all shares offered by this prospectus have been sold to Aspire Capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="c_02"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Cooley LLP,
New York, New York, will pass upon the validity of the issuance of the securities being sold in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="c_03"></A><B>EXPERTS<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 10pt">Marcum
LLP, independent registered public accounting firm, has audited our consolidated financial statements as of and for the years
ended December 31, 2018 and 2017 and the effectiveness of our internal control over financial reporting as of December 31, 2018
as set forth in its reports, which are included in our 2018 Annual Report on Form 10-K and incorporated by reference in this prospectus
supplement and elsewhere in the registration statement. Our 2018 and 2017 financial statements are incorporated by reference in
reliance on Marcum LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="c_04"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The SEC allows
us to &ldquo;incorporate by reference&rdquo; information into this prospectus supplement, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated
by reference in this prospectus supplement is 001-37939. The documents incorporated by reference into this prospectus supplement
contain important information that you should read about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The following
documents are incorporated by reference into this document:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_10k.htm" STYLE="-sec-extract: exhibit">our
                                         Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the
                                         SEC on March 15, 2019; </A></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         information specifically incorporated by reference into our <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_10k.htm" STYLE="-sec-extract: exhibit">Annual
                                         Report on Form 10-K for the year ended December 31, 2018</A> &nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419016692/tv517415_def14a.htm" STYLE="-sec-extract: exhibit">from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 28, 2019;</A></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and
                                         September 30, 2019, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419025316/tv520511_10q.htm" STYLE="-sec-extract: exhibit">May
                                         10, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419038714/tv526456_10q.htm" STYLE="-sec-extract: exhibit">August
                                         9, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000110465919062594/tm1919554-1_10q.htm" STYLE="-sec-extract: exhibit">November
                                         12, 2019</A>, respectively;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                                                   Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419000592/tv510398_8k.htm" STYLE="-sec-extract: exhibit">January
                                                                   4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419001768/tv511068_8k.htm" STYLE="-sec-extract: exhibit">January
                                                                   15, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419008704/tv513933_8k.htm" STYLE="-sec-extract: exhibit">February
                                                                   15, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419009717/tv514584_8k.htm" STYLE="-sec-extract: exhibit">February 25, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419016685/tv517465_8k.htm" STYLE="-sec-extract: exhibit">March 28, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419019976/tv519053_8k.htm" STYLE="-sec-extract: exhibit">April 17, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419025325/tv521321_8k.htm" STYLE="-sec-extract: exhibit">May 10, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419035118/tv525447_8k.htm" STYLE="-sec-extract: exhibit">July 19, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419035266/tv525553_8k.htm" STYLE="-sec-extract: exhibit">July 22, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419037903/tv526825_8k.htm" STYLE="-sec-extract: exhibit">August 6, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000110465920015276/tm207425d1_8k.htm" STYLE="-sec-extract: exhibit">February 11, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000110465920027550/tm2011380d1_8k.htm" STYLE="-sec-extract: exhibit">March 2, 2020</A>, to the extent the information in such reports is filed and not furnished; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420416131272/v452031_8a12b.htm" STYLE="-sec-extract: exhibit">the description of our common stock set forth in the registration statement on Form 8-A registering our common stock under Section 12 of the Exchange Act, which was filed with the SEC on November 3, 2016, including any amendments or reports filed for purposes of updating such description</A>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We also incorporate
by reference into this prospectus supplement all documents (other than current reports furnished under Item 2.02 or Item 7.01
of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which
this prospectus supplement forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this
prospectus supplement but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We will provide
to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request,
a copy of any or all of the documents that are incorporated by reference into this prospectus supplement and the accompanying
prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such
documents. You should direct any requests for documents to Marker Therapeutics, Inc., Attn: Corporate Secretary, 3200 Southwest
Freeway, Suite 2240, Houston, Texas 77027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Any statement
contained in this prospectus supplement or contained in a document incorporated or deemed to be incorporated by reference into
this prospectus supplement will be deemed to be modified or superseded to the extent that a statement contained in this prospectus
supplement or any subsequently filed supplement to the accompanying prospectus, or document deemed to be incorporated by reference
into this prospectus supplement, modifies or supersedes such statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #FF4040">The information in this prospectus is not complete
and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it
is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #FF4040"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #FF4040"><B>SUBJECT TO COMPLETION, DATED
JUNE 14, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tm2011417d1base_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">From time to time, we may offer and sell up
to $200,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities
as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including
any applicable anti-dilution provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This prospectus provides a general description
of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these
offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained
in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B>This prospectus may not be used to consummate
a sale of any securities unless accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will sell these securities directly to investors,
through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional
information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus
and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect
to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts
or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net
proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our common stock is traded on the Nasdaq Capital
Market under the symbol &ldquo;MRKR.&rdquo; On June 13, 2019, the last reported sale price of our common stock was $6.10 per share.
The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital
Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>Investing in our securities involves
a high degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo;
contained in the applicable prospectus supplement and any related free writing prospectus we have authorized for use in connection
with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus
as described on page 5  of this prospectus.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I></I></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL
OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 92%"><A HREF="#h_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><A HREF="#h_001">i</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_002">1</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_003">5</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_004">5</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_005">6</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_006">7</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_007">10</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_008">16</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_009">18</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_010">21</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_011">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_012">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_013">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#h_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h_014">24</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This prospectus is a part of a registration
statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &ldquo;shelf&rdquo; registration
process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in
one or more offerings up to a total aggregate offering price of $200,000,000. This prospectus provides you with a general description
of the securities we may offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Each time we sell securities under this prospectus,
we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings.
The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus.
You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the
information incorporated herein by reference as described under the heading &ldquo;Incorporation of Certain Information by Reference,&rdquo;
before investing in any of the securities offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE
A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Neither we, nor any agent, underwriter or
dealer has authorized any person to give any information or to make any representation other than those contained or incorporated
by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on
behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free
writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing
prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom
it is unlawful to make such offer or solicitation in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">You should not assume that the information
contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date
subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct
on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus
supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This prospectus and the information incorporated
herein by reference contain summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits
to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_002"></A>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This summary highlights selected information
from this prospectus and does not contain all of the information that you need to consider in making your investment decision.
You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus,
including the risks of investing in our securities discussed under the heading &ldquo;Risk Factors&rdquo; contained in the applicable
prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus,
including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is
a part, before making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Unless the context indicates otherwise, as
used in this prospectus, unless the context otherwise requires, references to &quot;we,&quot; &quot;us,&quot; &quot;our,&quot;
 &quot;the company&quot; and &quot;Marker Therapeutics&quot; refer to Marker Therapeutics,&nbsp;Inc., formerly known as TapImmune,
Inc., and its subsidiaries. We own various U.S. federal trademark applications and unregistered trademarks, including our company
name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and trade names in this prospectus are referred to without the symbols &reg; and &trade;, but such
references should not be construed as any indication that their respective owners will not assert, to the fullest extent under
applicable law, their rights thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We are a clinical-stage immuno-oncology company
specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines
for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our
MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize
tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells
are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing two MultiTAA T
cell pipelines: our autologous T cells for the treatment of lymphoma, multiple myeloma and selected solid tumors and our allogeneic
T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically
engineer our MultiTAA therapies, we believe that our product candidates are easier and less expensive to manufacture, with reduced
toxicities, than current engineered CAR-T and T cell receptor-based therapies, and may provide patients with meaningful clinical
benefit. We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors,
as well as PolyStart, a proprietary nucleic acid-based antigen expression technology designed to improve the ability of the immune
system to recognize and destroy diseased cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We are pursuing post-transplant AML as the
lead indication for our MultiTAA program. Our MultiTAA therapy was well tolerated in our recent Phase 1 clinical trial, with no
drug-related serious adverse events. Eleven of the thirteen patients in the adjuvant disease setting dosed with our MultiTAA therapy
after receiving an allogeneic stem cell transplant survived, ranging from 6 weeks to 2.5 years post-infusion as of March 2019,
with nine of these patients in continuing complete remission. As of March 2019, survival of the six patients with active disease
ranged from 4 to 21 months, as compared to a historical survival rate of 4 months for patients who receive the standard of care
post-transplant. We intend to submit an investigational new drug application to the United States Food and Drug Administration
in the third quarter of 2019 to initiate a Phase 2 clinical trial in post-allogeneic hematopoietic stem cell transplant patients
with AML in both the adjuvant and active disease setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We are also evaluating our MultiTAA therapy
in a Phase 2 clinical trial for the treatment of breast cancer and in Phase 1 clinical trials for the treatment of ALL, lymphoma,
multiple myeloma, pancreatic cancer and sarcoma. As of March 2019, our MultiTAA therapy has been well tolerated in all clinical
trials in hematological and solid tumor indications with no drug-related serious adverse events, including cytokine release syndrome
or neurotoxicity. In our clinical trials in lymphoma, ALL and multiple myeloma, we observed that our MultiTAA therapies have shown
the potential to mediate a meaningful anti-tumor effect, as well as significant <I>in vivo</I> expansion of T cells. We may initiate
additional Phase 2 clinical trials in other indications in 2019 in addition to our planned Phase 2 trial in post-transplant AML
patients. We plan to report additional interim data from an ongoing Phase 1/2 clinical trial in pancreatic cancer in the third
quarter of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In addition to our MultiTAA therapies, we are
developing peptide-based immunotherapeutic vaccines that are designed to precisely target breast and ovarian cancer cells, in contrast
to standard therapies for the treatment of cancer that target both cancer cells and normal cells. We are currently evaluating TPIV100/110
for the treatment of breast cancers that overexpress human epidermal growth factor receptor 2 in a Phase 1b clinical trial and
TPIV200 for the treatment of breast and ovarian cancers that overexpress folate receptor alpha in multiple Phase 2 clinical trials,
including in ovarian cancer, for which we expect to report interim data in the fourth quarter of 2019, and triple negative breast
cancer, for which we recently reported that 26 of the 27 patients evaluated for immunogenicity showed significant immune response
to treatment as of March 2019. We believe that our peptide vaccines and our PolyStart technology, which is currently in preclinical
development, can be used as both standalone therapies and as complementary therapies that enhance the efficacy of other immunotherapy
approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We believe that our therapies present promising
innovations in immuno-oncology. We developed our MultiTAA therapy in collaboration with the Cell and Gene Therapy Center at Baylor
College of Medicine, which was founded by Dr. Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in immuno-oncology. Baylor
College of Medicine remains an important strategic partner and conducts early-stage clinical trials of our MultiTAA therapies pursuant
to a sponsored research agreement. Our cell therapy founders include Drs. Brenner, Ann Leen, Ph.D., Juan Vera, M.D., Helen Heslop,
M.D., DSc (Hon) and Cliona Rooney, Ph.D., who all have significant experience in this field. Drs. Brenner, Heslop, Rooney, James
P. Allison and Padmanee Sharma serve on our Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our clinical-stage pipeline, including clinical
trials being conducted by Baylor College of Medicine, is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tm2011417d1base_img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>MAPP: autologous</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>LAPP: allogeneic</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">We were incorporated under the laws of the
State of Nevada in 1991 under the name &ldquo;TapImmune, Inc.&rdquo; and reincorporated in Delaware in October 2018 under the name
 &ldquo;Marker Therapeutics, Inc.&rdquo; On October 17, 2018, we completed a business combination with a Delaware corporation that
was then known as &ldquo;Marker Therapeutics,&nbsp;Inc.,&rdquo; or Private&nbsp;Marker, in accordance with the terms of the Agreement
and Plan of Merger and Reorganization dated as of May 15, 2018, or the Merger Agreement, by and among us, Private Marker and Timberwolf
Merger Sub,&nbsp;Inc., a Delaware corporation and a wholly owned subsidiary of TapImmune, or Merger Sub, pursuant to which, among
other matters, Merger Sub merged with and into Private Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune
and the surviving corporation of the merger.&nbsp; In connection with the merger, we changed our name from &ldquo;TapImmune, Inc.&rdquo;
to &ldquo;Marker Therapeutics,&nbsp;Inc.&rdquo; and Private Marker changed its name to &ldquo;Marker Cell Therapy, Inc.&rdquo;
and became our wholly owned subsidiary. Our principal executive offices are located at 3200 Southwest Freeway, Suite 2240, Houston,
Texas 77027, and our telephone number is (713) 400-6400. Our website is located at <I>http://www.markertherapeutics.com</I>. We
do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not
consider it as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may offer shares of our common stock and
preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in
combination, up to a total aggregate offering price of $200,000,000 from time to time in one or more offerings under this prospectus,
together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined
by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities
we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement
that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">designation or classification;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">aggregate principal amount or aggregate offering price;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maturity;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">original issue discount, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">rates and times of payment of interest or dividends, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">redemption, conversion, exchange or sinking fund terms, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">conversion or exchange prices or rates, if any, and, if applicable,
any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property
receivable upon conversion or exchange;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ranking;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictive covenants, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">voting or other rights, if any; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">important U.S. federal income tax considerations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The applicable prospectus supplement and any
related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained
in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus
will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration
statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B>This prospectus may not be used to consummate
a sale of securities unless it is accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may sell the securities directly to investors
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable
prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the names of those underwriters or agents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">applicable fees, discounts and commissions to be paid to them;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">details regarding over-allotment options, if any; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the estimated net proceeds to us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>Common Stock</I></B>. We may issue shares
of our common stock from time to time. Holders of our common stock are entitled to one vote for each share held on all matters
submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall
be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are
entitled to receive ratably any dividends as may be declared by our board of directors, subject to any preferential dividend rights
of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to receive ratably our net assets available for distribution to stockholders
after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders
of common stock have no preemptive, subscription, redemption or conversion rights. There are no redemption or sinking fund provisions
applicable to the common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 13.2pt"><B><I>Preferred Stock</I></B>. We may issue
shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors
has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock, par value $0.001
per share. You should refer to our certificate of incorporation and our bylaws, both of which are included as exhibits to the registration
statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; background-color: white">Our board of directors
may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series
and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend
rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of preferred
stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares
of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of
our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares
of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control
by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of
directors, without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely
affect the holders of shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; background-color: white">If we offer a specific
series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement
for such offering and will file&nbsp;a copy of the certificate of designation establishing the terms of the preferred stock with
the SEC. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be
provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that
contains the terms of the applicable series of preferred stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>Debt Securities</I></B>. We may issue
debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible
debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities
will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt,
to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or
other securities. Conversion may be mandatory or at the holder&rsquo;s option and would be at prescribed conversion rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Any debt securities issued under this prospectus
will be issued under one or more documents called indentures, which are contracts between us and a national banking association
or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We
urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided
to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the
debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part,
and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed
as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports
that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><B><I>Warrants</I></B><I>.</I> We may issue
warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants
independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate
from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to
read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related
to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain
the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants
that may be offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental
warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus
is a part or will be incorporated by reference from reports that we file with the SEC before the issuance of such warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Any warrants issued under this prospectus will
be evidenced by warrant certificates. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant
agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the
particular series of warrants being offered.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Investing in our securities involves a high
degree of risk. You should carefully review the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo;
contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2018, as updated by any subsequently filed periodic reports and other
documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being
registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors described in the
documents referenced above could adversely affect our business, operating results and financial condition, as well as adversely
affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part
of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly
impair our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">This prospectus and the documents incorporated
by reference herein contain forward-looking statements. These are based on our management&rsquo;s current beliefs, expectations
and assumptions about future events, conditions and results and on information currently available to us. Discussions containing
these forward-looking statements may be found, among other places, in the sections entitled &ldquo;Business,&rdquo; &ldquo;Risk
Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; contained
in the documents incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Any statements in this prospectus, or incorporated
herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts
and are forward-looking statements. Within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, these forward-looking statements include statements regarding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing, progress and results of clinical trials of our MultiTAA
therapies and other product candidates, including statements regarding the timing of initiation and completion of preclinical studies
or clinical trials or related preparatory work, the period during which the results of the trials will become available and our
research and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing of any submission of filings for regulatory approval of
our product candidates and our ability to obtain and maintain regulatory approvals for our product candidates for any indication;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations regarding the potential benefits, activity, effectiveness
and safety of our product candidates;&nbsp;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations regarding the size of the patient populations, market
acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our manufacturing capabilities and strategy, including the, ease,
scalability and commercial viability of our manufacturing methods and processes;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations regarding the scope of any approved indications for
our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to successfully commercialize our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the potential benefits of and our ability to maintain our relationships
and collaborations with the Baylor College of Medicine and other potential collaboration or strategic relationships;&nbsp;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to use our MultiTAA platform to develop future product
candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates of our expenses, ongoing losses, future revenue, capital
requirements and our needs for or ability to obtain additional funding;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to identify, recruit and retain key personnel;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to protect and enforce our intellectual property position
for our product candidates, and the scope of such protection;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our financial performance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our competitive position and the development of and projections relating
to our competitors or our industry; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of laws and regulations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;In some cases, you can identify forward-looking
statements by the words &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;can,&rdquo; &ldquo;will,&rdquo; &ldquo;to be,&rdquo; &ldquo;could,&rdquo;
 &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;objective,&rdquo;
 &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;likely,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or the negative of these terms, or other comparable terminology
intended to identify statements about the future, although not all forward-looking statements contain these words. These statements
involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">You should refer to the &ldquo;Risk Factors&rdquo;
section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in
the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause
our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties
and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus
will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking
statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve
our objectives and plans in any specified time frame, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Except as required by law, we assume no obligation
to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments
occurring after the date of this prospectus, even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will retain broad discretion over the use
of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement
or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently
intend to use the net proceeds from the sale of the securities offered hereby for working capital, capital expenditures and general
corporate purposes.&nbsp; We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that
we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions
as of the date of this prospectus.&nbsp; We will set forth in the applicable prospectus supplement or free writing prospectus our
intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing
prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_006"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><I>The following description of our capital
stock and provisions of our certificate of incorporation and bylaws are summaries. You should also refer to the certificate of
incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt">Our certificate of incorporation authorizes
us to issue up to 150,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share. Our board of directors may establish the rights and preferences of the preferred stock from time to time.
As of March 31, 2019, we had outstanding 45,484,483 shares of common stock and no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. As a
result, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of
the directors standing for election, if they should so choose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Holders of common stock are entitled to receive
ratably any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of
preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to receive ratably our net assets available for distribution to stockholders
after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Holders of common stock have no preemptive,
subscription, redemption or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock.
The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of
the holders of shares of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Pursuant to our certificate of incorporation,
our board of directors has the authority, without further action by our stockholders, from time to time, to designate and issue
up to 5,000,000 shares of preferred stock in one or more series. Our board of directors may determine the rights, preferences and
limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of
any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of
dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in
the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our
common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage
a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal
of incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval, we may issue shares
of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our board of directors will fix the designations,
voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the
preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of
designation relating to that series.&nbsp; We will file as an exhibit to the registration statement of which this prospectus is
a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that
describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This
description will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the title and stated value;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the number of shares we are offering;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the liquidation preference per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the purchase price per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the dividend rate per share, dividend period and payment dates and
method of calculation for dividends;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether dividends will be cumulative or non-cumulative and, if cumulative,
the date from which dividends will accumulate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our right, if any, to defer payment of dividends and the maximum length
of any such deferral period;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the procedures for any auction and remarketing, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the provisions for a sinking fund, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the provisions for redemption or repurchase, if applicable, and any
restrictions on our ability to exercise those redemption and repurchase rights;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any listing of the preferred stock on any securities exchange or market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the preferred stock will be convertible into our common stock
or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion
price, or how it will be calculated, and under what circumstances it may be adjusted;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the preferred stock will be exchangeable into debt securities,
and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may
be adjusted;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">voting rights, if any, of the preferred stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">preemption rights, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on transfer, sale or other assignment, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether interests in the preferred stock will be represented by depositary
shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a discussion of any material or special U.S. federal income tax considerations
applicable to the preferred stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the relative ranking and preferences of the preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our affairs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any limitations on issuances of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any other specific terms, rights, preferences, privileges, qualifications
or restrictions of the preferred stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The General Corporation Law of the State of
Delaware, or DGCL, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately
as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the
par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change
the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may
be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The issuance of preferred stock could adversely
affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments
and payments upon liquidation. The issuance could have the effect of decreasing the market price of the common stock. The issuance
of preferred stock also could have the effect of delaying, deterring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-Takeover Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-indent: -10pt; background-color: white"><I>Section&nbsp;203
of the Delaware General Corporation Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We are subject to Section&nbsp;203 of the DGCL,
which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of
three years after the date that such stockholder became an interested stockholder, with the following exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>before such date, the board of directors of the corporation approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes
of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares
owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange
offer; or&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on or after such date, the business combination is approved by the board of directors and authorized at an annual or special
meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock that is not owned by the interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In general, Section&nbsp;203 defines a &quot;business
combination&quot; to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any merger or consolidation involving the corporation and the interested stockholder;&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of
the corporation to the interested stockholder;&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
or series of the corporation beneficially owned by the interested stockholder; or&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
by or through the corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In general, Section&nbsp;203 defines an &quot;interested
stockholder&quot; as an entity or person who, together with the person's affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting
stock of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Certificate of Incorporation and Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Because our stockholders do not have cumulative
voting rights, stockholders holding a plurality of the shares of our common stock outstanding will be able to elect all of our
directors. Our bylaws also provide that directors may be removed by the stockholders upon the vote of a majority of the shares
entitled to vote an election of directors, and if a director was elected by a voting group of stockholders, only stockholders from
that voting group may vote to remove such director, and such vacancy may be filled only by the stockholders of that voting group.
Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and
newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only
be filled by a majority vote of the directors then serving on the board, even though less than a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our bylaws provide that only a majority of
the authorized directors on our board of directors, the chairman of the board or the chief executive officer to call a special
meeting of stockholders. Our bylaws also provide that stockholders seeking to present proposals before a meeting of stockholders
to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and
specify requirements as to the form and content of a stockholder's notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The combination of these provisions may make
it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control
of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these
provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition,
the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting
or other rights or preferences that could impede the success of any attempt to change our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">These provisions are intended to enhance the
likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover
practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and
to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging
others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a
consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored
takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages
of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The transfer agent and registrar for our common
stock is Island Stock Transfer, with offices at 15500 Roosevelt Boulevard, Clearwater, FL 33760. The transfer agent for any series
of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Listing on Nasdaq</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Our common stock is listed on the Nasdaq Capital
Market under the symbol &ldquo;MRKR.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="h_007"></A>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we
have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the
particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of
any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires
otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a
particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture
Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement
of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated
by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The following summary of material provisions
of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of
the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and
any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete
indenture that contains the terms of the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and
may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of
all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other
provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or
transactions involving us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may issue the debt securities issued under
the indenture as &ldquo;discount securities,&rdquo; which means they may be sold at a discount below their stated principal amount.
These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &ldquo;original issue
discount,&rdquo; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of
the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described
in more detail in any applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the title of the series of debt securities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any limit upon the aggregate principal amount that may be issued;
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the maturity date or dates; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the form of the debt securities of the series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the applicability of any guarantees;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether or not the debt securities will be secured or unsecured, and
the terms of any secured debt;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the debt securities rank as senior debt, senior subordinated
debt, subordinated debt or any combination thereof, and the terms of any subordination;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if the price (expressed as a percentage of the aggregate principal
amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of
the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of
the principal amount of such debt securities that is convertible into another security or the method by which any such portion
shall be determined; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the interest rate or rates, which may be fixed or variable, or the
method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our right, if any, to defer payment of interest and the maximum length
of any such deferral period;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable, the date or dates after which, or the period or periods
during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional
or provisional redemption provisions and the terms of those redemption provisions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the date or dates, if any, on which, and the price or prices at which
we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s
option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the denominations in which we will issue the series of debt securities,
if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any and all terms, if applicable, relating to any auction or remarketing
of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms
which may be advisable in connection with the marketing of debt securities of that series; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether the debt securities of the series shall be issued in whole
or in part in the form of a global security or securities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms and conditions, if any, upon which such global security
or securities may be exchanged in whole or in part for other individual securities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the depositary for such global security or securities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable, the provisions relating to conversion or exchange of
any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable,
including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional
(at our option or the holders&rsquo; option) conversion or exchange features, the applicable conversion or exchange period and
the manner of settlement for any conversion or exchange; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if other than the full principal amount thereof, the portion of the
principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">additions to or changes in the covenants applicable to the particular
debt securities being issued, including, among others, the consolidation, merger or sale covenant;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">additions to or changes in the events of default with respect to the
securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if
any, with respect to such securities to be due and payable; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">additions to or changes in or deletions of the provisions relating
to covenant defeasance and legal defeasance; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">additions to or changes in the provisions relating to satisfaction
and discharge of the indenture; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">additions to or changes in the provisions relating to the modification
of the indenture both with and without the consent of holders of debt securities issued under the indenture;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the currency of payment of debt securities if other than U.S. dollars
and the manner of determining the equivalent amount in U.S. dollars;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether interest will be payable in cash or additional debt securities
at our or the holders&rsquo; option and the terms and conditions upon which the election may be made;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms and conditions, if any, upon which we will pay amounts in
addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that
is not a &ldquo;United States person&rdquo; for federal tax purposes; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any restrictions on transfer, sale or assignment of the debt securities
of the series; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any other specific terms, preferences, rights or limitations of, or
restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may
be required by us or advisable under applicable laws or regulations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Conversion or Exchange Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other
securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory,
at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock
or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Consolidation, Merger or Sale </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as
an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations
under the indenture or the debt securities, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Events of Default under the Indenture </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if we fail to pay any installment of interest on any series of debt
securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however,
that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall
not constitute a default in the payment of interest for this purpose;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if we fail to pay the principal of, or premium, if any, on any series
of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise,
or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a
valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall
not constitute a default in the payment of principal or premium, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if we fail to observe or perform any other covenant or agreement contained
in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and
our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating
that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding
debt securities of the applicable series; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">If an event of default with respect to debt
securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the
trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice
to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any,
and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs
with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall
be due and payable without any notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The holders of a majority in principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and
its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we
have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Subject to the terms of the indenture, if an
event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding
debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that
series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the direction so given by the holder is not in conflict with any law
or the applicable indenture; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">subject to its duties under the Trust Indenture Act, the trustee need
not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the
proceeding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies
only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the holder has given written notice to the trustee of a continuing
event of default with respect to that series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the holders of at least 25% in aggregate principal amount of the outstanding
debt securities of that series have made written request, </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">such holders have offered to the trustee indemnity satisfactory to
it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the trustee does not institute the proceeding, and does not receive
from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting
directions within 90&nbsp;days after the notice, request and offer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Modification of Indenture; Waiver </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We and the trustee may change an indenture without
the consent of any holders with respect to specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to cure any ambiguity, defect or inconsistency in the indenture or
in the debt securities of any series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to comply with the provisions described above under &ldquo;Description
of Debt Securities&mdash;Consolidation, Merger or Sale;&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to provide for uncertificated debt securities in addition to or in
place of certificated debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to add to our covenants, restrictions, conditions or provisions such
new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to
make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions
or provisions an event of default or to surrender any right or power conferred upon us in the indenture;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to add to, delete from or revise the conditions, limitations, and
restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth
in the indenture;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to make any change that does not adversely affect the interests of
any holder of debt securities of any series in any material respect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to provide for the issuance of and establish the form and terms and
conditions of the debt securities of any series as provided above under &ldquo;Description of Debt Securities&mdash;General&rdquo;
to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt
securities, or to add to the rights of the holders of any series of debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to evidence and provide for the acceptance of appointment under any
indenture by a successor trustee; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">to comply with any requirements of the SEC in connection with the
qualification of any indenture under the Trust Indenture Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under the indenture, the rights
of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least
a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make
the following changes only with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">extending the fixed maturity of any debt securities of any series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">reducing the principal amount, reducing the rate of or extending the
time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">reducing the percentage of debt securities, the holders of which are
required to consent to any amendment, supplement, modification or waiver.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discharge </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each indenture provides that we can elect
to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations,
including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">provide for payment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">register the transfer or exchange of debt securities of the series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">replace stolen, lost or mutilated debt securities of the series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">pay principal of and premium and interest on any debt securities of
the series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maintain paying agencies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">hold monies for payment in trust;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">recover excess money held by the trustee;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">compensate and indemnify the trustee; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">appoint any successor trustee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and
interest on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form, Exchange and Transfer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will issue the debt securities of each
series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement,
in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series
in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository
Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to
that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms
relating to any book-entry securities will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the option of the holder, subject to
the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement,
the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series,
in any authorized denomination and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to the terms of the indenture and
the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities
may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office
of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents
for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment
of any taxes or other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will name in the applicable prospectus
supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for
any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent
in each place of payment for the debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we elect to redeem the debt securities
of any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">issue, register the transfer of, or exchange any debt securities of
that series during a period beginning at the opening of business 15&nbsp;days before the day of mailing of a notice of redemption
of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">register the transfer of or exchange any debt securities so selected
for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Concerning the Trustee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth
in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent
person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation
to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Payment and Paying Agents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will pay principal of and any premium
and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless
we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the
holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series.
We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities
of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All money we pay to a paying agent or the
trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end
of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt
security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The indenture and the debt securities will
be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_008"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following description, together with
the additional information we may include in any applicable prospectus supplement and in any related free writing prospectuses,
summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants
to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently
or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to
or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer
under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the
applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus
supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that
are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its
effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed forms of the warrant agreements
and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement
of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form
of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries
of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference
to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we
may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of
warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements
and warrant certificates that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will describe in the applicable prospectus
supplement the terms relating to a series of warrants being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the title of such securities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the offering price or prices and aggregate number of warrants offered;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the currency or currencies for which the warrants may be purchased;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable, the designation and terms of the securities with which
the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable, the date on and after which the warrants and the related
securities will be separately transferable;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable, the minimum or maximum amount of such warrants which
may be exercised at any one time;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in the case of warrants to purchase debt securities, the principal
amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal
amount of debt securities may be purchased upon such exercise;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in the case of warrants to purchase common stock or preferred stock,
the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the
price at which, and the currency in which, these shares may be purchased upon such exercise;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the effect of any merger, consolidation, sale or other disposition
of our business on the warrant agreements and the warrants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms of any rights to redeem or call the warrants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms of any rights to force the exercise of the warrants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any provisions for changes to or adjustments in the exercise price
or number of securities issuable upon exercise of the warrants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the dates on which the right to exercise the warrants will commence
and expire;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the manner in which the warrant agreements and warrants may be modified;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a discussion of any material or special U.S. federal income tax consequences
of holding or exercising the warrants;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms of the securities issuable upon exercise of the warrants;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any other specific terms, preferences, rights or limitations of or
restrictions on the warrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in the case of warrants to purchase debt securities, the right to
receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce
covenants in the applicable indenture; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in the case of warrants to purchase common stock or preferred stock,
the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights,
if any.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the
warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately
available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate
and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant
agent in connection with the exercise of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Upon receipt of the required payment and
the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate
for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender
securities as all or part of the exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the
warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each warrant agent will act solely as our
agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right
to exercise, and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_009"></A>LEGAL OWNERSHIP OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We can issue securities in registered form
or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons
who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain
for this purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We refer
to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names,
as &ldquo;indirect holders&rdquo; of those securities. As we discuss below, indirect holders are not legal holders, and investors
in securities issued in book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Book-Entry Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may issue securities in book-entry form
only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global
securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions
that participate in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants,
in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Only the person in whose name a security
is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary
or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities,
and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its
participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants
do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms
of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a result, investors in a global security
will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other
financial institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may terminate a global security or issue
securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names
or in &ldquo;street name.&rdquo; Securities held by an investor in street name would be registered in the name of a bank, broker
or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities
through an account he or she maintains at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For securities held in street name, we
or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in
whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make
all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the
beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do
so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our obligations, as well as the obligations
of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not
have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means.
This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing
the securities only in global form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For example, once we make a payment or
give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under
agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly,
we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our
obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval
only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect
holders is up to the legal holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Considerations for Indirect Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you hold securities through a bank,
broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities
or in street name, you should check with your own institution to find out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">how it handles securities payments and notices;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether it imposes fees or charges;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">how it would handle a request for the holders&rsquo; consent, if ever
required;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether and how you can instruct it to send you securities registered
in your own name so you can be a holder, if that is permitted in the future;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">how it would exercise rights under the securities if there were a
default or other event triggering the need for holders to act to protect their interests; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if the securities are in book-entry form, how the depositary&rsquo;s
rules and procedures will affect these matters.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global
securities will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each security issued in book-entry form
will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or
its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the
depositary for all securities issued in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A global security may not be transferred
to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination
situations arise. We describe those situations below under &ldquo;&mdash;Special Situations When a Global Security Will Be Terminated.&rdquo;
As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities
represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with
the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will
not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the prospectus supplement for a particular
security indicates that the security will be issued as a global security, then the security will be represented by a global security
at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Considerations for Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As an indirect holder, an investor&rsquo;s
rights relating to a global security will be governed by the account rules of the investor&rsquo;s financial institution and of
the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If securities are issued only as global
securities, an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an investor cannot cause the securities to be registered in his or
her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations
we describe below;&nbsp;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an investor will be an indirect holder and must look to his or her
own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe
above;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an investor may not be able to sell interests in the securities to
some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an investor may not be able to pledge his or her interest in the global
security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of
the pledge in order for the pledge to be effective;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the depositary&rsquo;s policies, which may change from time to time,
will govern payments, transfers, exchanges and other matters relating to an investor&rsquo;s interest in the global security;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we and any applicable trustee have no responsibility for any aspect
of the depositary&rsquo;s actions or for its records of ownership interests in the global security, nor will we or any applicable
trustee supervise the depositary in any way;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the depositary may, and we understand that DTC will, require that
those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and
your broker or bank may require you to do so as well; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">financial institutions that participate in the depositary&rsquo;s
book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting
payments, notices and other matters relating to the securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special Situations When a Global Security Will Be Terminated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In a few special situations described below,
a global security will terminate and interests in it will be exchanged for physical certificates representing those interests.
After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors
must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so
that they will be direct holders. We have described the rights of holders and street name investors above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless we provide otherwise in the applicable
prospectus supplement, a global security will terminate when the following special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if the depositary notifies us that it is unwilling, unable or no longer
qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within
90 days;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if we notify any applicable trustee that we wish to terminate that
global security; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">if an event of default has occurred with regard to securities represented
by that global security and has not been cured or waived.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The applicable prospectus supplement may
also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee,
is responsible for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may sell the securities from time to
time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may
sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
securities from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">at a fixed price or prices, which may be changed;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">at market prices prevailing at the time of sale;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">at prices related to such prevailing market prices; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">at negotiated prices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may also sell equity securities covered
by this registration statement in an &ldquo;at the market&rdquo; offering as defined in Rule 415(a)(4) under the Securities Act.
Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or
through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or trading service on which such
securities may be listed, quoted or traded at the time of sale. Such at the market offerings, if any, may be conducted by underwriters
acting as principal or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A prospectus supplement or supplements
(and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of
the securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the name or names of any underwriters, dealers or agents, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the purchase price of the securities and the proceeds we will receive
from the sale;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any over-allotment options under which underwriters may purchase additional
securities from us;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any agency fees or underwriting discounts and other items constituting
agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any public offering price;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any discounts or concessions allowed or reallowed or paid to dealers;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any securities exchange or market on which the securities may be listed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If underwriters are used in the sale, they
will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at
a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities
to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement,
other than securities covered by any overallotment or other option. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship.
We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may sell securities directly or through
agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe
any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent
will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may authorize agents or underwriters
to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts
in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may provide agents and underwriters
with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution
with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may
engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All securities we may offer, other than
common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee
the liquidity of the trading markets for any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after
the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from
a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters
may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any underwriters or agents who are qualified
market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital
Market in accordance with Rule 103 of Regulation M under the Exchange Act, during the business day prior to the pricing of the
offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume
and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid
at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive
market maker&rsquo;s bid, however, the passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded.
Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the
open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In compliance with guidelines of the Financial
Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent
broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise indicated in the applicable
prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this
prospectus, and any supplement thereto, will be passed upon by Cooley LLP, New York, New York. Additional legal matters may be
passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Marcum LLP, independent registered
public accounting firm, has audited our consolidated financial statements as of and for the years ended December 31, 2018 and
2017  and the effectiveness of our internal control over financial reporting as of December 31, 2018 as set forth in its reports,
which are included in our 2018 Annual Report on Form 10-K and incorporated by reference in this prospectus and
elsewhere in the registration statement. Our 2018 and 2017 financial statements are incorporated by reference in reliance on
Marcum LLP&rsquo;s report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_013"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is part of a registration
statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement
and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under
this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration
statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus.
We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in
any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any
date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale
of the securities offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s website at
<I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Copies of certain information filed by
us with the SEC are also available on our website at <I>http://www.markertherapeutics.com</I>. Information contained in or accessible
through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="h_014"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information into this prospectus, which means that we can disclose important information to you by referring
you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this
prospectus is 001-37939. The documents incorporated by reference into this prospectus contain important information that you should
read about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following documents are incorporated
by reference into this document:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our Annual Report on Form 10-K for the fiscal year ended December
31, 2018, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_10k.htm" STYLE="-sec-extract: exhibit">March 15, 2019</A>;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the information specifically incorporated by reference into our Annual
Report on Form 10-K for the year ended December 31, 2018 from our Definitive Proxy Statement on Schedule 14A, filed with the SEC
on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419016692/tv517415_def14a.htm" STYLE="-sec-extract: exhibit">March 28, 2019</A>;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our Quarterly Report on Form 10-Q for the fiscal quarter ended March
31, 2019, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419025316/tv520511_10q.htm" STYLE="-sec-extract: exhibit">May 10, 2019</A>;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419000592/tv510398_8k.htm" STYLE="-sec-extract: exhibit">January 4, 2019</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419001768/tv511068_8k.htm" STYLE="-sec-extract: exhibit">January 15, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419008704/tv513933_8k.htm" STYLE="-sec-extract: exhibit">February 15, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419009717/tv514584_8k.htm" STYLE="-sec-extract: exhibit">February 25, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419016685/tv517465_8k.htm" STYLE="-sec-extract: exhibit">March 28, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419019976/tv519053_8k.htm" STYLE="-sec-extract: exhibit">April 17, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420419025325/tv521321_8k.htm" STYLE="-sec-extract: exhibit">May 10, 2019</A>; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.65pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the description of our common stock set forth in the registration
statement on Form 8-A registering our common stock under Section 12 of the Exchange Act, which was filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1094038/000114420416131272/v452031_8a12b.htm" STYLE="-sec-extract: exhibit">November 3, 2016</A>, including any amendments or reports filed for purposes of updating such description. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We also incorporate by reference into this
prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such
form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness
of the registration statement, or (ii) after the date of this prospectus but prior to the termination of the offering. These documents
include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
as well as proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will provide to each person, including
any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the
documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that
are specifically incorporated by reference into such documents. You should direct any requests for documents to Marker Therapeutics,&nbsp;Inc.,
Attn: Corporate Secretary, 3200 Southwest Freeway, Suite 2240, Houston, Texas 77027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained in this prospectus
or contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified
or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus,
or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FF4040">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FF4040"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FF4040"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2011417d1-424b5img3.jpg" ALT="" STYLE="width: 430px; height: 156px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; background-color: white"><B>$30,000,000
of Common Stock</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; background-color: white"><B>plus
345,357 Commitment Shares</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<DIV STYLE="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; padding: 1pt 0in"><P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.65pt; text-align: center; text-indent: -26.65pt"><FONT STYLE="font-size: 10pt"><B>February
28, 2020</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.65pt; text-align: center; text-indent: -26.65pt">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FF4040">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2011417d1-424b5img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011417d1-424b5img3.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "; :X# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)K0T-]:UJXT3XU>%-$0;R  GA=!A5&WKGP _\'07[?9_YI/^R+]/^$#^+_\
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M/"'Q#TC4-2\3> Y= &DZ-KJ:_P#&+Q?&F@7"Z^S3-"D,LA"+%+;G#+_/:?\
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MR;6(.U/YK/\ @HU\*_\ A3/[=?[5'@""#^S;?2_C!XHUK1[3['C[!X7\=?\
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MX@PF:625KPLFW?FC+776^G]=?\G&'_50?3^HK]C_ /@@K_RE"^ 7_7C\4O\
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M9O\ 9<K3PN4Y7%WTIQ7II=)_?M]^NA>HHHKS3T HHHH **** "BBB@ HHHH
M_%K_ (*':UJ&I_''PAX&U&8W/A%/AOI.L-I? $FK:[XO\=Z&TBXQ@;M&T13U
MY4]<XKY\\$_LH_L]>)/M$VN?"OPWJ5QJEGJFBWEW_P 3GG2^?\^WXD5[O_P4
M%_Y.>\'?]D@\,_\ J;^/JT?A5_JK;\/_ $$5NMEZ(#Y^U/\ X(8_\$X?B3I]
MP!\'?$?P_P!1N_\ F+_#[XC^,M.%AT_Y >A:_P")?%OAC_RT*_,3]IW_ (-D
MOB!HNFZCXB_9%^,]MX^6U)O;+X:_&*S_ .$<\2 !5(_L;QQX? \,:XQ^8#/@
M_P 'I@ >8'<+7]6W@G_CTM_\^E>^Z>0(ADXX_K7VN7>(O&.52YHYW*+TT^*#
M2OHXM:-W^*,E+UM8\3$\-Y/BUKDZ_)_?_F?Y._QE^!WQA_9\\;:A\-/C?\.O
M%GPO\;Z8,W?A_P 5Z1_9HO\ TUK0CT\0>'?^II\)Y'Z5^@7_  2J_P""IWQ#
M_P""<'Q.GL=6@U+QI^S%\1-8^V_%'X;6:J=5\/ZF=OF?$OP/N!/]ORJ DGA5
M2K>-5^:.2.18Y4_OJ_:T_8P_9Z_;>^&5[\-/CUX*LO$.G+#?-H'B:V$=AXU\
M$:M(JH-;\&>(E1[G0[R,)_K(V\MEVK(K'#K_ )[G_!2/_@FY\6/^"=WQ6/A_
MQ!]K\5_"'QA?ZK=?"/XJ6]B4L/%&GKUT+7E/&@?$/PH"&B\-(6BGB:.>"26"
M2.1OW/(^+N&O%K!+A;/E'A_/)6::M*G4?Q)TVVW=6YDG[ZM=-I<R_/\ ,<ES
M;A7%_7\O?-';T\FO1^CV\C_1T^!?Q[^$G[27PR\,_%_X)^-=%^(7P]\562WN
MCZ_X?OUG0E5M?,TW58U"2Z-K4$LXBGT*[CAFC=<NHBD0UZEJ/$)P.@X'XU_E
MD?L@?MN?M,_L(>/+CQQ^S;\1KGPW;ZG>:6?%_P /=6/_  DGPT^)1P03XV\$
M Y'B/!(_X2GPECQK@D9P:_KI_92_X.3_ -E7XN6.G>'OVI?"WB3]F+Q[<L;.
M\UVVM-7^(OPBO<A]Q37O#T;>)M!)RB)'XM\(0J/F+2D':/Q7BWPMXCX<QDI8
M**XAR3^:$+R:;V:2;;5KZ73[)Z/[?+.+,GS;9OT>W_ WZG[T^,/]5<?4_P S
M7PM\3O\ EZ_'^E?0'AK]HKX!?'+1O[5^#OQP^$OQ1T_[']M^U^"/'G@WQ)]@
MYZZX/#_B3_BG_P \]_6O /B?-!Y5S^_[\=\?7_)ZU\$?2'R]\!_^3M/@M_V.
M&J_^H9KU?T(5_/?\!_\ D[3X+?\ 8X:K_P"H9KU?T(5S@?PM?\'2/_)Y?[/_
M /V;$O\ ZLOQY7\R<W^JG^G]37]-G_!TC_R>7^S_ /\ 9L2_^K+\>5_,G-_J
MI_I_4U_;OAA_R;_@[_%4_P#3]4_"N(_^2BS?_#'_ -(B?OM_P<5_"R?P3^WK
MH'C^"'[/I_QD^!7PR\3_ &O&/M_B?P,Q\":V#UZ>&M$T(9[]?:OP2K^QK_@Y
M_P#A.MY\)OV1?C9;P?Z1X5U?Q)\-M9N\\?V;XBT70]=T( =O^*C\/ACG^]GC
MM_'+2\,<R6;>'^3+^1SAU>L*DX[O5Z.+OU;=MA\2X;ZIG.<>>OWH_=S_ ()Y
M_!]H?^"57_!7SX^WM@-MU\*_#7PE\.7N1P=!4>.O'"[>OS#7O!+%AP-GN!7X
M1U_9=\'/@TOPG_X-DOC)>36(M]:^,/PJ\=_&S6P2,W8\=^,='3PZX'4;_AUH
MG@V///W3CH:_C1I<"YD\VQ_&^/=]>-HN.NT52C!6^:EWU;U>C'GF&^IX+)?2
M_P"+>_\ 2/Z@_P#@UM&?VGOVEO;X%>%O_4U(_K5[_@Z-^+YUW]H']FKX(6-S
MOMOAS\+O%/C_ %6VM3\W]H_%76AH&U^!RF@>!Y%' RNO*223FJ?_  :U\?M/
M?M+?]D*\*_KXW K\SO\ @M7\7A\8_P#@I9^TIJ4%^]UH_@SQ%I7PPTAI+U3I
MY;P-HGA_06.C$<%SXD.NLY&06)(SUKY/#94L9XWYQCVD_P#5WA'G7E)4%135
MU:Z4IZIIJ^FC:/;^M?4^ 5YM_@[_ *_YGY=Z;9P:EJFGV,]];:=;W5YI=E=Z
MMJW_ "#+#O\ VUKG7Z=>*_I__P""[W[4W[#G[1_[,G[,7AC]F/X]^!_B?XC^
M!?C!?#5IX>\.WNLMJ>G> ]=\%MH7]K%O^$=;<$;P3HH5@%!R<+S7\N$,,\TO
MD007-S<8_P"73Z=.G]/\*L3:;?0Q&>>PU*VMQSS9]?S[_7OVST_2,UX?P><Y
M[D6?>TJ17#+F_9QY?9U'.+C>HG%R;BOAY91L]7<^9PV9?5,'G.":5^(=F]UZ
M>NST*]?Z0'_!#+XJCXM_\$ROV>7N;Q+O6/AU8>)/A+K)$VYK$?#[Q#K.B^&8
MV;)W!?A\?![+T"^:2/NDG_-_K^T7_@UH^+4NH?!S]I[X)7$R[?!_Q'\,_$K2
M[? W*/'>A/H.LG/<!O!&BC!R 9#TR:^!\<,NGBN#Z>.@K_ZO5:<9+5^Y.3A)
MV7:\7KHDF]['N<$XCZMF[C_,FO\ +^NO73?^,*[_ ./^^_Z_-5_K7MO[,/P6
MF_:2_:(^#7P%A\1'PG/\8/B-X9\ 'Q MFNI'0AK:DG6AH9(7.!@995R1D@<U
MXE=_\?\ ??\ 7YJO]:^Z_P#@E[S_ ,%&_P!B4>O[1?@C_P!.S5^CYSC)8'(,
M_P PR]I3A0K3BVDTI0HUIQ;B]&E*$6TVDTFGHW;YO")8S'13V<DG\W%/\&SY
MZ_:3^!_B']FSX]_%[X">*+C^U->^$_CK4O!UUJ]G:#31KZZ(-V@:W[_\):""
M"."#Q7Z!_P#!#GQW\._!?_!2'X)V'Q+\+^%/$6D?$8>*?A_X;O/%.D:3J#>$
M_'6N:*&\$:OH+ZXKR1^(Y/$.A'PIYD2F5!XAWQ 2JM?97_!RW^SZWP__ &Q?
M WQTTO3]ND?M#_#C3(]6NQW\;?"C&AZL0.O_ "*S>!,DC[ZOC.*_GL\$^,-<
M^'OC+P?X_P##E]<Z;XA\!^)/"_C3PW=VG_+AJFA:U_;NA'/0?EZ_2O&RO%/C
MG@#22<N(.#90E*.WM(-PFTD[JU2$KQO=7Y=[-^GBE_8^=-=I;=]=/O74_P!#
M;_@O^<_\$K/VCCZZI\"S_P"; ?#CI^-?YT-?Z!O_  6+^*>B?'#_ ((A>//B
M]X>&W2/B=X;_ &8/&NGVI8,UO%KOQH^$&OC2S_$&1F,#;N25#G"LH'^?E7Q/
M@=AY8;A?-,'-<L_];X\Z>\9I6FO.TD[/9II[-'M<;_\ (WC_ (5^1]#?LI_L
MU^/OVO?V@/AS^S[\-/L]KXF\<ZN;0ZM= MIN@Z5H.B?V_KVM:VJ@LQ/AL' 4
M,S9 &3P?"=8T?5=!UG6/#FN6-SIVL:#K&J:+K&DW?_(3L-4T+_B0Z[HOX=._
MZ<_TS?\ !KAX9T/5/VF_VE_$.H:9;7.N^&/@KX7L= U*[17U/28]>\9.-?@P
M>!YG]B:$"1R ,=\C\Y_^"UOP#_X9]_X*-_'[3+&Q^R^&/BCK&E_&?PX/L@.F
M*WCG_B>Z^I(XROB7^W0?<=N:^MPO%SQG'^=\+V2C'@V*6NLI-<\GH_A2<5M?
MFN[M6/$Q.6?\(JSONVONM_P]_EN>R?\ !OK^T;_PH_\ X*%^#_!VK7JV_A?]
MHKPYJ?PFO-RA\^)^=<\$J 2,-)KVB2Q9!^4>(B>>5/\ 6U_P6_7'_!+#]KO'
M0^$_!GY?\+1\ _XX_P#UX'^<G\/?&WB/X8^._ _Q-\*S_9O%'@/QAX8\:>&[
MS[9_S%-"UK^W>?YBO]!O_@JK\5M ^.7_  1-^-7QF\+S?:O#GQ.^"/PD^(.C
MMT']FZ]XU^'6OQ ?[L;LI/<K7Y?XIY#+#<=<'9VOAXAK8.377FIXNC9^:<)-
M>L5TT7TG#.(OPYF^"_E4_N<7?\E]Y_G:5^\__!O_ /LM_L__ +6/[27QG\'?
MM#?#/1/BCX<\,?!5?$^B:-XA&J%K35%\9Z#HKZJ@T2:W0N\>LR!29!L/SL"J
M$5^#%?>W[ '_  4%^*7_  3M^)?C?XF_"WP;X)\7:SXZ\"CP#=6GCC^VO[,T
M_31K.@:]D'P\0<@:(0>@QD8Y(/[%QCA,XSGAC.L!DK:SR22]V4H2MS1<K3C[
MT79-733UM=7NOD<DQ.#PF<9/C<;^2?1VT>Y_?%X3_P""2?\ P3E\!^+/#'C3
MPG^RA\-]#\6>#O$ND>,O#.M62:V-0T/Q1HNMMX@T?6X2^O2AIX=;4SQJRO&\
M@V,-N['U7^U, ?V9?VA=_P V/@I\42GR8VG_ (0K6\'L!@^@^O>OXV_^(H/]
ML?\ Z(;\ ?P/C,?R\35]H?L4?\%F/CY_P4&?]J[X*?%+X=?#+PCH.@_L5_';
MXA6NJ^!Y-=.HMJ>B:-HGA\AU\0N5V ^)'<   ,(R>(U4?S!G'AWQ]A83SK/)
M0G'AZ2DU/BB%9I*I3ERPBY2UNH\K2O!I32YH)K]3PG$O#E_J6">Z:LE97UV>
MK7W^74_C'A_U4'T_J*^O_P!AC]E.^_;6_:9\!?LW6/C"W\ W'CJQ\4W_ /PE
M=UI"^)&L?[!T0Z_@:&Q503T&YE7.,D#)KY A_P!5!]/ZBOV/_P"""O\ RE"^
M 7_7C\4O_4*\05_5'%&+QN"X7SS'X%V<:=22;U2<83E=K:R<4VM+VLS\CRS#
M?6\;DV"\TOO:/RH^(7@K7/AE\0/''PR\50?9O%'PY\8>*/!?B2TX L/%'@76
MO["UW'/3_B1]1Z^E?N1_P;E^._AWX<_;W;P?X]\,>&-9UCXB?#GQ);?"WQ'K
M>CZ/J>K^$O'/AYU\0/\ V%K2J7T(>*_#0UTO%&OFRH/#44?SNM>>?\' GP#F
M^"O_  49\>^*[&Q%MX7_ &@O#/A;XM:1M((75@!H'CQ.,C*^)-"/B<CL=>(/
M.:_+G]F;XU:G^SE^T+\$?CIILHAE^&7Q&\,^,;]&&5?2-$UG;KZL""&!\-'7
M P/!!(KSL3S<<< _[&ES\0<&)M*32YXV;CS+7E52+C=IWC>\7>43T_\ D3\2
M_P"%_D_\OEJ?ZS5%<UX>UO2O%&AZ-XCT247.D:_I>G:[I%X""+S3M:C358F4
M<X\V$JQ0G*[L9 YKI:_A<_= HHHH **** "BBB@ HHHH **** /S._:[_9A^
M*/Q8^+WA#Q[X*M=+U/1[3P-I?A;5K:[U<:5?V.HZ/KWB+7;?5XVP%<A=<$6$
M+,77IR,\5J_P^\2? /P/K7Q!^(MI]E\)>%F%UXCU30%;Q$+33#JRZ.?)T300
MOB:<")E9VA,@3D.0RD+^LU8.L:38:]IE_HVK6=OJ&D:K9W^EZI8W0!L[[3M6
M0QS1MP0X>-O*.!D&1]I#;6H ^'?V=/CE\'?C9I=Q??"3XF^"?'_]EXLM7M/"
M?B31M2U/0>__ !/-#_Y&?P_DD=/IZ&OL_3O]4/I_6OX^O^"L_P#P3V^,'PL^
M(2_M6?LJZ[XU\%?&CP)9F\OO$/PPO'\-^)/'G@70.&UI#H21MXCU[PJ?F\9>
M&]BK-$4FCS'(C5](_P#!(+_@N3-^TEK>E?LK_M=MH_AS]H:2U^R> _B5;VS>
M'O"_QF8Y_P")+K&AN6/AOXA'C]TI$7C':#&B$ON^C?#F-Q63K.L$KQVDUO'L
M[6U5[IV=UO9J]O-_M*^,^I8W_A_G8_J36Y"],CKU'_UZ^<?VH/V</A=^UU\%
M/&_P(^+VBP:QX/\ &&E/:-*D<8U+PQJ?ER#1/%VBR2KG1-?\+SO]J@F7RG5U
M*M)Y+R1-Z#_PDMO_ ,]C_P!\T?\ "2V__/8_]\UX%&IBJ&*CB\)?W'&49)VE
M&<=I1?=/U35TTTVGZ44L3LDEVZ,_RY/VM_V9?'W['G[0'Q&_9]^(L!_M[P+J
MX-EJQLO[,TWQ9X7)_P")%XST13R#XK\.?*00"K @C((KYQK^U7_@Y _9=TKX
MF_ CPA^U=X<LA_PF_P "+P^&?'=U9C'V[X7^.-: .26.3X4\1XQP!C7O$XQP
M37\55?W'X><2OBWAG)LYDTYQ]V;BK)S2C>2C=\JE=346W922U23/P'B7+?[)
MSCZELOT_K\@ATW^TKJVL8+'^TKBZO/L5G:?8\_VAJ@S_ #_KQ7]W'['G_!+V
M]^('[+GP4\(_$#XM?$_P!/\ #'3(KF^/A6]TE=2UWQ/X@==<UW1=;_MR*8OH
M7A4G0D@A"J;B=_$4"NK2 C\7?^"+W_!-#Q1\8O'7AG]IWXH>%KD>!?#^L9^$
M'A[5K(D^//%'_0YZT%!9OAYX4/"JH+,2 H)P*_NZ\$^&++P9X8TKP_:2+.-.
MM(_M5TQVO?:B=BZIJ4F<8>:9GDQ_ &\ML\&OPWQMXMP>;8Q<,8+;A]J-^BNO
MZ\NKL??<$Y+B\)A%C,:]7LOU]/\ +U/FW]G3]C7X?_LY%K[2-=\7^,/$!M!9
MC6O%%ZAFV@\G9I,2QHQQM.\2  DA2<$?95%%?A1^@'\4?_!R5\#OC1\4/VNO
M@3K?PQ^$GQ&\?Z1I/[.0T6]U;P1X1USQ-8V.J/\ $GQS*NCW T(!XIW1T=XW
M^959?8#^=J?]C_\ :O,5Q_QC+\=>>?\ DE?C(=S_ -2V?7W^O&*_U"_B-^T+
M\"OA!?:?HWQ6^,/PQ^'6JZE;27FE6'CGQQH7AN[O-.C;RWU")-=N+:1UC=65
MF"R1[E(,C'.WB8?VU/V.[NZM[*#]J'X 37-W<FUL[9?B_P"!B]U(<91 /$&'
MZGYCD8'0YK]KX8\5<[X<X:RK)<'PC&I3IIR]M)U7*:<IR<G&%!PM%/E3IRJ)
MJ*LM'?X+,^$L'C<:\<\W<6];>[9;+?F^?0^#/^"UOP"U_P"/?_!-+XD>'?"W
MAN^\6^//!+?#3XC^$= T:P&I:IJ&J^'M<T;2-932-(QEF3PQKGB!@G'E[W.#
MG)_@FL_V,_VMM8O]/TJ#]G/XZVUSJEYI>BV=W=_"OQE_H']N_P#<MCIUQ_.O
M]7+;QC<"..I)]LGC\\_CUK$T[4=*UB*>YTF^TZ_@M[F[M6N-/NEO5CO$;]['
MNC!0.NXETW$#*J"4(-?.<#^*&8<(915RBEE5.K"K5=5.=1QY.:$(RC%PC-./
M-34ES--<THVLD>CG7">#S?&+&2=I)6:^;M>]O3Y=#\G?V]/@GK'A'_@CO\9O
M@%\/_"VIZWJ_AC]E_P /> O#GA7PUH_]H7]_J&@6_AZU$6D:+HB_.YF@:0)
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MM]^S9\?KF_\ B-X\\4>-+S[7\*_&7_,=UHZ]U_X1O^?]<5_I)?\ #<'[&JA
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ML/BE\7/AS\-K_787GTBW\;>.-"\-7FH;?D<Z5#K]U;FX7<I7,88;@1LX.&^
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M1_H_:-K&C^(M*T[6=$U/3=8TC5+-;W2]5TJ]AU/3[VQG4>7?:=JD >.1&23
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M_%'PM^&NO:]XBU/6M2M?$B^ /"&JZGJ=TKHN-6UH^'%1V0,KLLDZF5R6RS
M+\ ?V'^T)_T0_P",?_AM_&7_ ,SE<[:Q6[2]6E^;.H^E_P!H2&Q^/'P,^,'P
M<U7[-<V_Q&^&_BCP7]DN_P#H*:[HO_$B]O\ D8_[#YY/:OQ\_8,_X-[-)\/7
M7A_XC_M1:WX=^+>KVI%YHWPQ\(W3O\(K$EE7_BM_&J*S>( K,-_ACPF J#YV
M(4%A]Z?\(K^T9-%_R0[XM>W_ !0?C+VZ>GM^M?OIX<>>;P_H<FHV@T^Y.DZ<
M;FP(!-G?"*,2(.G21F_VNF<Y)/MY=Q;Q)P[DV<9-DV<VCG]W*ROHE]Z[NVOH
M>;B<MPF+QCQN,5WVO8YWX?\ PYT/P%I=O9:;#:K,MFEFL=K9'3M-T_3PVY='
MT/1E#QZ'H<;*/+MD+ ,NYBQ*!/3:**^</2"BBB@#B-:\$^$/$LL%[X@\+Z!X
M@NK:W^S6UUK&CZ9J3*K'E5-S$V!N&=H"J,G:5R0?A7]@+X;_  \O/@5XAFN_
M ?@NXGM_VF/VR0+JY\(Z(#O_ .&M/C$<@&)R&.  <XR =O9_T;(PJ_C_ $']
M*^+/V&O"OB?P=\&O$NE>+="UWPWJA_:*_:RUA-+U[3DTZ[FTGQ+^T_\ %OQ#
MH&O0J"=^D>*?#6L:'XFMI 0-MTQ4R9VCT:5>V5YFN=KWZ%ES-7Y95^9635TT
M]=&G9)[12YJO^\I][_Y?U^!]HL<*#[$?J?\ &OQS_9O_ &Z_V5?@MX=^(_P[
M^(OQ4_X1SQ9H'[0/[1@UG1V\"_$74DLF/QE\3*0^M:#X3D\.X&Y.4F7.[E0H
M<2?L8PRH'L3^I_PKY _8^\+:WX7^&_BNS\4>']3\.7UW\=?CMKEI:Z_I@T[4
M=0TC7OB=XCUOP_K!3D?OM GBV.H._8<LHC 9X-X58+,?K*<DY4>51E&+MS5>
M9MRC.\5&W,DD]5[T;7>&(6,>)C]5M\+O=772VA\4:M^U7\ OVC/V^OV$K'X,
M>/6\9:EX7TG]I^_UFU;PEXS\//8Z;K7PR\.QQON\2>'?#?WA&C+_ *QL8RAD
MW+7T?_P53$ _X)X_M>?: /);X-ZXQ(Z$;H.H[=1_3K6O\</!OBG5OVS/V'?%
M^D>&=4U#PWX/F_:6L_%WB#3M)34-,\(G7_AC;1: =:UA1NT/_A*;E6@M4*[I
MYHUMPV2)#)_P4>\)^)_'?["'[4WA+P1X;UWQIXLU[X0^)[#1O"WA?1I/$7B7
M7=2EA3;I.B:#I;"75M:DD0Q101Y)FV\D%Z]C"8G!K-^#98=J"IPP\JDISC[C
MCQ34E+VDVX0CR73;?)&W-)\L6FN9K%_5,WZR?-RZ/6ZCZ[[;ZO3NCR@_MZ_\
M$QNWB7P5^/[/WQ$_^=?S^E?H#\--6\$^(O!'ACQ#\.X=+A\$^(]*BUSP\ND:
M4N@Z9=6&K*)DE71Q% $=U(9@T*'+?+A6!/QM_P /"?AR"/\ C&G]O0COG]@_
M]IC_ .=S7UE\(_BGI'QB\$Z;X[T'PU\0?"%CJT^I6JZ!\4_ASXT^%7C6SDTO
M4Y=+!U;P9\0-"\-^)+19!&LZ22VQA:*2-(7E9B!XV,PRHX=N."JIIK25;#U4
MU9VBHTVU'75M[I67EU8?$=&EK?HU9^KM<_/[XN>-?@9X'_X*.6=[\>O%_P (
M/".A77[%BV?A^Y^,7B/P5X>L;O4S\;#)*-''C6:$%U&Y7\EVRQX24G#>?_MA
M>,?V1/BO\-$\/_LTZQ\)OB3^U0?$'AL_L[7G[-.L>#/$/Q+\(_$Y-76'P[XP
MUO6/ )N1X&^'/AQS-<^.?%7BR:+PE!X(7Q''<E]ZHWT;XJ^#5IX]_;ZB\6>/
M?A=IWC;X=V/[(O\ PC^FZ]XH\%GQ#X9M/%J_&5];;1!JFNQW.@+KKZ 5NA&I
M2<0@2/)Y8='YOXI?![4/V8OB3I_[4?[,GPW%WX>U,Z5X-_:6^ 7PX\+FVO\
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M7DL!E:<I-/VMDY-I<U:FTDG)VLKI*RLKI:&>'_WK-/-P7_DLOO\ ZZGYY?\
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M[=M-OX=VM&ULVFT^6ZW-L/\ [LO1_DB2BBBN4Z@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2011417d1_424b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011417d1_424b5img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? L(# 2(  A$! Q$!_\0
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M_A _^F/_ (__ /6K[(_X0K_IA_X]1_PA7_3#_P >KH.<^-_^$#_Z8_\ C_\
M]:C_ (0/_IC_ ./_ /UJ^R/^$*_Z8?\ CU'_  A7_3#_ ,>H ^-_^$#_ .F/
M_C__ -:OZ@_ACKFH^+?AS\/O%6JFW.K:[X%\,ZYJR6W"#4]9T/1M6D"@C[H:
M0Y[$,H7Y<8_$3_A"O^F'_CU>U^'O^"COP*_99D^'GP6^.FF_$_PY;RZ/K.H:
M3\4;#P__ ,)OX$@TQH]<UV--;CT9S\15\1I+##X<B\,>$_!OBUDFUSPSB:.&
MXO8_"TR5UIT.@_96BO%OA%\:_A1\<?"4/C7X/?$'PS\2/#,JZ=]IU7PY?1ZB
M^DZE+HNBZTND>(-+02:[X?\ $YT76-(O'\,>*$M?%=M%=P+=6<.58^TUB 44
M44 %%%% !1110 4444 0-T;_ '!_):_S>_\ @O3_ ,I8/VL/K\"__6:/A'7^
MD(W1O]P?R6O\WO\ X+T_\I8/VL/K\"__ %FCX1U^Q>!'_)9YI_V2&-_]USXO
MC[_D2/\ Q+_TD_(*BBBOZV/R,**** /[E?\ @V2^+\/C+]CKXL?!V_\ %]_K
M7B3X0?'6\UBS\)7AU4KX(^&WQ5\*>'=?T)M( C30[;0?%/Q(T+XR>)+71+.>
M62&Y?Q!/+;A/$,1D_IN QGK]S/H>V1^GY5_#+_P:_P#Q>O?#?[5WQS^"EQ>>
M'K;P_P#%;X*6'C0PZK(L?B+5/'/PJ\7:(VB:7I)=QLC/AWXH?%+Q"WAV*.:X
MA31W"B.#PI<RK_<X?X\]@,'\/\>?KS7\3^*N5+*./>(*5K+VTJJMHFJZA4DU
M:,5_$4[VYM6VY.3D?M?"F*^M<.9/+^Y;_P !;]7M_P ,0,/]7GC )/?H3_G_
M !K_ #"?^"KWQ1UKXN_\%'_VR_%.M6-CIM_IGQU\4?#6SM-/9FL?[.^"!/P,
MT76W+DG_ (24^'O!6B>*2N=J9V(H4!1_I-?&WXI:-\$_@U\5?C/X@L]6U#PU
M\(OAQXX^)GB"QT6S6;7KW0_ GA36O$.KP:-#J$L"3ZR]KI,ZVJ2S(LC%$=B9
M2Q_R7?\ 6_YQC'Y^OOU_+[_P RWFS;.<Z2CRX?#0I)V3?/6J.<M;W2]G2@FN
M6TKI\SY>5>)Q]74<)E>#OK4J.7RC%12MZW^84445_3)^7A1110!_H[_\$%/^
M44/[*W^_\=O_ %I+XOU^Q ^XW^Y_A7X[_P#!!3_E%#^RM_O_ !V_]:2^+]?L
M0/N-_N?X5_ '%G_)7<7?]E5F'_J54/WW)O\ D4Y9_P!>8?\ I+).Z'M@#G\C
M_.OQR_X+J?&"3X/?\$SOVB)-,\5VWA/Q/\38/"7P@\-[@%O_ !=_PG'C#1(_
M''@O1AL(GN_$7P>@^)RD' A@BU69)/,B /[%YRJ_C_):_D^_X.F_BAJ^B_!S
M]DWX+)IMC=Z'\1/BE\3?B9>ZI(Y.IV&J?"CP9H7A[0M,5  FRY'QIUF?&&*3
MZ%H*ALF3/;P3E;S?B[(<NT:J8FDI7MM3E*J[)J2;:HQW6NOE;FXAQ/U7)LUG
M_P!.Y+YNR_7\3^+^BBBO[R/PL**** /[E_\ @V2^+:>,OV.OB_\ !Z]\57^N
M>(OA!\=+[6;3PW>KJ\VG>%?AO\3/"GA^^\//H,<\D,5MH/B?XA>'/BOXD@T&
M-Y)1=3Z_/(J)KT1;^FU!AN?3/\O\_6OX<?\ @UT^*>KZ%^U-^T5\&%72CX8^
M(GP.TKX@WEW.P741XH^%/C'1- T#1M+&Y6>W_P"$?^*GC7S%0,P.@*Q&Q78?
MW'-_'[;17\3^*F6++^/L_@E92KRJ12_ZB(TY3?PQ7\2,G975W\3;9^U\*8KZ
MUPWE$O\ IW9_]NMM=>UEL'_QNOYNO^#H/_DPGX.?]G>^ _\ U37Q]K^D7_XW
M7\W7_!T'_P F$_!S_L[WP'_ZIKX^UY'AW_R7O!O_ &'X?]3?B/\ Y$&;_P#7
MNI^<3^$"BBBO[O/PT**** "DXAF]A^'7^GY#GL*6B@#],?@)_P %BO\ @HS^
MS]K_ /;VB?M/?$CXC6-SK/A2_P#$?A7X[:TWQH\-Z]IGAYMR:,W_  GC>+/$
M_@+P[XJ;7"?&J_"GQAX0\98:12"OA3P@K?UY?\$N_P#@M5\*_P!O6:#X2^/M
M"T_X-?M0V>C:=>'PB^KW$_@?XLQZ-I\4GB#5OA5K.M,;F/7#")O$H^&/B7S_
M !G8^#666T\3>-X/!WC;Q+X2_P ]RMC0=>USPKK.D>(_#FK:EX;\0:#K&EZU
MX;\0^'KP:;JF@:IH6=>T+6M#UP?\B_XB[=N]?G7%OACPSG^"O2R=<,9\MO9Q
M48/RG3CR0DNCM&$K-\LD]_I<NXESC*M)KGCU3O\ F[M?CZ'^O$H#A7/'[L_I
MT'YG\/>OYP_^#H+_ ),(^#G_ &=YX#_]4U\?:^N_^".'[?ES^WA^R9IFO^.]
M;M+_ /:#^%&JMX ^-EOI]EHVB-K5]#,EQX0^)(\-Z#KMZVB:)X[\.R.7G^Q^
M$_"=YXZT'XG0>!O"L?@_PUI^/D+_ (.@/^3"/@[_ -G?>!/_ %37Q\K^:.#\
MJQ>5>)&0Y3CX\M:GQ;0P\H_R\E75+O%M7@^L)1>EVE^CYYB\-BN'<UQ>#ES1
M=.3OLVXM6TZ:/\'U/X0Z***_MP_$PK^[S_@U^_Y,)^,7_9WGC[_U3/P"K^$.
MO[O/^#7[_DPGXQ?]G>>/O_5,_ *OQ_QP_P"2#I?]?>#/_35<^LX*_P"2BG_U
M[G_Z2?TD-CY1G''7V_+J?_UU_";_ ,','[3<?Q)_:H^&O[-/A[4+"\\.?L[>
M VUGQ<;>VUW3]7L/B?\ %231-=&B>(O-2/P_KVC)\.=#^%GB/P@OAQ3=)+XZ
M\41W+R31O)X/_ME^)OC_ ,*_";X=>-_BGXUU1]"\&?#OPAXF\?\ C'5X[+4M
M4?3O"_@O2)]<U[5VTO1XI=7U=K/1-,FE>*".YN'2%8XX9=RPR?Y2_P :OBQX
MI^/?QC^)WQN\;_V9:^+_ (L>._$_C_Q'9Z0-9&EZ?J?CG6?[=&B:$/$'B/Q<
M/^$<QK?_ !1&!Z=*_+? K(Y8_B?,L\:O'AR#JWOO5FN2-E_=A*<GYR2L[77U
MW&V8K!X+ZIUGOM:R_I?B>84445_61^2FQX<\.>(_%^O>'_"WA;1-:\1^)_%&
ML:7X9\-^'O#^CZSJ7B77O%&N:U_8.A:+H>A^'\_\)!XB\6 <GMZ]A_J9_L3_
M +.&C?LD?LJ? S]G73(=.6X^&GP_TS2?$=UH\^LW^E:WX]U=VUWXI>(-'?Q&
MTNO?V-XJ^(FKZYXH7SRK+_;$8=8@A5?XE_\ @WK_ &1I_P!H;]MVW^,NLZ9:
MW/PV_91T73/B!JD>J6NB:A9:E\3-;;7- ^%VD0!O$$OB709(_$&C:W\3X?%$
MB^,(9+GX2P022Q#QJKC_ $']P#8 !QD#'MW],\CMW^F/Y>\=N)98W,<JX7P=
MO8\-TG&=[:U:DD[=[0I*[T3YJBWTM^H<!8!0P/UW6\M(^:7_  ?+H?Y8'_!0
MC_D_O]MS_L[O]HG_ -7+X]KX\K[#_P""A'_)_?[;G_9W?[1/_JY?'M?'E?T+
MPQ_R37#?_8)A/_43"'YQB_\ ?LX_QO\ -A1117N',%%%% !1110!_=O^P]_R
MK4>-/^S0O^"@O_J7?M)U_"17]V_[#W_*M1XT_P"S0O\ @H+_ .I=^TG7\)%?
MCOA?_P C?Q*_[+'_ -S8X^IXA_W7A7_LDW_Z;H!1117[$?+!1110 5]A? K_
M (* ?ML_LVGPQ#\&/VF_B_X4T'P?:ZE:>'?A_=^+=7\2?#6Q;6CKAULGX6^/
MQXN^&>5_MC6<'_A$./&B+XY' %?'M%<..P&69E'^S\THTJT+WY:U*G5BGRN-
MTJD)I2Y6X\T>67*VE))M/JPN*QN#?^PMKIHVOR?^>O0_LZ_X)U?\'&6B?$+7
M/#?P7_;LTSP[X U_Q!K>E>'?#O[0?A2U;P[\.(S_ &*#*_QHT7Q!XB=O 3R^
M(XHE;XF>%<>!IY/$$D]WX&^$W@7PI-XNN/ZQ%9)$R#G/4?YP>H_SR*_R :_L
M?_X-TO\ @H]XM\=V^N_L(_&CQO\ VWJWA/P;%XA_9FU7Q'J6E#4/^$8T"1QX
MT^#D6L:_XE7Q-KMSX1\.SZ/XH\#>&8/"OB&;PEX.T'XD1/?VW@+P?X'\*6O\
MX>*?A7@LKP7^M/"[7U2S56E)2E[/GDDJE-MR<::<K5*<KPC']Y3<;2@_O^$^
M+,7CL6\#CE>3^&77T]>WW/HS^NFBBBOP0_1PHHHH **** (>6/;I] !7D?Q/
M^)_@CX+^!?$OQ'^)/B;2?"/@;P?83ZSKWB#6I5BL;>&&6-"L<R%I]6U>>>6#
M0O#7A^&WE\2^*/$KVNGV%C<W,\;UQ7[1?[2/PP_91^%VM_%3XLZE/IGAFR:+
M3]#TK3U;5?%7COQ;>"5]*\'>#](,X?5-?UT0-LC,Z6\%G'KOC#Q9<^&O!GAG
MQ1XGL_XPOVP?VS?B9^U1KGB+XL_';QDW@+X,:'K9M/"/PTMKS5]2\$>%"1KP
MT'1=%T-54?$'XBKX:UO6D\;>*\;F"^)B[>#_  -_PAW@WP?OA<+B\9BU@\&E
MS65]/^'M:_YF=>NL*FV[W=O+3[S],/VMO^"TOQ4^(^NZ_P#"7]C'0)/"FA#6
M=0T6U^,VJVXO_'7C'3H&\/\ E>(?!.A:S';^%?A[H<B+KBW"^)T\6^+Y?!'B
M+PUXPD3X/^,TC1/YT_C!\8/ &FZ]X@USXF_$;Q)\8_BAJG^FZQ_PCWB3_A)-
M3_M7^Q= _P"1X^*GB#_D8.WA<'PG_P )C_R #7S/\8/VG-<\81:CX.\ 07/@
M#X7W5Y]B%I:7G_%3>+=+YT'_ (KC7!T_YCG_ !2W_(EXU_Z5\KS]OP_K7]$\
M-^"=L']=XG]%8_.\RXVN_J>2]>I_HX?#'6-#^*GPY^'_ ,5/"L&I6WA?XC^
M_"_Q!\-_VM9_V;JG]E^.M%_M[0O[<]S_ &Y^GIS7<?\ "*_],?\ /YU\/_\
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MP[I'BOPCX@TLB33M=\/>(]+36="U;29,%G2YT.:*:$E(V='5WC7)6OY=\?\
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MY'>\9*=[IIJUF>[Q-PS@LHBL=@7N[-;VT[_\ ^+****_8SX\_H-_X-LOC0/
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MUKV5['F\<8?ZJLEP:=UK%/ORM+]0HHHK]W/ASV7]G_\ 9^^,'[4GQ2T'X-?
MKP>?'_Q.\366J7VD>'U\1>#_  \;\:%HO]O:[C6O'OB/PEX:8_\ ".Z'@!5)
M/0#.*_163_@@W_P5@CC\U?V4BQ&"1_PNK]FS(]\'XU#UY/X'-=%_P;^#/_!5
M'X  ]_#GQC_]4SX[K_1H^51@@8 QG\,GW[@\GUYXY_!O$SQ*XDX4XAED66RP
M\*$*-.;]I2J3J2J3G5YDI1JPC&"C"-O=;NV[OI]QPUPU@<VP2QN-4FVVM'96
M5O)]?ZN?Y%?COX?>/OA;XLU?P#\4O!'BSX<^-M"_LLZOX)^(/AS6?!7B701K
MNB_V]H7]N:)K_P#Q4_A\?\(YKFA^* ?S/)KCZ_HY_P"#H( ?M^?"#'?]D/P&
M?_,S?'K\^G6OYQJ_6>%<]J\1\+Y)G=:,85>(5)5(TY2E!2C.<7R2DE)Q?(I+
MF2DE*SNU=_-9GA5@\;G.!6NO73_@=;!7V!_P3[^,=U\!?VW?V5_BQ'XEB\'Z
M7X9^.7@BQ\6>)I[4W\-I\,]>U<^ _BFDKK%,T<;?#S7/&P9Q%(4 +B-F&T_'
M]%>EC\##,LMJY7/X*U*I1G;E;Y:U.=.5N:,HW4:C:O&234;Q=K/FPN*>#QJQ
MRW337JFG_6J9_L$4445_GJ?T,%%%% !7C_Q3^*O@CX-^"?%/Q/\ B%XDTSPM
MX)\&:=_:_B'7-9<QQ6@0RVQC6*WMY;K6=9N));7P_P"&/#WAV*Z\2>+?$TMK
MX7LHY[N4;/8*_F2_X+#_ +3NN^/?B+HW[)_@#6M6/AWP8-)U;XO6FGWNL:=I
MWBSQWK"MK>A^$M;CC\."VUS0OAAX>?2?%S2P>)_$O@^7Q=XDABN((O'_ ,'1
M%& ?E=^VO^UUK?[3?Q&\:_'/XM:[K>B_!_P$NI6/PX\$FUD8>%/ NN:RHT32
M-#T262;PW_PL7Q>PT1_'/BI_&LCN[,\LDG@CPGX/\'>#_P %OC/\9O$?QF\1
MV]_?06VB>%]!_P!"\'^"+2\_XEGA+2\>A/\ Q4'B+'_(\>*?^9TZUZ?^U1\9
MX/'GBC_A7_@[5;G_ (5OX#O/L-E]DO-&_LSQ9XHS_P 3WQI_Q3__ )9&/^9+
M'_4W5\GU_7OA=P!@^'L'_;6-_P"1X?CG%O$G]K8SZE@O^1&%%%%?L9\4?T._
M\&X/[22^ ?VJ?''[-VO7-J/#W[1GA!=7\-$VFLZAJ7_"T?A7H^O:XJC/_%+Z
M!X?;X=GXIKXT49);0?"ZKDD9_MS_ +'_ ,Y_^RK_ "C_  3X\\5?"SQYX'^)
MG@'51HGC?X<^,/"_Q \'^(#9:-J0T'Q1X&UK^WM!UK^P_$'_ !3'B#/B/0_I
MZU_J'_L=?M'>#?VP?V:OA3^T3X(@^RZ1\4?"37VK: ]]K6J_\(KX[T9CHGCK
MP4NO>(]!\*OK\?A#Q3I&N^%$\2_\(?$GBX:"GC*"-8A'N_C[QDX=>"SQ9QR^
M[43:DME..\9:VO.*O#3[$DW>R?[%P3F7UO!?4NWIM^&WZKY>P_V/_G/_ -E1
M_8_^<_\ V5>@?8O^F/Z__94?8O\ IC^O_P!E7Y ?;'G_ /8_^<__ &5']C_Y
MS_\ 95Z!]B_Z8_K_ /94?8O^F/Z__94 ?''[3W[)7P@_;#^#WB#X'_&CPZVL
M>%=<*7UCJ]F?[+\3^!/%:._]B^,?!.LO&?\ A']?\+* N_+AD9O!/CD>+O W
MBOQ=X0?_ #U/V]?V"OC3_P $_?C)<?#+XG6_]L^$->.J:S\*_BQI-F--\,_$
MOPN#CCG'A_Q#X4/]AGQOX6_YDOH1XQ\">+?!OC/QC_IY?8_;_P >KQ'XW_ #
MX/?M%^ ;_P"&GQS^'/A3XI^"M4$NSP]XJL&OTL=272-?T+^V-$UU\^(O#_B7
M9K6LB'Q5X8E@\7^$PY>&5$?>GZ'P%XC8[@;&O"P3GDC<>>":2E9-)PYG:,DM
ME>*FG:332DOF^).','Q KO\ Y':5^9]/7RW]/N/\RW]GO]H35?@SJESI6JP7
M/B3X7Z]>9\2>$\?\3.PU7G_BM? _?_A(N_\ U.A[_P#0F_TQ_P#!/?\ ;"3]
MF7Q]IVO'QCJVN?LR?%4&_P#'%IHNDZUXDTT$:1%HVA?$[0/#SR)KNA^*/"3P
MQ^&/&!\.K)XN\8>$/#Z^"9/ GC3QQX2\()X/^-_V[O\ @WN^/OP.N-8^(/[)
M=]J7[0OPGM;1KP^";R[TG2_V@]!*Z1K^MZ^?[#=$\,_$!2VAZ&4?PFO_  F/
MCCQAKX\%1_!%HS_PFU?GI^QS\5?$?@GQOJ'[-GQ-@UO1!_;&J:+X;TGQ8?[-
MU/P'X[T+_D.^"]<.O_\ (O\ _"6_\BO_ ,(MC_D=/^QN\:5^D\?9-POQWD\N
M,."[2SU)*=.6DDI7LIP>J4K.S:<96=I-II?-\-YEC.'L7_8N===FOT?EZ]NF
MK_TO_#WB/0O$^C:1XC\,ZMIVO:#KFDZ7J^B:[I-XNJZ9K.EZS''<:5J>F:O;
MS&#5-*N(K@31RQNPDB=)E;:\>_J:_$7_ ()*_M&ZOJVD>(OV;_'.NZEJ.J>$
M+)/$WPQDUZ[U?4=3/@8S#1-?\)-+/H0B@M_"'B)M'F\'Q^(O%4<TOA#Q"_@W
MP)X)\*^"/A((V_;JOYS/T@**** "BBB@"!NC?[@_DM?YO?\ P7I_Y2P?M8?7
MX%_^LT?".O\ 2$;HW^X/Y+7^;W_P7I_Y2P?M8?7X%_\ K-'PCK]B\"/^2SS3
M_LD,;_[KGQ?'W_(D?^)?^DGY!4445_6Q^1A17T/\"/AS>_$;PY^TA9:+X6'B
MS7_!O[/FI^/]'-K: :GH.F>!OB?\(=<\<>,P<XSX5^'9\;J!_%X,/B90,G!^
M>*Y/K46W%.+:2;2:;2E?E;5[I2Y9<K:2EROE;L[ 5_H^_P#!#[XT7?QK_P""
M9_[.UWJGB_2/%GBCX<Z3K_P9\20Z0VBF;PG#\+/&7B+P]X#\)Z]%H-RD,7B"
M#X-I\-)FE8++J%MJVA>+A;NGB*.23_."K^TC_@UD^*E_JWP5_:N^",VD0P:?
M\//BAX#^)=KK_P!J,E[J&J?%3PCK/@;7-#= <*WA5?@AI&'VX(U]@[95!7Y3
MXXY<\3PA1Q\4G_J]7ITW=VM&MS4V]FW:7LW9.-]W*T;/Z[@C$?5LW<?YE;[M
MC\M/^#D;XL:7\0/^"BB>!]*;56G^!7P0^&_@#Q#9WZ!=)7Q-KLOB+XL'6-%(
M)WS?\(]\4O!#3OP?.T)UP HK\ J^V?\ @I3\4M=^,?[?G[7/CS7/$.F>*S/\
M?_B9X6\.:_HZ:-'I5]X%\":P/ ?PJ704\/LQUU1\.O VA@>)]Q_X3$87)QD_
M$U?:\$9=+*N$L@P<E:4Z-.I->\K3JPC6FK22DO>K2NFDXM.+2Y4EXF>8E8K.
M<YQBV3LOD[*UO3[@HKZ=TSX7:E:?L5^,OC9JGA[3#I6N?M3?"SX3^$?%.=%.
MK+J/@GX9?&'QU\5-'*_\C1X>5F\:?"_Q.IZ$IX: /_%(&OF*OH<)BXXU/E:D
MDY0=FFE*+M*+L])1>DEO%Z.S/,"BBBNL#_1W_P"""G_**']E;_?^.W_K27Q?
MK]B!]QO]S_"OQW_X(*?\HH?V5O\ ?^.W_K27Q?K]B!]QO]S_  K^ .+/^2NX
MN_[*K,/_ %*J'[[DW_(IRS_KS#_TEGSQ^U7\5M1^"/[,G[0WQKT6#2[O7/A1
M\$OBC\1_#MEK3"/2[[Q#X&\#Z[XAT33-3<$L(9]<TJ&"8PL&5),1L& :O\H>
MO]"3_@XI^*.F_#K_ ()J>.O"]UIVHSZA\<_B?\)/A5HVHZ>B>5HFI:=XB/Q<
MFU37&(+?V!)H/PHUC0+G9M(EUN++%68-_GMU_1/@'@%0X>X@QRC99W46%B]-
M51A"<K-.]E4KM-22]Y72:;9^<^(&*OBH8+O%2^_;\ HHKZQ_8,^',/Q=_;8_
M9/\ AY>^$;OQYH/B7]HGX06GB_PNND1^(].UOP(OC#0]?\<OK6AS PCP\OPZ
M&N'QMYH,0\&#Q-O!7<#^T8[&QR[+JN9R3<:-*K5DHI<SC1I5*LE&[2NXTVDF
MTFW&[5VU\3A<+]<:2ZM+7S:6_:[/E[6='U70=9UG0]<L;G3=8T&\U31=8TFZ
ML_\ B9V&J:%G^W=%_E_]:L^ON+_@IAX0\2>"?^"@_P"VEH?BO29]#U&Z_:7^
M,'C.ULKDY5?#/CGQEKWCOP-K /&5\5^'=<T3Q.. ?^)]R.E?#M&3XW^T<MR'
M,[<OM:-*K9/F4?:TJ53E4NO*YN-^O+>RNTNG%87ZGC7@>S:^YM7_ *[A7^F'
M_P $</BKJGQ?_P"":/[(?BC5=,L],N-)^%S_  O2VTXJT,NF_ _Q=XA^"6A:
MXK,S.%\3^'O FE>(MIPL7VEUC&S:J_YGE?V\?\&NOQ9TS7?V7_VA_@P;O5Y_
M$GPS^.6G>/KI;]5_LS3?#?Q5\%Z'HNAZ3HCL1F,>(?A7XWF=?E*_VJNTDMM'
MY%XY9?+$<(X?,(JZX>KPISVNH5E.FW=M-)35-M)2;=E:R;7UG!.(^JYM+ =X
MO[UJ?U&?_&Z_FZ_X.@_^3"?@Y_V=[X#_ /5-?'VOZ1?_ (W7\W7_  =!_P#)
MA/P<_P"SO? ?_JFOC[7\]^'?_)>\&_\ 8?A_U/O.(_\ D09O_P!>ZGYQ/X0*
M***_N\_#0K^O[_@U*_YOS_[MA_\ 17Q_K^0&OZ_O^#4K_F_/_NV'_P!%?'^O
MR_QA_P"2 S3_ +"<+_ZD4SZ/A3_DHLK_ .O53_TW(_L$';_=;_V:O\N'_@IQ
M_P I#?VU/^SEOC!_ZF.NU_J/#M_NM_[-7^5Q^WYXV\/?$C]N;]KOQQX7U/1?
M$/AK7OVC/C#>^'=>\/ZOHGB/PUK?AD^,=>_L/6-$USPX\JZ_X=\5'/B<A))%
M'178?,?R7P"3_P!9<XE;181J_2[Q2:7;9-[]#ZWCW_<LK_Z^O_TA'R)1117]
M5'Y>?KY_P07_ .4K_P"R?_O?'/\ ]9I^+=?T@_\ !T%_R87\'_\ L[WP%_ZI
MKX^U_-]_P07_ .4K_P"R?_O?'/\ ]9I^+=?T@_\ !T%_R87\'_\ L[WP%_ZI
MKX^U^ <9_P#)\.#/\=#_ -.\8GZ#D?\ R1V<>D_RB?PA4445^_GY\%?V+?\
M!$[]HO0_V2O^",G[9G[0^NR::#\-/C]\4=9\,6.J_P!H+I^N>.=:^#O[/^B?
M#'P=K+:$C7/_ !5WQ$UWP[X6)@'[N36X7W1/B1?XZ:^]H/VK#X;_ ."9L'[&
M_A;7=3MM7^(G[9WCKXV_%"RTF\U33E_X030_@Y\)=$^%NC:Z! /#WB#P]XM^
M(RZMXG!-R\?@SQG\(O#.R")AX/>7XWCO(O\ 63),HR%QYHU>,N#J4UJDJ=2,
MXS;:U2Y;QOWE:ZO=>YD69+*,8\:_Y96ZZZ67W]5T3/B'7=>USQ5K.K^(_$>J
MZEXDU_7M8U36O$GB'Q!>#4M4U[5-<QKVNZUKFN'_ )&#Q%V[]!6/117V5K:+
M1+1):)):))*R2222222222/#"O[7_P#@VA_9,NO GP/^*'[7GB;2K!]7^.NI
M?\(+\+YYK+3CJ]G\-/ VOZY'XMU;2=?MM<NG@L_&'Q-SX7N/#+6_A02Q?!_P
M[XY,%Q9^)_#JQ?Q05_K'_ 'X-^$_V=_@M\,/@;X%AG@\%_";P/X<\!^&I+A-
M+BO[ZP\.Z4FC1:OK@T3P_P"&-%N?$?B=K67Q)XKN8+&UAN/%NK7MR+94G@9O
MPKQQSV6$X?HY%@).,>(7*O4EM>G1M:%[/XZLX<VWN0=W9Z_;\$9:L5C'C^VB
M]7U^23^\]YHHHK^7#]9/\KK_ (*$?\G]_MN?]G=_M$_^KE\>U\>5]A_\%"/^
M3^_VW/\ L[O]HG_U<OCVOCRO[\X8_P"2:X;_ .P3"?\ J)A#^>,7_OV<?XW^
M;"BBBO<.8_U_,>__ )#_ /K48]__ "'_ /6K^#[_ (BA/V_/^B3_ +(G_A!?
M%[_Z(RC_ (BA/V_/^B3_ +(G_A!?%[_Z(ROXV_X@;QY_T#8;_P 2K"'['_KM
MP[_S\_\ )&?WEG!Y8$>__P"HG]:/E ]A]?T/U[CH?I7\CG_!-#_@NU^U[^V=
M^VW\$OV;?BA\/_V=M$\"?$B3XD_VWJ/P\\&_$.P\1V7_  @_P?\ ''CW2'TC
M7?$?QD\8^'I%EU[0M&ANMWA0,]L\R1R0RE)H_P"N#/R?CCO]?S_I^%?$\0<.
MYMPKCWEN=TU1Q$:<*CIJ<)\L)RE&+YH)1=W&2T5UU/:RW,<)FN$6-P3YHR;B
MFU;5).S/CC_@H=_R8'^V[_V:'^TM_P"J:\<5_EAU_J>?\%#O^3 _VW?^S0_V
MEO\ U37CBO\ +#K]_P#H]_[AQ+_W*_\ J/4/@^/_ /?,F_Q5/_2D%%%%?T ?
MGQ^SG_!OY_RE0^ /_8M_&3_U3'CRO]&1.@_W3_Z":_SF_P#@W\_Y2H? '_L6
M_C)_ZICQY7^C(G0?[I_]!-?R)X[?\EEE7_9(83\L0?KG '_(DC_U\_\ ;3^#
MW_@Z&_Y/X^$/_9H/@/\ ]7/\>J_G!K^AO_@YH\3^'];_ ."@W@;3=%UK2-2O
M?"'[+W@3PYXI@TS5M$O;[PQXAE^)'Q7\1QZ1JD/G2S>&]?7PWK^B>(IOM2V\
MTGAC6M"G$"02PL_\\E?T#X9)QX X.3_FJ/[ZU22_"2/S_B;_ )'.<?+_ -)0
M445H:/H^JZ]JFGZ'H=C<ZEK&O7FEZ)H^DVN?[3U#5->X_L7_ "*^Z/#/]?BB
MBBO\YS^D HK\W?VC_P!LO7OAAJE]X>^&WAK2-:U'0KL66M:[XJ.L-IAD5]^K
MZ3I&CZ,_ANX>6#HGB873VJDM^[D&UJ_&SXI_\%)OVW++4]6O=!^+%MX:MIY_
MM%CI&D?#CX:ZEI>GQX V'_A(/#GB[Q.RX QNS@\C!8F@#^BC]I7XTZ-^SI\$
M?B!\9M=M[2XMO!GA][S2-*N[K4]/37?%NK'^PO _@Z;5]&T3Q)+HDOC+QSJ^
MA^%8?$"V-U'97&N+<3))%!^\_@L_:B^*>N>"/AIXW\<7VN?VE\4/BSXDU31?
M[6N[S1=-\2WVJ:Y_Q/OBOXTQQVUS_D:?"?\ S.GCZOLKQ?\ MN_MC?M'^;\.
MOC%\9M:\3?#FQ;^WM4T'3?#?PU\'6&MZN4DCT+2-:D\!^'/"?BK7_#XCED\2
M#PQN!'C#0_#?C48C\)$5^+O[=7BJ^U+XR6_@<?:;73_A?X;TO1;.T_MC^TM,
M_M77?^*\UW6O^I?_ .0YH?A?'_4 &0*_1O"SAB.?\8Y4\6K?V%-SEV<FDK_=
M'R_S^;XNS+^R<H;?7;R6]NG5O\#XOHHHK^VC\+"BBB@"O-#Y\0_(G^?3_#OZ
MU^^W_!OY_P %%+/]E+]H6\_9T^+/B&32_@1^T?J^EV>D:CJ:ZTVD?#KX[;DT
M'0];D6+9X>T/0/BI$)_"GB_Q-_PBI@5](^&<TOB[PMX(\&>*_+_!&L?4K/SH
MO/@SVY_SW^F>O7M7P_''#.#XCR;ZC>SWC*R?+))VDD]&TWML]4W9L]K(\R_L
MG&?U^GD?[!'D>_Z__6H\CW_7_P"M7\W?_!!W_@KCH?[57P[\-?LE_M!^/]5F
M_:U\ Z5J<7A7Q+XUNU%_^T/X&T*,ZW#K6C:^I276?B5X4\.D)XO\.^)S_P )
MKXY\&: /C.\GBZ1_BRW@G^E3 "YR3@]_3&?2OXFS# 8S*\;/ XR+4J;Y6FFK
MW7-%Q;2YHR5VFKIV:W32_=<-BEB\*L7_ #)V_5>1G^1[_K_]:CR/?]?_ *U;
M%5_(]_U_^M7 =)G^1[_K_P#6K'O._P#P&N@G[?A_6N?O._\ P&@#C]3_ (?\
M^E?#W[2O[&/[+O[4,<-Q\=O@OX*\?ZS;VFF6=GXL-JWASXEV&F:%K&NZWH6B
M:#\4M!;PE\3?#OAS_A(M9UL_\(HOB\+N\0,Q&YV8_<.I_P /^?2O-]8_U(_S
MWKHP^(QF%QGUW!+_ (#[K5/^ONYL3AOK?^^GYFZ)^QOX6^$/Q8^'/Q8^''CG
MQ;H>L?#KQ=IOB6\M=7L_!WB7^WM+(_L'7-&T,+X<5O#_ /PEGAS7==\+_P#"
M4*RG_B?\,#\U?IJO[5/@ZRM@=7\/^)HK]?\ CYM-+70=2,9[E=GB!"/3KGCO
MBO#/$?;_ #_>KY_\1]O\_P!ZN<Z3["U+]N;X3:9_KO#_ ,2.^?L^D>$W_GXK
M_P .E/\ AK^W#\&?B7XVL?AUI]IXL\.^(=<1AHTOBBQT6RTN_P!2P%&A)K6@
M>)O$R-KRJ,M%\I88"MNP&_*+QA_#^-><?"7_ ).(^!W_ &6'X7_^IKH-;.*U
MW^\#^G>BBBL0(&Z-_N#^2U_F]_\ !>G_ )2P?M8?7X%_^LT?".O](1NC?[@_
MDM?YO?\ P7I_Y2P?M8?7X%_^LT?".OV+P(_Y+/-/^R0QO_NN?%\??\B1_P")
M?^DGY!4445_6Q^1G[&_\$1?A.?CK^U#\8O@FNL/X8;XP?L5?M,_"@>)X]-2[
M?1?^$V\)P^!O[831Y7AB\0-X4_MKY8Y9(HIS^YE=(Y&(_'*OWQ_X-NAG_@I'
M9?\ 9!_B?_Z'X>K\P_V\OA=;?!;]MG]JWX7:3X0N? 7AWPA^T%\3K3P;X5^Q
M?V9_87@)O&>O:_X$.A\<>'#\.#H7_"$#MX+/Y?'99F-O$#.LF_GX*X+Z?\^W
M*/KM4T6VCZZ'NXG#?\8SDV-\W^2>WYGR57[Q_P#! 3]IC0_V9_C[^U)XI\8Z
MU?GP3:?L7_%[XG77@#2[M#JOQ$\5? ]_#_Q3&F>'=$=6&N^*8?ASI'Q5>(@;
MMX\3*<!C7X.5U_@7X@>*/ASKVH>(O"%Z-/U?4_"/Q.\ 7ETUD-4 \,_%3X9Z
M[\*/&^CX(X*>'O&^MNK8!5@",$ UZ7%&12XDR3.LCC+ED[.,GTE&<)7>C;3Y
M6G;6S^:\S*\5]3QJQW1/\T_\[G(4445[YRG[<_&[X7Z%X _X(0_L7>)=)FU#
M^T/C3^V3\7?B=XEM]58%K'5M%T3XA?"<QZ,, KX>3PS\*] < DY28,,!J_$:
MOZ^/^"[?PMUKX(?\$M/^"<_P:\1/H]YXI^%%Y\+/AGXCNM"4)8W?B3P-\ KC
M0M8UC1%"JPC/B+1#) ' D,<H+X)K^0>OA/#K-%G619IF*::J\7\8U4TXM.-3
MFG%J44E)<C@XR2UC)2N[W?N\387ZGC?J*_EC]_+KOYW"BBBONSPC_1W_ .""
MG_**']E;_?\ CM_ZTE\7Z_8@?<;_ '/\*_'?_@@I_P HH?V5O]_X[?\ K27Q
M?K]B!]QO]S_"OX XL_Y*[B[_ +*K,/\ U*J'[[DW_(IRS_KS#_TEG\=/_!TW
M\8[>75?V3_V?=*\7O]JM++XE?&#QYX!']I_9]NL#0_ _PF\7W/D*(PJII/QN
M\.VZ*P/E7'B8M%&[$O\ R+5^V_\ P<+_ !5USXE?\%-?B?X9OAI":1\%_ GP
MP^%/A"YTV0R?;]+/@H?%G7#K.9)%CUYO$/Q2\;>&D1"H T+PP619&<5^)%?V
M%X7Y<LK\/LDPZ7+[:]>SW_>OG5[QB[\KA=-:?"FTDS\>XEQ/UK.,X716C\DK
M>?8*_<7_ (-W?A;K7Q _X*:_#WQ3I>HZ?9V'P4^'7QB^)WB*WNDD-]?:9K'@
MH_ \Z)IDB(RPZR_B'XG:+XDGDE*1E-"\3Q!Q))&K?AU7]7?_  :O_#+P_J7Q
M1_:[^+][:WY\3>#? GPO^&_AJ]:\WZ>?#7Q.U_QQXD\<0QQ8!=Y-?^%/@QE9
M6!C,0.&#96O$W%+!\ <88Q_;E3I[7NZDXP6G9ZJ[=EN[K1KAK#_6LXR=]DY?
M)*_GVV^1^>G_  <'?#SQ%X._X*B_%_Q#KEE;V^D_%GPC\'?B%X3NC>+NO?#6
MC?#+0?A6RLH^Z1XC^%WC?"GD*P)SD$_B?7]0G_!TA\--8TG]IW]F[XT2WFEC
MPWX[^!6H?#/3H$4#4;;5_A5\1=9UW6YM;(!#>'3'\;M 0<EU1/$@;"["?Y>Z
MZ/#G$K%>'W!N+7+:'-3]UMI.E.=.SOKS)17,GM)M:I(.)</]5SC.'WM+5=&D
M_NU"OZ2_^#8OXNWWA;]L7XN?!^\\3:;HWAKXR? G5-8LM!NVT6/4O%?Q.^%'
MC3P_+H4>DR@-*FL>'/A]XR^)OB*Y\+11S'8_B5I(6B\'.Z?S:5^B_P#P21^*
M,OP=_P""E/['GC"+17\1)J7Q?TGX4-9QW8TYK,?&[1]>^!AU8H4??'X8'C7_
M (2.5 N9(M#=%(+!AOX@9<\TX'S["I)NE3E6C=I>]1BZRU::7\)ZK5*]FFTS
MGR/$?5<YR?&/:3L_GI]^O];'^G;_ /&Z_FZ_X.@_^3"?@Y_V=[X#_P#5-?'V
MOZ1?_C=?S=?\'0?_ "83\'/^SO? ?_JFOC[7\>>'?_)>\&_]A^'_ %/U_B/_
M )$&;_\ 7NI^<3^$"BBBO[O/PT*]=^%'[0'QZ^!8\0CX)?&WXP?!\>*/[+_X
M2,?"KXC>,/AS_;W]A'7SH7]N#0/$?A(>(/\ A$SK>MGOSKXYZ5Y%148S!8#,
M(.&8PIU(.W-"I"%2$K.ZO"I"<'9I-7B[.S5FDT)M.Z;3[IM/[TT_Q/IKQ1^V
MM^V5XY\/:KX0\:_M;?M-^,_"7B6S?1?$/A7Q5\?_ (D>(_#6MZ5(09-$UK1-
M?\1 Z]YAY?!&[&6S@&OF6BBN3!8'+LNBXY92I4HMN3C2ITJ,7*R7,XTJ=.+=
MDE=INR2YK))-XIXS=M^K;_%MVMN%%%?HO^PA_P $Q?VH?V^O&&D0_#WPAJ7A
M/X,C5OLGB_X_^*='_L_X<^%=+(D_MI= C!W?$'Q))Y3K%X4\)#]Z^N^&(O'7
M_"'^!B/&5/-\WR[(\ \QS.I&G3C:\IR45=[)7=Y2>T8Q4I2>D8R=[=&%PN-Q
MG^PX%7?E_7_ ^1^M7_!L+^S]XFU[]H?XU?M,:AHEO_PK?P!\+?\ A4VD^(-3
MTK6$:]^)?C77/#NO%_ ^M_\ "/#PU(OA3P!X*U2'QO#_ ,)9/XQ\)'XB>%X)
MX6M_&4S+^GG_  =!9_X8*^#I_P"KOO O_JFOCWC]!7['?L<_LD_"3]BSX&^%
MO@3\&M$MM.T+05:^\1>(!;R'Q)\0/&<ZP0:]\0_&FK7*M)JGB3Q/]EB+11NM
MGX8\,P^'O!?@Z*R\%>&?"]G9_CC_ ,'09_XP+^#P_P"KO? 9_P#,-?'ROY(H
M\2U.+/%_),\J77M,PPZIQ>O+2BYQA?M*7+.<EWDEO'7]1Q.6+*>$<UP:UM2J
M7?=OEO\ *UDN]C^$*BBBO[$/R4**** "BBB@ K_2;_X(J?M$6/[1O_!.;]GW
M4_M.FGQ5\*O#2_ 7QOI.F-JQ.A:M\)A#X<T"+5AK>VY.L^)/AY'X'\8W0D#X
M?Q/E)#'F*/\ S9*_JM_X->OVC;G0?BQ^T!^RIK5_?#1_'7A/3?C+X$M+CQ'"
M=)T_Q3X)U9_#_C?2-*T)\2'7?%&@ZYH&%A)8>$/A&CR+Y2.T?Y1XT9)/-.#X
M9A!7?#=2',M_W<Y*%3S]U24]/Y'?2Y];P3B%ALV<7M*+7ZK^OUL?VMT445_'
MQ^QG^5U_P4(_Y/[_ &W/^SN_VB?_ %<OCVOCROL/_@H1_P G]_MN?]G=_M$_
M^KE\>U\>5_?G#'_)-<-_]@F$_P#43"'\\8O_ '[./\;_ #84445[AS!1110!
M^OO_  06_P"4L'[)_P!?CI_ZS1\7*_TA%Z+_ +A_DU?YO?\ P06_Y2P?LG_7
MXZ?^LT?%RO\ 2$7HO^X?Y-7\D^.__)9Y7_V2&"_]V#]<X!_Y$B_Q/_TD^.O^
M"AW_ "8'^V[_ -FA_M+?^J:\<5_EAU_J>?\ !0[_ ),#_;=_[-#_ &EO_5->
M.*_RPZ^V^CW_ +AQ+_W*_P#J/4/$X_\ ]\R;_%4_]*04445_0!^?':^ /B+\
M1/A1XEL?&GPO\>>-/AEXUTX:JNE>-/ 'B/6/!GB2R77O^)#KRZ+K6@Y\3,",
M@@C!KZ&_X>#_ +>O_1[7[7/_ (DU\8?_ )I*^1**X,9DV69A)3S+(*%2:7*I
MU*-&I-1O?E4ZE&I)1N[\JDE=WM?4ZEB\:MFUZ.2_)HL7EY?:E?ZAJNJW]SJ6
MH:I>?;;R\N[W^T=3U#5/3]??'3K5>BBN\Y0K]*?^"0?P'\4_'[_@HK^RYH/A
MZWU.WMOAY\4O#'QQ\9>(;/PYJOB/3/#_ (6^!^M?\)RTFNF9EC\/IXG\0Z)H
MOPTD\4'<?^$P\=^&@J.V$;Y9_9U_98_:&_:R\6GP+^SU\)_%GQ.UVT*KK!\/
MV9TWPWH;N^NI'%XT\:Z^#X;\!RRR:+K4<47BCQ?X0DED98XT9V53_H"?\$K?
M^"5WPU_X)S?#FZO[Z\TCQ]^TUX[TFUM?BU\5[+3YDTS3-.%TVK1?#'X71ZPZ
MW6B?#CPW=#?--*5\2>._$J#QMXY3R_\ A%_"W@[\O\3N.,GR#)LZRR"4N(.)
M(\LHIKW(5$XN<U=N*<7/D35YRMRIQ4I+Z7AK),9FN-6.VR-:KS:::M\TK]NO
M8_8&BBBOXW/VL_E'\-Z]KFO?O]<US6]:[?\ $VO/[2Y_/_)ZU],>$/\ EW_'
M_P!FKY/\$_ZJW_WO\*^N/"'_ "[_ (_^S5T'+AMOD?2'AW_EW_X%_2O4-3\!
M^!_B1HW_  BOC_P=X2\?^%[K_3;SP]XX\-Z-XD\,7XY_Y@?B#TZ?GVKR_P .
M_P#+O_P+^E>\>&_]=_WU_*@ZCQ;Q+_P3?_8#^(?A?4?!WB/]D/X!6ND:H-+%
MY>>"/AOHOPW\2C.M?V]_Q(_&_P /_P#A$O$V@8P#_P 4IXP/0CID5\1_&;_@
MW+_86^)R:A>_"35OBS^SQKP\-G1M(M?#_BT?$CP._B8A\>,=:T/Q_)XN\4:\
MT9",_AGPK\7/!RE=!"CY]S#]M='_ ,?_ &:O2-,_B_SZU[&7\4<7Y6U+!9U4
MC)7^"I**^SO&\HR^%;QVNMI._FXG),HQ?^^Y.OFD_P#@I>A_!O\ M0_\&\W[
M;_P-A\0>)OA WAG]I_X?Z8E_J"OX)B;PY\63IFC:+-KVNZOKGPNU\'^WFC$/
M_",>#?"OPL\7?%[QIXR\R$'YY-E?A=XC\.>(_!7B+5_!_C#PYK7A/Q/X8UC5
M-%\1^$_$.CZSX;\3:%JFA9_MW1=;T/Q!_P B_P"(CUZ_B:_UR+,@@8Y'S?Y.
M?ZU\>?M6?L'?LN_MM>'KCP]^T-\*_#_B+4QH\VC>'/'NDV?]@?%'P&94+0MX
M1\<1,FOV<,4FH76O_P#"-2FX\&7=R GC3PGXF3=;2_JO#'CMF>"M@^)LIABJ
M3M[R4:=9=+^XW1J_)4I^3;T^3S/@' [Y-[KU>NWXZJWG==S_ "XZ*_?_ /X*
M&?\ ! CX]_LL6^L?$_\ 9RN]:_:8^!-JNI:UJUMI6BLGQM^'.G_V_);Z/#J_
M@K0@H^(.BVVBPZ+;7?Q(\*8N;.<^)/&MSX"\$^!?"T7F?@!7]&Y#Q1DG$N"^
MO9'G+35E*$DXU(-J_+4@_>A*VMFK-)N,IQM)_FV99;C,IQGU+&[/9[IZ[I]5
MZ?.VP>&_$GC#X9>,O"_Q-^'6N:EX2\<> _$>E^)_#?B#2;S.IZ#XHT+6O[>T
M+6M#'/\ ^JO]##_@DO\ \%E/A)_P4&\'Z!\./'>J:/\ #?\ :\T+2I8O$?P[
MOYEM-)^(YTG3HY=<\9?"E]T0UB.*WCDU[Q9X1?/BKP4XUPO%<^#(8/%MS_GG
MUGV<WB/PYXCT?QQX US6_"?C#POJ^E^)O#GB#P]K&L>'/$VA>*-"UK^WM"UK
M0]<\/_\ (O\ B$^(O^9I[YXK\X\0/#;!\0X/Z_@+*:349-7T>MGLW%NVEU9Z
MJSW^DX:XE^I_[%C?^&9_L'<..N/Z8_/U]^M6/EV_[/X]S^?7\J_E+_X)7?\
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MZ=ZU?@C\/O&'B/XW_"/5]#T47^GZ5\4? NMWE]:WFC$)I>@^,]!U_76(#*Q
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M_J#AC_DFN&_^P3"?^HF$/RW%_P"_9Q_C?YL****]PYC^OW_B*V;_ *,,B_\
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MQ_\ 1J$G_A]/V;/_ )]5?J'^N/!G_19<%_>__D#YK^P\Y_Z$[_'_ "/Z_O\
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M\>_V(00 .221A0/0<8K_ %4B<E,GJ",>V.!^G;_&OXD?^"LO_!([]O[]I/\
MX*!_'SXV? K]GZ/QA\*/';_#2X\->([?XF_ WPTU\?#OP>\!^&]<$FB>)?B)
MX1\5*?\ A)-#UH+)+M6X7]_"7A=6KVO!?/\  Y%Q!F<\QS:.'HU,+*+JSJ0I
MPA4C7C*%&2;2<W&<W!Q322FFTGKYO&F78S'83+(X%>]&KK%)MV<5KZ:??;0_
MEOHK]?/^'#'_  5C_P"C4)/_  ^G[-G_ ,^JC_APQ_P5C_Z-0D_\/I^S9_\
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MS9_\^JC_ (<,?\%8_P#HU"3_ ,/I^S9_\^JOZA_UQX,_Z++@O[W_ /('Y?\
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M?8?_  X8_P""L?\ T:A)_P"'T_9L_P#GU4T_\$&O^"L(Z_LHR<?]5T_9L/\
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M^)>L?%3PKH>M_P#"O_'EY_;6L>(?^0E]@\4:[_R'?[<QQ_PCO_$\''_0Z?\
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MWAL>*)K1?!/ASX(P7?@KP7X\\*^,E'VE117\SGZB%%%% !1110!$1Z(?U/\
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MJ8SZ[DVC[.WS]?D?N'_PD?\ TW_7_P"QH_X2/_IO^O\ ]C7P?^SM9^./AO\
M!+X;_#GQ_KG]M^*/ ?AO2_!?_"0_;/[2_M_2]"_XD.@ZU_;G3Q!XB_X1S^P_
M^$W/_0Z8^M>T?\)5_P!-O\_E7YP?2GT1_P )'_TW_7_[&C_A(_\ IO\ K_\
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M444 ?D+_ ,%S/^45W[7'_8#^%/\ ZNOX7U]2_P#!//\ Y,$_8A_[-"_9O_\
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M(?\ Q'7P?_\ /HH_X?\ WP$_Z,M_X*0_^(Z^#_\ Y]%<_P#J-Q?_ -"/$_\
M@NG_ /1$']N9/_T-(_\ @<?_ )$YG_@VI_Y1TWW_ &<'\3?_ $R>!:_H'/\
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MIXSU[Q+<QO>?%K0OBA:K +;3]Q_6TJHRQYR.G4\ 9^G?'I].:_GM^(&CS?\
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M'Y?PP_Z,(_X*@_\ B+FB?_/=H_X?E_##_HPC_@J#_P"(N:)_\]VO,_U$XO\
M^A+B?_!=/_Z(SL_MO*/^AK#_ ,"7^1^Y]%4X9A+##*O G&0)^& YX ]3U Z'
M/7FKE>">D?S8?\'/_P#R87\(O^SO_ '_ *I7X\U_1X_?_<E_] -?SA_\'/\
M_P F%_"+_L[_ , ?^J5^/-?T>/W_ -R7_P! -?6YI_R0_!7_ &'<8_\ I7")
MX&'_ .2BSO\ P<-_^DUBTW0_0_RK\F?^"XO_ "BQ_:P_[%SX;_\ JY?AW7ZS
M-T/T/\J_)G_@N+_RBQ_:P_[%SX;_ /JY?AW7E<*_\E3PG_V5."_]2X'9G/\
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MV Q/3W R>3UJ[7.=04444 %%%% !1110 4444 %%%% 'Y"?\%S/^46'[6_\
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MHDF_2]_Z]3\3_&OQE_;N_:Z_X*+>)?VW/V%?V<?!_P"U#\"OV/K_ ,=_LI_
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M"?[1NDZUIITK6-*^,WPQCTF+7;K6-+7PSX.T32+[QMX?UK0?B5-X<\,>'?\
MA&/!@\<#P9#<M/X9G5_TC:/>BE",\'=C!;9V)P,$ \=L>]?SV^%/"/B_]AG_
M (+<:AHOA/3()/V>/^"J'@?QQXSOK>TET?3!X6_:$^"FAZ[XZ\8ZN8YW\4^+
M=?<2S:WK,JLW@/PM=7?[2,T44/B>3X5QQ1[4\SH<2Y+F.2_V7A,EJ9-[7BG
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M0@ACTQ'LX']TISU'IS[_ *_R#?'_ /:X\(_\$R_^"Z'[5?[3/[0'@?XA:O\
M#7XV?LP>"=#\ -\,6\'>(?$&IVJ^'OV>].GU6]T?7/%7A2ST'1(]7^$GBK0Y
M$E>3Q1*FG6%^D#VEU9EOL. <)BL?1XOP>#C[7,Y\&8E>R5G*I-8OA.5113E%
M/6+^TMMTCPL\Q$<*\GQ&);BO]9J,5*WPJ4:L8-^B:>Y_81D?['Y'_"C(_P!C
M\C_A7\UW_$4)^P__ -$/_:N_\)?X/_\ SZJ/^(H3]A__ *(?^U=_X2_P?_\
MGU5A_P 0ZXZ_Z).M_P"4/_EA7^L61?\ 0T7WS_\ D#^E GY0""#G//3_ #ST
M_&F,H88/&,]NO7V_ @XZ#GT^'OV$OVZ/AK_P4#^#VJ?&WX1^%?B#X7\+:5X\
MUGX=/:?$>R\+Z;K5_K.@:5H6L3W8C\-^)/%D$6E;/$%O%$S72W)D>8BU5$K[
MDPHR"3D'''I_GK^E?,5Z&)R_$RP>+3C4A*46O=YH3BDW&7+*2O:4>KW6S32]
M/#XB&*@L5AG>^S:TDO1VMIL?@G_P<5_![5/BC_P3=UWQ3I5VRGX#_%SX9?&2
M[TRVL5OCKNDEM?\ A7JUJ(U.#]FM_BH?$N[M_P (\2 2S$?L[\+O'GA7XO\
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FX6W?_&LJ;U>OUNFKZO6UM+[VZ7MT/+_L+C#_ *+"7_@#_P S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2011417d1_424b5img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011417d1_424b5img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 S$# 2(  A$! Q$!_\0
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M\@F6)89'BF(,R#H'/?Z]:.:%MA<M2^YR4DJQW&I>9$)0WB&%,,S#;G'(P?\
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M$"[$#')Q]:4I)Q2_KJ.,6IM_UT+5%%%9FH4444 %%%% !1110 4444 %%%%
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M %?_ #.8_P"$3N_^AFU?_OX/\*/^$3N_^AFU?_OX/\*Z>BCVDOZL'LH_U?\
MS.8_X1.[_P"AFU?_ +^#_"C_ (1.[_Z&;5_^_@_PKIZ*/:2_JP>RC_5_\SF/
M^$3N_P#H9M7_ ._@_P */^$3N_\ H9M7_P"_@_PKIZ*/:2_JP>RC_5_\SF/^
M$3N_^AFU?_OX/\*/^$3N_P#H9M7_ ._@_P *Z>BCVDOZL'LH_P!7_P SF/\
MA$[O_H9M7_[^#_"C_A$[O_H9M7_[^#_"NGHH]I+^K![*/]7_ ,SF/^$3N_\
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MH_X1.[_Z&;5_^_@_PKIZ*/:2_JP>RC_5_P#,YC_A$[O_ *&;5_\ OX/\*/\
MA$[O_H9M7_[^#_"NGHH]I+^K![*/]7_S.8_X1.[_ .AFU?\ [^#_  H_X1.[
M_P"AFU?_ +^#_"NGHH]I+^K![./]7_S.8_X1.[_Z&;5_^_@_PH_X1.[_ .AF
MU?\ [^#_  KIZ*/:2_JP>RC_ %?_ #.8_P"$3N_^AFU?_OX/\*/^$3N_^AFU
M?_OX/\*Z>BCVDOZL'LH_U?\ S.8_X1.[_P"AFU?_ +^#_"C_ (1.[_Z&;5_^
M_@_PKIZ*/:2_JP>RC_5_\SF/^$3N_P#H9M7_ ._@_P */^$3N_\ H9M7_P"_
M@_PKIZ*/:2_JP>RC_5_\SF/^$3N_^AFU?_OX/\*/^$3N_P#H9M7_ ._@_P *
MZ>BCVDOZL'LH_P!7_P SF/\ A$[O_H9M7_[^#_"C_A$[O_H9M7_[^#_"NGHH
M]I+^K![*/]7_ ,SF/^$3N_\ H9M7_P"_@_PH_P"$3N_^AFU?_OX/\*Z>BCVD
MOZL'LH_U?_,YC_A$[O\ Z&;5_P#OX/\ "C_A$[O_ *&;5_\ OX/\*Z>BCVDO
MZL'LH_U?_,YC_A$[O_H9M7_[^#_"C_A$[O\ Z&;5_P#OX/\ "NGHH]I+^K![
M*/\ 5_\ ,YC_ (1.[_Z&;5_^_@_PK2TC1YM,EE>75;V]#@ +<,"%]Q6K10YR
M:LQJG%.Z"BBBH+"BBB@ HHHH **R;_7K:SO5L8V2:]*[S;J^&"?WJ=8Z[:W=
MT+*1EAOBN\6['YBOJ/6BP&I15'6-0&DZ/=Z@T9D%M$TI0'!; SC-<5H?Q6LM
M9M-5G;3Y;8Z?:FYVM*&\P=,#TYQ^=7&G*2ND2Y).S/0Z*X;PA\2+?Q9<7T2Z
M=):"T@\]F>4-D9Z<"F>$?B;:^+-:?34T^2V<1-(CM(&#8/3&/>FZ,U>ZV#GB
M['>45Y5_PNB,BX=/#EV\5N<2NLP(49P">.,FM:'XI6%SK^F:;!8RM%?QI(MP
MS@; P.<CVP:;H5%T%[2/<[^BO-U^+,4FCZCJL>C3M9V<Z0*YF \TL3TXXX&?
MQJ*+XN32VK7?_"*:B+41M)YY;]W@#^]MQ[4>PJ=@]I'N>FT5Y;!\9[9OL\US
MH%Y!932^7]I\P,H(QG''.,C(KU$$,H(Z'D5,Z<H?$AQDI;"T445!044R65((
M7EE8)&BEF8G@ <DUSVF^-=+O-&EU.[+:?%%-Y++<?>R0"IP/[RD$52BVKH3:
M1TE%9,WB72(;:2X-[&R(64[>265-Y ]]O-5[+QEH-]'8LFH1H]\H:&*3ACGC
M!'8YX_E1R2WL%T;U%<_/XMM+7Q6="GADC(M_/^TDCR^ 25^NT$_A4.B^-]+U
M6QFN9B;(Q>8S1SGYO+4@;^.W(_.G[.5KV#F1TU%<]>>,](@BG^RW,=W/ \:2
M0QMAAN<)GGK@GFGW7B_28H[U;6[@N;FS&9(!)M/W@IY/'!-')+L',C>HK"'B
MO3I?$L&AVTBSW+B3S2C<0E #@^N<]J?;^)[![74KFY;[)!87;VLCRG@E<<C'
MKGIUI<DNP<R-JBLJ/Q+HLL7FQZC"T?EK)N!_A9M@/_?7'UJK;>,-*DMIYKJX
M2T,#R*Z.V2 LAC!X]2.!UHY)=@NC?HK#E\8^'8! 9=7MD$Z"2,EN&4D@'\P1
M3%\7Z4\JO'<Q/9&W><W(?@;7"D;<9ZFCDEV#F1OT53L]5L-0M([NUNXI8),[
M7#8!P<'K[U#JFK?8+:*2WA%U)+,L2HLJIR03R3P.E+E=[!<TJ*Q;/Q-9W4#3
MLLD40CC<%E+$[@QQ@9Z;3STJT-<TPW8M1>1F8@$+SW7<.>F2O.*?*^P71H45
MEQ^(M)FA:6.]1T!5?E!))897 QDY /3T-1W/B33X9;2**99Y+F2)$"'H'/!)
MZ=B<=>*.678+HV**SI]:M+2>>.ZD6)8V5 <[BQ9=V, 9Z U"WB.R2ZAA)9UG
MD1(7B&\-N0N"<=!@4<K[!=&O165;^(+*2V@DE<1O*I947+COP& P3P>*9;^)
M+&X@2YW&.V>%9%>0$,=S;0-O7KZ=:.678+HV**RSXCT<&(&^CS*-R<'INVY/
M''S<<]ZDN]8MK"Z:*Z=8HUC5RY;G+-M VCGDTN5]@NC0HJFU_P"=IWVO3XOM
MF[[B*P3<<X.2W3'-9 \7PM;PW*64YMRB/<.64>0'8J,C/S<@].W--1;V"Z.C
MHK G\3_9;RXL[C3YDN5V>0F]3YV]BB\@X4Y!Z]N:T]-OO[0M/-,+0R*[1R1,
M02CJ<$9'!^M#BTKL+HN4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-9U&
M73X8O(C1Y96V+O)"CCJ<5IU7NK*"\">>F[8=R\XP: /$[CPWXO\ "NOCQ:1'
MJBJYDN#"Q)*'[P*GG&/3IBO1(KKPYXVTVWOK.<-/;MYD;(^R>!NX]?PZ&KEO
M>:GI5U/:ZG$DMG]ZWO8Q@$?W''9O?H:\]D^&SZKX[DO--D^RZ,["662-\$-U
M:-0.>?TS73S*I\3LTM_T,K..VIVVMZC+?^#O$:RJH\FV=05[Y4]:\#M8KJUL
MK4VQ;&K(]JX^D@&!_P".U]-3Z-8OI-SIRVRBWN$*2(AVELC!Y_K7-0>$?#=A
M9:0[V,J+9S/<6R^:7VL?FY]>@HH5E3BTPJ0<G<\K\.W!T&+QOY3;6ALS;H?<
MR;/ZU5\#W]KI?C7P]- [$O\ N;G(QAG++CW&"IKUA/ WAF\N;J+['<#^T52>
M<_:&&<DN/UJQ<^$_#5XMO)<61B&DQKY3QRXX'3<1U/ Z^M:O$0=[WU_RL3[-
MZ>1X0EQ?V^FZZEN$-I,Z1W61D@;R5QZ<BM36]*FCUW1=-TJ5IYI+" 0N/E+%
MU)/TZFO6HO!OA>VTVYCALI7BU,;9D:<DY5MV!Z'-6+;P5X>L]:M+J*TN/M&G
M1J86:=B0%&0,=^OK5/%1O=+^K"]DSRFWO8I/@[J&GA%6>UU*-G]2&Z$_D1^%
M;FCO>Q?"O4Q>:[9S6DNGL+6P5E$L)W'.>YKM9OA_X8EAOY4LIV%R%GF1;DJK
M<EACTP<U7_X5GX1M7):PN%<V[.V+ACQP"/UJ'7@U\[_D-0DCR"R2ZOM.T+2[
MN9(-)N+]_+E"997)56)_,8^M?4*KL15'0#%<-<^ _#T>@6UC)I\WV>"Y:6,+
M<DE&8<L6].!7;PD&&,JVY2HP<YR,>M95ZJJ6MYETX..X^BBBN<T*6KZ<-6TF
MZT]IGA2X0QL\?W@IZX^HXKG/^$*TVWN?/T[49K-UDCEC&\2A'163/SYSE6QC
MV&*YSXS>(+_3K.QTRSF>".[WM,Z'!95P-N?3GFO$_.E_YZR?]]FNVA0E*%^:
MUS"I42=K'THOA*V_M(W3ZO*\9E><PG8 9'B\MFR!GISBJUMX'L;>YM)SJ?G-
M#'#$PEC1MZQ'Y/\ =('&17SIYTO_ #UD_P"^S1YTO_/63_OLUM]6G_-^!'M5
MV/I77/".FZ]/=37%])&UQY/,; %/+W< _P"T&(-4M2\&6MQ<67D3IY0U%KJ?
M+@?NF )B '4$HGY5\[^=+_SUD_[[-'G2_P#/63_OLT+#27V@=5/H?1<7@738
MO.1+_$32;XQL3<G[T2$;NI&1BE/@>P:)H'U65H%21+:,[/W(=P[<]6Y&.:^<
M_.E_YZR?]]FCSI?^>LG_ 'V:/JT_Y_P#VJ['TO8>%[73]:BOTU.1XH9)Y(;=
MMFU#*<OSU//K4%SX/M[E+^%M786]W>?;1'L3]W+D'.>XXZ&OF_SI?^>LG_?9
MH\Z7_GK)_P!]FCZK*]^;\ ]JNQ]&/X'L6\O9JAA!14G6*.-5EVR^8.,<?-Z=
M:;)X#TUC<M'J4D;7$_VB3[I!D$A=6P?3<5QW%?.OG2_\]9/^^S1YTO\ SUD_
M[[-'U:?\_P" >U78^D?^$,TXVTL)O0/-CA1BB(HS'*9,@#@9)YILW@NS>6XE
MBU>>&28RG=&RC'F2B0CW&1C'<5\X>=+_ ,]9/^^S1YTO_/63_OLT?5I_S?@'
MM5V/IFQ\(Z%;Z?%:W<=O?M&SLLLZ*2-S%B!Z#)JR?#NA+$D-O;6D$0G69TC5
M=LA4$ $?C7R[YTO_ #UD_P"^S1YTO_/63_OLTOJDG]L?MEV/J#4-"M;UI2EZ
M(1)L!10I3"JR@8_X%GZ@4@\/V0CB3[:?W<L<H.5ZI%Y8'Y<U\P>=+_SUD_[[
M-'G2_P#/63_OLT?5)?S?@'MEV/IJY\,V%R\$ANP)($B6/.TC]V&'([Y#FG+X
M=M8[F.2&^6*(20S/"BJ%9X^F/0'TKYC\Z7_GK)_WV:/.E_YZR?\ ?9H^J2_F
M_ /:KL?51TZU.I/>_:AO9U?;D8X0I_(U3M] MK46_DZ@5:"2)U)VG.Q"F,>X
M)KYA\Z7_ )ZR?]]FCSI?^>LG_?9I?4W_ #?@'MEV/IB#PO:036C#46=+8H51
MMI^[NZ'MG=S]*E70(5AA4:D?-MU189,+\H1BRY'?KBOF+SI?^>LG_?9H\Z7_
M )ZR?]]FG]4E_-^ >U78^F5\,6(6YS?,9+F-DE?Y>6:0R%L=N3C'I5^\TRUO
M-12\:ZVL@C&T$8^1]X_7BOE?SI?^>LG_ 'V:/.E_YZR?]]FCZI+^;\ ]LNQ]
M33:9&^CS:?#J+0"61G:12-V&8L5^AR15>;0+><!'OU6%XXXYXD15618VRH']
MWKCCM7S#YTO_ #UD_P"^S1YTO_/63_OLT+"-?:_ /;+L?3?]@(_GM+JOF327
M"W*S%%W(ZG*_50.,>F:UM/@AL+8QFZ$KO(TCR,0-S,<G@=*^3O.E_P">LG_?
M9H\Z7_GK)_WV:3P;>\OP!5DNA]=^?%_SU3_OH4>?%_SU3_OH5\B>=+_SUD_[
M[-'G2_\ /63_ +[-+ZC_ 'A^W\CZ[\^+_GJG_?0H\^+_ )ZI_P!]"OD3SI?^
M>LG_ 'V:/.E_YZR?]]FCZC_>#V_D?7?GQ?\ /5/^^A1Y\7_/5/\ OH5\B>=+
M_P ]9/\ OLT>=+_SUD_[[-'U'^\'M_(^N_/B_P">J?\ ?0H\^+_GJG_?0KY$
M\Z7_ )ZR?]]FCSI?^>LG_?9H^H_W@]OY'UWY\7_/5/\ OH4>?%_SU3_OH5\B
M>=+_ ,]9/^^S1YTO_/63_OLT?4?[P>W\CZ[\^+_GJG_?0H\^+_GJG_?0KY$\
MZ7_GK)_WV:/.E_YZR?\ ?9H^H_W@]OY'UWY\7_/5/^^A1Y\7_/5/^^A7R)YT
MO_/63_OLT>=+_P ]9/\ OLT?4?[P>W\CZ[\^+_GJG_?0H\^+_GJG_?0KY$\Z
M7_GK)_WV:/.E_P">LG_?9H^H_P!X/;^1]=^?%_SU3_OH4Y9$8X5U)]C7R%YT
MO_/63_OLU/::E?6%U'<VEY/#/&<HZR'@TOJ/]X/;^1]<45D^%]4DUOPQIVI3
M*%EN(%=P!@;NAQ^-:U<+5G9G0G?4****0!1110 4444 %%%% !1110 4444
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MZ#5K_P!^6_QH_P"%&ZC_ -!JU_[\M_C7ME%'UNKW#V,#Q/\ X4;J/_0:M?\
MORW^-'_"C=1_Z#5K_P!^6_QKVRBCZW5[A[&!XG_PHW4?^@U:_P#?EO\ &C_A
M1NH_]!JU_P"_+?XU[911];J]P]C \3_X4;J/_0:M?^_+?XT?\*-U'_H-6O\
MWY;_ !KVRBCZW5[A[&!XG_PHW4?^@U:_]^6_QH_X4;J/_0:M?^_+?XU[911]
M;J]P]C \3_X4;J/_ $&K7_ORW^-'_"C=1_Z#5K_WY;_&O;**/K=7N'L8'B?_
M  HW4?\ H-6O_?EO\:/^%&ZC_P!!JU_[\M_C7ME%'UNKW#V,#Q/_ (4;J/\
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M3_X4;J/_ $&K7_ORW^-'_"C=1_Z#5K_WY;_&O;**/K=7N'L8'B?_  HW4?\
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M9J'_ $"C_P!_UH^V:A_T"C_W_6CE8<R-"BL_[9J'_0*/_?\ 6C[9J'_0*/\
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M]:.5AS(T**S_ +9J'_0*/_?]:/MFH?\ 0*/_ '_6CE8<R-"BL_[9J'_0*/\
MW_6C[9J'_0*/_?\ 6CE8<R-"BL_[9J'_ $"C_P!_UH^V:A_T"C_W_6CE8<R-
M"BL_[9J'_0*/_?\ 6C[9J'_0*/\ W_6CE8<R-"BL_P"V:A_T"C_W_6C[9J'_
M $"C_P!_UHY6',C0HK/^V:A_T"C_ -_UH^V:A_T"C_W_ %HY6',C0HK/^V:A
M_P! H_\ ?]:/MFH?] H_]_UHY6',C0HK/^V:A_T"C_W_ %H^V:A_T"C_ -_U
MHY6',C0HK/\ MFH?] H_]_UH^V:A_P! H_\ ?]:.5AS(T**S_MFH?] H_P#?
M]:/MFH?] H_]_P!:.5AS(T**S_MFH?\ 0*/_ '_6C[9J'_0*/_?]:.5AS(T*
M*S_MFH?] H_]_P!:/MFH?] H_P#?]:.5AS(T**S_ +9J'_0*/_?]:/MFH?\
M0*/_ '_6CE8<R-"BL_[9J'_0*/\ W_6C[9J'_0*/_?\ 6CE8<R-"BL_[9J'_
M $"C_P!_UH^V:A_T"C_W_6CE8<R-"BL_[9J'_0*/_?\ 6C[9J'_0*/\ W_6C
ME8<R-"BL_P"V:A_T"C_W_6C[9J'_ $"C_P!_UHY6',C0HK/^V:A_T"C_ -_U
MH^V:A_T"C_W_ %HY6',C0HK/^V:A_P! H_\ ?]:/MFH?] H_]_UHY6',C0HK
M/^V:A_T"C_W_ %H^V:A_T"C_ -_UHY6',C0HK/\ MFH?] H_]_UH^V:A_P!
MH_\ ?]:.5AS(T**S_MFH?] H_P#?]:/MFH?] H_]_P!:.5AS(T**S_MFH?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7K
M6I26,2)#CS),_,>PKG_[6O\ _GZ?]/\ "N@UG37OXD:(CS8\X![BL#^R+_\
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MT_Z?X4?VM?\ _/T_Z?X4O]D7_P#S[/\ F*/[(O\ _GV?\Q0 G]K7_P#S]/\
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M_9%__P ^S_F*/[(O_P#GV?\ ,4 )_:U__P _3_I_A1_:U_\ \_3_ *?X4O\
M9%__ ,^S_F*/[(O_ /GV?\Q0 G]K7_\ S]/^G^%']K7_ /S]/^G^%+_9%_\
M\^S_ )BC^R+_ /Y]G_,4 )_:U_\ \_3_ *?X4?VM?_\ /T_Z?X4O]D7_ /S[
M/^8H_LB__P"?9_S% "?VM?\ _/T_Z?X4?VM?_P#/T_Z?X4O]D7__ #[/^8H_
MLB__ .?9_P Q0 G]K7__ #]/^G^%']K7_P#S]/\ I_A2_P!D7_\ S[/^8H_L
MB_\ ^?9_S% "?VM?_P#/T_Z?X4?VM?\ _/T_Z?X4O]D7_P#S[/\ F*/[(O\
M_GV?\Q0 G]K7_P#S]/\ I_A1_:U__P _3_I_A2_V1?\ _/L_YBC^R+__ )]G
M_,4 )_:U_P#\_3_I_A1_:U__ ,_3_I_A2_V1?_\ /L_YBC^R+_\ Y]G_ #%
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M<&&[!.> , 4D.J7\2+.I=MUM;K+<M Q*9+!B5[D4 =K17.:C>M!>Z%<RRRF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#\^LE']E7_ /SZR4 ']K7_ /S]/^E']K7_ /S]/^E']E7_ /SZR4?V5?\
M_/K)0 ?VM?\ _/T_Z4?VM?\ _/T_Z4?V5?\ _/K)1_95_P#\^LE !_:U_P#\
M_3_I1_:U_P#\_3_I1_95_P#\^LE']E7_ /SZR4 ']K7_ /S]/^E']K7_ /S]
M/^E']E7_ /SZR4?V5?\ _/K)0 ?VM?\ _/T_Z4?VM?\ _/T_Z4?V5?\ _/K)
M1_95_P#\^LE !_:U_P#\_3_I1_:U_P#\_3_I1_95_P#\^LE']E7_ /SZR4 '
M]K7_ /S]/^E']K7_ /S]/^E']E7_ /SZR4?V5?\ _/K)0 ?VM?\ _/T_Z4?V
MM?\ _/T_Z4?V5?\ _/K)1_95_P#\^LE !_:U_P#\_3_I3DUB_1@WVAFQV8 @
MTW^RK_\ Y]9*<FCW[L%^SLN>[< 4 =58W0O+..<#!8<CT-6*KV-J+.SC@!W%
M1R?4U8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEWW_ #ZR?E0 [^V-0_Y^6_(4?VOJ'_/RWY"F_P!EWW_/K)^5']EWW_/K)^5
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MY]9/RI5TF_=@HMG&>YX% '665TMY:1SJ,;AR/0U8JM86OV.RC@SDJ.3ZFK-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %07AE%L?)W;]R_=ZXW#/Z9J>B
M@#&^TZN'5?)5@Y SLQLSSD\]!@C\13!>:L\0!AVLX<?+&<J=O&<\8S^=;E%
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MUN_CGGE9HHC.T"M))EXH<QDDC'J14I\0:Q(D#QQ6\>Y(=ZR(W)D<KD>@X!H
MZZBN-;Q/J*2VL3" R>:8Y5\M@' DV94Y].<<UV5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'!G)4<GU-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 2?VO?_ //RWY"C^U[_ /Y^6_(5'_9E]_SZ2_E1_9E]_P ^DOY4 2?VO?\
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MBJ6KEQI-T8[G[,_EG$V"=A]>*Y-?$=W964"P([-O8-YNZ42X8 E')!QR>QH
M[FBN5.NZF%1Y'MH8I;F2(2-"Q"!"<9P>2U1/XEU+=<%(H2RI*?)\IMT)4@*6
M.>=WM0!U]%<F==U:VN9%N5MWCCE>%C%"^21'O# 9Z=L=ZT?#>K7&JV]PUP$S
M'(%5E0KN! /3)]?6@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2011417d1base_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011417d1base_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0@$D P$1  (1 0,1 ?_$ /\   (" P$! 0$
M      @*!PD !@L$!0," 0 !! ,! 0             '! 4&"  " P$)$
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MN9>355.](L8Z;HJRA3E$#=E7;3J_4Q[TA:EUM0NVJNKC1:4HJ1N]XI(2$G
M"666(D)05:RS6L:4[6EAL50I$KS@25FR@SGRG;QPD'JT,"J&(KZ[<N?9G<))
MN%E%B,M\4LT:%.83 W;!;,N.002 ?L4P7<J&X!V<3#H.TB4CONJB!B;4">4Y
M61^")H\2="-3X*L_.7"[NC%$+A@S=CNB\SNA;TWMI<!(@E-9K-D/(U\;(+G(
MN3'.,LUWXT(R>)%$ %I8K^^:KI\>(&&$4#W!T(=/V+M/>K>M0O)^BI=VVV?[
M1UAO,1RI;!!^6(F5QK]UI*AMR#TW<RE?)0M4O=41^;%#]"HEJRE>J5C*BQRD
MO=<B6RNT>I1B1#'.^L=JEFD)#H"!>(@D+YZ05#> B8&,/8 Z*]75T]!2NUU6
MK+2LMJ6L\24 J/B&'+$19:<J'4L,B;JU!('*3(1U8]KN ZMM;V\8=V]TTJ8P
M.)J'!5%)V1,4C3$FS:@K8+$X((B(/;+8%W4@O]59R8=4$OUWJ+]>:F\5/GJA
MU2Y<0)Z*>9*9)'((L);Z-NWT35$UU&T <YX3X3,^&.4E<?GE<_XXVO[X)'5_
M*;T9KZM'S1%>G/.K^6KRF+K>@;L_VZ[S]SF9,?;E,=HY)J-5P.>Y0,0O8;77
M"L+&7(-2A D@=U&<@7RYO)DFNEW:JIT??\>7F ! 9=[6H[SIFQ4U99'MQ4.5
M>11RH5-.[6J4EI4-H!F!.)3H^VT5TN#K%<C>-)9S 3(QS 3P(X##7_Y!OI2_
M]5-A_*EFO_:/JO\ _5C7_P#QY_=,?ZN")]D=/?\ #C\]?^=%6'7@VE;?MFO3
M#I>,-MV/T<;T><WJ4R[RD&C/VBQ%=6>0Q1D.&>28O;;-STBD9:-@VJ?=$6*B
M'=<0(!C&$9[W4:AO&I=<NU]Z>+U4BV+0%94IDD.MJ DA*1M43.4\=L1[5UMH
MK784L4*,C1JDJ(F3B4*$\23L A,#5EH&$.][1.GULKRGT3*SEV\;;,5R^6I/
M:GENW.LI!66C/(/G77V]^=0EC3M;,$)<LM&N(EL9,_>"4P(@0Y3)\2#5[46L
M-3T'>>Y;J6MJ$V]->R@-9B6\BMV%)R&8D9G@X9C&"K;;-:ZC2J:EUALU)IUG
M/+I3&:1GMF)"$?6JAE6K94X\3J((J'$ X )CIE,8> =@=HZM&H240-DX%(Q
M,6W^5Y+\AEY&\<7\F?E0.?Q+G'N.;\6_QO[#CPX>,_;.']_V^'0]W:/ZI[R0
MWGJ+;_S,O)$DS*^R>2?1[?\ Z*.E#JD\'&$E/: ]\,K:<I.<25"851@J&ZF*
M%6B-%S$(6<0100RO>@Y#<!DDW+A.MQRO$1031=JI"4RAM&+N=TBU?[VJ[5Z
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MEVE>73U"2AY"BE0.T$&1$')"T.(#C9FA0F#Q@QMYH=+^\#P?6^H;^WKE.-H
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M) )EC(R&.$VJ-7(=L?JA#!"]PEO,5"6  )E*>,L!.%R1$  1$0  #B(B(
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M]+GD&4\D?CW^FKAXHIP]%GFAZ"?._P '-Y(\]?>]]P[ON/MO'D]]H4^NZ/\
MK#ZNSIWGJG<[?UN??Y.?)P<>$2WL+_V,[3(Y>V9_R);O-S9O?B[^P0 [K91Y
M,9;LET<NI5505R5^U2<*U13.8P%09-A.\19-DB< (FF $( =@:J&4)X(,R%D
MC@CY%OZ(6T'<*YBI2P6K.]8E(JOLZ]&+URZUUPR9LFJSEP508V>ILH1=RNX>
M'.L<5 %4W#CPX:G^D^\J^:.H%6ZVM4BZ53I<5O$**BHA(Q4E:< $@ 2PB/WC
M3-!>JGM-4MY+H0$C*1( 3.PI/"3. :SY[,)D^+BWL]M7W$0&256Z2JZ- S'
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M^>H>"'S6]-N+X71L=:2KPCHGYH@/.CYAT<X]2K:74E6Q'<77LCERK.IJD!1
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M9QV^AFGV9;;/=(]D5S9MND!#9FC5"(F4=A7FM]N-2OC=(Q0$2MDZG9W#]8/
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M:DLS%ZHL&7T3*=I0L8+0>5*@1RB1V& '<:!ZV5KE"_UT*V_"!Q2H<XQY-G!
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M 0!( 8 <PB2-:1[&:R,C-9&1FLC("3IW^JK6OPJ[GOYT69=2C67M]S^7I?\
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M.M=>DT_L7S:O9W5ZWZWXWP>2))8?-N>G=8>D[=GXO)Q\L3:/YQLOQ+U)S?\
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3_P"8A%_X;_S7_-[/XO\ HX__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2011417d1base_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2011417d1base_img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!6@** P$1  (1 0,1 ?_$ 0<  0 " 04! 0$
M       ! @,$!08'"0@*"P$!  (" P$               $" P0%!@<($
M!0,! P,'% <,$@\$"@,! @,$!0 1!@<A$@@Q$PE!46$B%!49<8&1H=$RU)75
M%E:6UA=7EQA8"AJQP9(C,U.30E)B<M(D-"55)C9W\.&"HK)#8].4-<5VAB<W
MA[<YPN)S@U3$A;5&9K;&1R@X1&1G2/&S=(1E=::825FDM$41  $" P,%# 8'
M!@4$ @,! 0$  A$#!"$%!C%!D1(746%QH=%2$U-4%18'@>$B,I(4\+'!8G(C
MDT+2XC-#58*B)#1$\6-S-;(VPD4(@R7_V@ , P$  A$#$0 _ /W\"-MHT15W
MR]?RA\RB)OEZ_E#YE$5@&^T*(E$2B)1% & >0:(IHBKOEZ_E#YE$3?+U_*'S
M*(F^7K^4/F413<+7ZE$0! >2B((@'+1%(#?:%$2B*!, ;!'[-$0! >2B)O!>
MU]M$4T15WR]?RA\RB)OEZ_E#YE$4@(#R4131%C.%_&"X^34"Q\<T%1S=<ZJ\
MY^/;I(] NCK9::2>NT5J#)M]4W^11V-A@D*SG%$G&,MF#N1&2!Y*1O<Q#)R:
M6X("?>&_):N6PEA.]L1NFR[M;KS8QM,+ N-O.\*2[Y8%63T=GJ7G('TFCH_0
MY,2XB#!<+[N"0QA !&P")2Y2)@"_5ZG*-@VUW&?Y18JI 'SY<ML=UX7 S,=W
M,(2I>L[-D_ZH/TFWH^"[?6OQ!@')O!@\':XC8 [;+ ':;9XNSEK*[RDQC,%C
M9?QMY%E\7W-][0LB?TFOH_5 $4L2XBU2EV&,3 (8Q"]J93MC>NK=)][*)MMK
M %QL%8V^46,6'5U61_\ (WD4G%]S;CM!5OK-71][@J&Q7B((F V,J? 8<J11
ML(B!E?73S8#8+VO<0V@ A64^4>,@YK-27K.R?F-Y%'BZYOO:"H+])IZ/Q2Y2
M8KQ$7 MSWP*& $PV[5#>NNQ"B)1"X[+[!L-JK-\HL923J3&,M&0/;'ZE(Q==
M)_EZVNN4Z>?2+.!74_43!--L=QG7M+(=0<LQS"H)>0PN):QR<OD\JC$1JL@J
M3)E546B;MR45#;AA*0;@ UH5'E=BR[KK?/F2@*< G6+@2#O!;E'BFCK']"SW
MMQ?H' >I?: ;>7[==#%@@NPJU2B@# /(-$0W(/B5CFM+Y;FC*0D86KYPXKN)
M# ^$C0O..(74QMD#W!=.F3)[/-,79(R,ZLG)2C*(;%8,EW+-%<_=;XF\!E"@
M!+CU*ST5UU%[WG)H*>V:<@W\RPU%3+H91GS+&KQ?#Z3+T?=D[XIQ&#OF(D42
MZ>Q1P,H8@F*4HERD1.<P!<"A<]MMK;:]'G>4^,Y+O;9+&M:/S&\BZTW$]T5!
M<X G5)BJ%^DV='P:V[B_$0/)L]84)>P[HWMZ[-H !NIXG+LK.WR=QN6:PERH
M'_N-Y%K>,+EUM7VHBQ6^LT]'Z/G\2XBR$$@J%,II_#E3.!;@.X<<JW3& 0L(
M .P1L.VX5B;Y/XT#R6L82!;^8WD6R_&%T,8'.+H$PR*?K,W1]@ &]:7$44@J
M)I"<=/XD"D44ON$. Y5<@F HB%PMLY:QL\J<7U#C+:V5KC-T@Y%$S%MST[0]
MVM;O*OUFSH^AM^];B(MO;@F' 88 *I<P"F(>NJ^^7=$1  '841K/L<QP![<M
M@_QMY%A\;7-]Y2Z^DP\ S)=R@\P[B.:N6RADG#1WIU%MW#94@F*JBNDIDY3I
MKHG*('(8-XAM@@%8=D>,Y3^AG,ED/$1[8R:%D;B^EB#+!Z)V1>Z&@>KN.Z^Z
M0:>:V8>E*-\1U3Q"!S?&6TT@FUEV\-/L$W[-.1:I*+)MW94E0 Y .>PARUY]
M649NRMFW9,_G2':KN%=FI:DU4H3H6'(NX:UUL)1% B <M$6WO7)&S=XZ.8=Q
MJU7<'W N<"H(F5-NE'8)K%V=FM,FDFU7RPC\V8;OHWLBESH2X[B_/(^^DL\
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M'*H)LP5468$RV7@950[1NFD5,CE/=..\H4,U+=-Y.J)<FHO1G0,UB#KVD'6
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M"];RQ\VB)N%ZWECYM$4B #RT12 6V!1% @ \M$4T1*(J[I>MY8T12  ')1$
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M"[PQ-Q+G%"E.H)27WC% =2IPYB:DE&:63Q +'0XPPW.J-4396KN0 ^I??2.
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MP=D$[C]BD*CFLT+3BZ.29QI;K 80ZXD$!\BU(5'-;H5Q+:X1=TD?2FZ'Z/\
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M@^=[2XP?HR>%1%HT?K<56K"+-^TE'S-5;06114=-H=NS<OU&[50Y7:Y6Q)!
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M4-YW?,#P.V&^S: U&S5_6MXN5-J]3_QI9+]^.10/27:F]7 ,#$0.4US+3P&
MQ;" ;W=MP'D'L]6IV:OC_,'%RIM8O3]N5[&?+DSJ3=)7J:( 0^GN"&W $MCK
M3^]80$H@;]=@/4'QP&FS.;SQH'*J;6V<TJOA*M3-Z_O?X,([@$$HN<@, DM8
M+W>"-]O+RU.S*=F?Q!6VLB'N.XU8_25:F*$!,VG>!B4OG2\[/6*;=W=X %V(
M :WV>O4;-)G6#0%.U@MRL=QJR?26ZGH;XIZ>X*05#"<QN>GQ-SAAN8]Q>#<Q
MAY;W ;5&S.9U@T!5VLCF.XUC-TE6IAR@4=/\%L!C'"SB> 0,8>6X.P$;!L"]
M]@5.S.;U@XN53M:',=QJP=)5J84-WWN\#W=@;IE9X2V N[:PN[6M39G-ZP<7
M*FUH9=1RU"?2;:I)D*F73_!+%"P!ST]]IX%8W>6<R/OMXDVM?</T]"R>$XU5
M^#_!?RL_Z,JNS.9SVZ FUK[A^GH4#TG&JEMNG^"6_P!UG_1E-F<SGMT!-K7W
M#]/0H#I.=4PY, P/\K/>C:;,YG/;Q)M:^X?IZ%(])QJH/_A_@GY6?]&4V9S.
M>W0$VL_</T]"QCTG&J8#;U@8$ ]85<@OY3L0ILSF\]O$IVLC.P\?(K>$XU2^
M#_ _RL]Z,ILSF<]O$J[6?NN^GH3PG&J?P?X'^5GO1E-F<SGMXDVL_==]/0I'
MI.-5.KI_@GCJSWHRFS.9SV\2G:S]P_3T*?"<:J6_R?X);_=9[T939G,Y[>)-
MK7W#]/0H#I-]5.II_@@_[[/>C*NWRSF0]\: HVL_==]/0@])WJJ%O\7^"#M_
MX1/$  #:81-W4?D* V"VT;!U:S,\K9TXEHF"($<V94?YOB5!Q8X@F&3U+T)X
M7N*&"XB,9.H=-"$SJ&*GZYL7(J:R)5%>;0DHOGC&5<Q3FX!OB(F34N0^VU^@
M7[<-1<<_H9A,(Y=U>I89Q3(O^2)C(!QS+ZTKA%VY*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HBZ/UA_A%H%_'8T_T::F41=W@%@ *(IHB41*(L:OG?'"L,W]G\85)
MGN%?&?'M_P"F+.O_ +3C?+_^<M*[3@TPQ$TKI6/HG"LP#+ ?45^?6.<I,Y*,
M?+MDW:#&19/EFAMW==)-'2+A1L<3E.3<7(F)!N @(&KZ"GR#44C@W+ V[B^8
M;MUI=4#59%WQ%Y9IR<'*D/I4C/N64?/3LZXR%RT 6K1.3(Z;J$*F9-DL5BR<
M&3'=*43F,F&[=/MNK.H+WDRR63@)<! ;F[I7<3/N2IFF2)6M/8;3NE<X(#"0
M%E$8YPUN"GR&"(=9.10,@50JR9),_>IV9N*@$;F03%%R!BJ]MN%"URFTPRMG
M/)J*IOLY+<RW9\Z0&L8RG/LC<1JL95 Q6/#/)'*HJZD(\R3<H 9,S)M"2*J:
MYXX^\#8S82;@")3&,*A@$P"8V&92O UI]2PR[(B.6!CR+'+GRX@-IW%W!O+9
M)?(,5QA,TLKH,:&8KNV3%N\<N6CUNFY-$1SLD>F=W&*%:2BIFQG!@)S?-;ZM
M@WKVO"?6N$NF?&6#8.".F,?J5GUEW2P65-.0[@W5T5E4S"3DDQ=P./I8TV28
M-V[E@BHFLFJ_*H N'O= ))JJF<^>'?N<#&$+B4"@':J2CF4].2_*NF5M5*?/
M IK5YP:@@/OAY(8+ )9T![;SH!=M83"8-P"B(]79<*X=TYLVK,@>P^SVN%=C
MII,V9=K7SAKPC[.?*<R]/L<S_%8O&F&/S&GD#.F30E.[IM83(33H[]4IFG-N
MB% R:<<V'<2$3&,!P*<!  $IMZ?=-7)Z.;\^UX>8!L0=6$+5J2[TIISS2MHG
M2S*M+B"-:-D/1!;7!95CD*T%$V.IR+E"3<.6J[T69RJL)#O4D_9/"]SE+S@-
M8];F3E 034=B8I2BF FO54LWIVGY@:EF>V(CZ(9%D^8E$?[<QX%KU<MPMX[D
M5G6'\TV6>8P\CV4:^9-2H%A$5T9-@Y64;*#W%.BL!U.9*0P&( #O -JQNIIY
M<(5#0R!CNQS0XT$^7GD.T+DQM6\-0.IWNTCQ-,BSV9DE$7Q^[2IKRB7-(,T1
M!H02PK0#G $C"81*)2D,02 :M"?<]Y54YKQ7L@#9[68?;]JRT=\.I&/E_+.@
M8PL^EBX)'9?$M4\21>XS%/4L=FY*4?B5%L@O,MGRQ%$(URX%NJLJA'6,*0*F
M.2X@4Q1* @;F)U"][?SJQKIVJ #$&$%K2:D&+IM.8EQS+E_OBX"DW5*AIVV7
MDG+>:1>R[UXR,J\4?K[\>Y&/:L$8Q@I'(V( -DDB]J'YFY:U)U$YK6N;4LC&
MV!WN7=S+,*D,:XRZ=VL1N+;XG4'%$8=A$Y!I]%SP-&$8R4>D.2*?*JLY1X]<
M/>[V;?NDRKMFND@8#B>Y4KB/;5@-)4.<!*JFAT<Y^D%K4E8X%_2TSC+A;9FS
MK?6>=:/ \6-):3)]P"Y26;$:SSHRZ*9)!X\434!4Q!<&<-CH-A[<I2$3$VT;
M5<W7>D+*^7'A"R_/W-V$_"N Y?-89+!%ABF/>MQ1-237DR&>'<D64</!%@W;
M"98Y0(U8% R@@4H*'.-@  "VY=;:QLV9)J*EKF-,(QW,L#]2T+TF2M1DRDIG
M $1 @5PT3D+YXX>2 ?T0@-;[VR)3R&U#;=]:+)E7.8#-IW1&2S,HYQ,-N\4>
MP*B?ZJJ=)*[0S2K:L_L[M"GGD_T'C" ^66X4UY7:&:0FK.[.[0H!5,.0Q1\4
MY #RS4UY7:&:4U9_9W:%//)]<GC"0?(L:FO*[0S2FK/[.[0HYQ+\]37E=H9I
M40G]G=H3GBWY4[=G8/CB-@O37D]H9I"F$[L[M"GGD_T'C"4WEEN%->3VEFD)
M"=V=VA1SB7Y[R1*'EF$ IKRNT,TI"?V=VA3SI ZI!\4Z8C_14Z25VAFE-6?V
M=^A.>3_0?R>-37D]I9I"0G=G=H3GDQZI/*#RQL 4UY/:&:0D)W9W:$!5,.J4
M?'*;^A$UJ:\GM+-(2$_/3NT)SJ?+O%\3>(/\Z!M[RJ:\GM+-(2$_L[M"<ZF/
MYHH?S1"^48P#37D]I9I"0GYJ=VA290H (_>^K;: ]01M8MS"(@&P  ;CLK;H
MV2)TTAU4QH:TNRC-"Q4F3:B0TEM*]Q=[.3=SKT;X!-!,QR+-8S6AP_E,6PO&
MUSIQR[,RC=?,WYQYI>-3"P@K )%V.CB E5,'-EL("8/+\?W]=A<:-K!.G9 [
M*!FC9N+UKRSPO>A=WAKF3)#@=7)$"V'I7N;7DR]W2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(NC]8?X1:!?QV-/]&FIE$7>%$2B)1$HBH?:6J/+1JZPB-8*KA%I&
M\OE;C"@8S*-",K@9G+(C"&#MUC_.9)/D=*1+4Z<HW6(FX*R34<[RXI[A=T!N
M)@KG,,5@I[\+V,+W@& &4F"ZOBVC-3A_4>_5$1$YAO\ H7C&&@6G8_\ S2Z/
M=?:UR@O]%&"%>K#%5[M;J-HYP;P+Q&9AB[7NUIE6PNX>1;O"Z08ACCQ1]"\6
M6D+!VLS<1RZA([(G!%V#PAB.FBZ3B)5;KH+E..\4Q1"^WE *UYE_5\VR90S3
MZ#]A66GP]14KS-IJUC)ARF(CQQ7,$8)XT+NM>-_ 4/O+1N4S<,H24328$%)H
M5)4D9SB(HIC:Y1*(]41KCW5376ONQ\?\7*M\R',]^\6DG\/[JT*N()K)(HJ\
M:FG9D6Q%2((BEE ))%75665*4A(T L91P?J; -8-E@JIJ&"UMV/C_BSY?VE=
MC'1A+O%H=N^QR+0S.GT5D4>G%3O&/IA*1R3LCY-J\:Y.HF5VF@9LFO?O6!S'
M(@<Q N(@!3#UQK:I;XK:)VO2W?,8X"%@.3TDK6GW1+J;9]>QWP_8%Q8- =/"
MF*/RHM'QL)?Z5D0 /6N/>SM0$PUROB>]'2"TT<VW>7!,PE=K*D%E4T'A7>O"
MST=O#7E&2S>JF5:FXIQ!2S/('*B.*8ZLF7#\<=(@5)L6>BEE>_4J_*H0#E2<
M@BV,(CVB@6&O-K_Q/?(G.D?+NER;/:&7?7KF&,,7*R6V>Z>)U5G$1Z+.!?1+
MWA'UF<Q[1@RF-%(M$!5=/I VG,,_EW+D)15P0K,ZF.-^]C!U'%2)W&0#)M2
MHF4RQE"*I<%)O-[!KMJ)IFG+[61=OF7'1SWELREDAK<AAE6F8<*G$2@^EG;N
M4X9U47ZC)5BP/H_%N6L0BV=OC'1;[L&U44%5BH@5<!-O.A3$"BW.(JFSNOBH
M<03432?Q%8_#5V]GE?3TK6'X5=?$Y5X\1E^'96.(6.;Q[)SH]C>XH5(T8>5>
M/46V.$.*SM1NOS2:9@YM%4Z?.[YDEDH[WJ.T3?B4^&KL[/*X^5:EWPEZN24;
M(L5Y'1)C*L7\')8W-QNFT%&(2I>;Q]+)(G)8YE!B5*/,+%^HUYHXJ"+TI3'
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ME@2;3;D7HD7H8N*6'9M)-76/A\BDUR"VB05U+RB.D7T<L^.B1]"1ZN)-I-_
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M-=_6\:Q"F7?Y$^4.UW1OXE^6]3"FZ^F^ _O*>D?UJR\T3\67^>\VHA3=?3?
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M [Y*T#3H)L!<NF3)#C?3(]DUD46<>MPX:A@].JM*)PQ;-C2W/"W!ZIM6*44
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MV'D$ $*QGSY>3$75(T_PJ? -%UW&5?ZJGJ!\\;#OBIEO=14;>9G]JD:?X4\
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MT!O2U%:D2BBD2B@#%-R#>EJ*1&VT>I2)10!@-R#>U+45J1*)4(L8J$_/!57
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M7:\RDG%T(>[,'U!1WK=0L+V:5<>/O@8 =[Y7'#V8=[>$3:IXB([PD,4Q@M(
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M.CL7B$CB^;8[AQV(/W**C=<)4V0]V(J@!FB3%$QCJB?M"TK,9W?23=2?1P=
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M;(*N@.<J*:BHD*;<*8U@K[DGU$BZZ$U4P:S@(PSKQ)D[I7BF.0V+[1>]'7Q
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M#?T:P-:,T]B)<ILIUES9-S!::8VU:'(L]$9=9$QLB>MT2&'N2.(X<W"QB%*
MFKHV+\5W-A><[7<77E82T6Y1$6<"YNY,.55?.+2?R^)>C\QT$LLS*RDGW&WP
M^, G5"NH=FZPK5I&7?L)!PY38R9(Y6#*Z")? DH=NN(<VH@8% [0;AT^3YY3
MRUAFTS2QA]DV+G)N":MLQS6.@1FM_P"BP,>@L7D7;UJUX_>%;GX]5LD[65B=
M36R G75.CS3==S ID=%05:*)KG*/ZV5+NJ[HJ )LT_SV-4 Y]&"6YK%4X(KK
M1TEF[:J(]!*X.Y69#T@'"R5=HVCEW8G@=3T&[,DD1(L:99TK $;I&.1TFJ'.
M&)N)F!0UDRB),&VUF:C&M_AWOIZ%LT^":_(9BWY#H(LTQMM'Y/$\>>@+5!S*
M>ME";QG']6P&/DW[J,CSL95W'Q+5S"-7*F0-BBHOS2*@*B C?95G^=TE[82Z
M(-X86^A#@F\ X@3!E6UDZ!YXH5(2=(%PE&*Y<)-$RG8:E(W.Z<JLP0,;O,)B
MG,NV, @<""5(+FLF<AQP;<9;+)]&'3#NAN3<^FZG@FOC;-'&M6AT$\N@F*;/
MI#.%I)"21:,UB,6.I_Z\8OW,>5LF<K2% '+->0>MBJ$/=,%CIIG$#& H7;YW
MW?-<.GNULYC;0+! [M@.3(H."*LV3)@@3#.MSE_H_N7XYD@XID/'!PV0TV6/
MC9A1E)8WJDQYJ*EVK=['R*SIU!)MT6KELL7=$YBV..Z(W((5M3?/.DG %ET%
MC66QUO=A;'(CL SI$"UP@XJS;H ,E=<\5/COX6071=N&1&ZD;J,DLX<-VB+T
MQ$D#Q .E 5;.T#H[A![H*H'-"<#$$:'S^I[(4SS'?%BMX$G<\!)7Z/OGN/ST
MQCF4<9.@>)R4(=R1Z.3X7JO#1ZAF0,E7!8Z5>01&$D<J,BA^".83F4W2 80&
MVTWSXN\M&M=.N[G:WO;^3/E51@2>3[P@LOU?C*"K @KQY\*:1S )B\\QU!0#
M<3%Z55<ZJD;S!615&"I1<;PI!N6OO" #(\]Z B/<O^;U*PP'.RZXXU8WT?;+
M"%0-\NKA@7!VQ-(-SLX;49VEW*BJT16<.U4(HZ;%+G'9  %!!01. %*80L+;
MO=\8&Y?\WJ4> Y^9R[)Q7Z,IK[FD<XE,9XM.'F79-)!Y$.EF^/ZC%%M*,C%!
MPR<I*Q9%$';7?*"I! !*8;;!N 1MXN_/<P!_%ZE/@.=G>.-<D^JQ<4_SG] ?
M:]J#Z IM]N_^SCX_4L'@&=SF\:?59.*0.7B;T"$>N&/ZA;?_ / IMZNTVFYV
MQ_'ZEC.!ZEIU0\0]/(GU63BD'DXG= B^+CVH0W\EAU*;?+N;DN8?'ZD;@:H?
M[SVV</(GU6+BG^<_H#[7M0?0%-OMW_V<?'ZE?P#.YS>/D3ZK%Q3_ #G] ?:]
MJ#Z IM]N_P#LX^/U*? ,[G-XU/U63BD^<UH'[7]0_0%-O5V_V=OQ^I8O!-5S
MQQ\BCZK'Q2CR<3N@1>P./:A#_P 0IM\NX6"YA\?J5FX$GN$7/;'T\B?58^*4
M.7B=T"-V Q_4(/L,*;>[N.6YV_'ZD=@2H9:U[>/D4_59.*3YS6@?M?U#] 4V
M]79_9V_'ZE7P15\\<?(GU63BD^<UH'[7]0_0%-O5V?V=OQ^I/!%7SQQ\B?59
M.*/YS^@0=CUNZA;.Q^P*PGSWNXF/<P^/U+9;@2<6@EXC#?Y$^JR<4?SG- S]
MGUO:A!XW[ J[//B[0(&YV_'ZEBFX'J6N@UXA#?Y%'U63BD'DXG- B]D<>U"'
MQOV!5]O=VMM%SM^/U*@P-4O,'/;#T\B?58^*;YSV@(A_>]J$'_$*;?;O/_Z<
M?'ZED& IV76;Q\BM]5DXH_G-Z!>D&H?J?4;>KM_LX^/U++X$G<\<:K]5DXI1
MY.)_0$.L'K>U"'QKBPO4[?+O%@N80_'ZEB. IQ/O-X^13]5AXI_G/: ^U[4+
MT!4;?;O_ +./C]2CP%-Y[>-1]5BXI_G/Z ^U[4'T!4[?;O\ [./C]2GP#.YS
M>-/JL7%/\Y_0'VO:@^@*;?;O_LX^/U)X!G<YO&K?59.*/YS>@7I!J'ZGU&WJ
M[?[./C]2R^!)W/'&H'Z+'Q2]3B>T!#L>M[4(?+%A4[?;N%@N8?'ZEB=@.<7>
M^WCY%'U6/BE#EXG- C>)C^H06\AA3;W=QRW./C]2H[ M0SW7MMX>18S?19N*
M@+B7B=X?]G( X_J&'C"8(\PAY UKU7GK2S*=[*.[!)J2/9?K>Z=W)N6*G@:J
M?[.N+>'D7:.A_P!%\U A=5<.FN(;7[3;*-(H:42D\PQ73N*S-EE.4,6A3JIP
M+24EVC-I%,Y)<A4G:Y!%P1L8XI64W1#3OKSVO*\;I%!22 RJ ]Z(^Q;]U8,%
M-4?Z@@A?L)P[",7P/'(#$\-AF.-8QC4/'P6/8]$(),X:$AHQLFU81D:Q;E(W
M;-&R"8%*4H;;7&X[:^<IU177A4.GU))>7$G?),2O0Z=DBB9T;! 07,R7W=MK
M]@+!6T#$6*\6FUN17HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1%T?KU_![!_XZ-&_](4%1%WA1$HB41*(J'\[_)UA
MJCLK?Q!5?[AX%\/](7@^-:A\'VMV&YE&)3>+Y!"0C:6B557"";Q!/)8APF0R
MK51!<FZZ03-<IPV -<[A-Q9B:6X90\$<(R+JF,#J89>_.T$Z+5^4$G IPIH#
MSJ.D,0D<@@<JB<MD29TU$Q!1(Y5$Y8JB8\Z4"@8H@)=Z]PM>OIZ9?E=\L8@K
MYD9?L[YD0W5]8M.%3@$BW$.MCV/:BXRK+04?C^=N\;SC4=LLZ;*-E'<XBZ,Z
MF';ITB>910+N-S;@IG.<!4 QB5T%UZW[,J'DLBP/)%FCB*[K+OBE=*:YY/2D
M6K92<%/1Q 2(*]QC4"12C"-Y$D8OD^>@P8RJYEFSY\P_;!11JY4C0;%YU(=X
MQ2;@;X=J7>%^8@DB#&0UA;9')_U*QS+PH)WM/=:W(M=I=PU\'V$!BLDTBLJP
MZ?B"3CMY*8[E&I9YYG*NF3R%:.(54^0N,?;1JT"+=N)@: ]*FB9,QRIB6U*J
MNO6JES \1B! 0&8QA'+N[PBL4J]9#9@:3^7&TK3K\'71_3#E(LI#ZINF#I>,
M:2I9+.<Z>&7CT0DTUUVXED54S)&!<# D8 %!%RJ!!5,)RCBI[XOZC/Y$O,;0
M,D<WTR[RVN]Z6&5=.YOP6<($@]398_IY-R>.HF,^2)E6795(*]_I$HJ3<FBS
M<2946SEPMNE55W><<;@&.80-8.PW/>EZ-D%]4S5<=[-F77KWOYQO!ORUN1?6
M7"+T@\KP<QK'AP]8,1,Z#XA*O(7$HV#%2.RG#XR6D%GCI!H[=++M9]N5Z^44
M KO=6'>$.=$+!7G.+\.U-]7C,O*2\!SPT0S^R /L7HN'L955'*;)J0>C;;IM
M7IZ3C$X/&AS"&B3@5MQ8A5BX'B9Q!-PX5>+)7[N,*1!=+F.( &TQC#LN(5UV
M7@7$#Y8+7C5WUSSO-"[&3")PUG+2(<7G!FW4*+?0M5.Y4@.(:?8>)C"@HJLC
MO"+FQ]Q98YKCM$37'D"K> L0<YJ;4KFYA68W%_P?J.CN3Z*.Q.LJ1RX4-@>'
MG56<$,@8AE#+/#\\"?<Y=W>V@)0'KW> L0<YJC:E<W,/%RJP\9'"&;OD!]&Y
M90LPI&J2Z:N&XLJC**Q"@+QCATB>1%(Z[!<A3)B)1$! .H4H!'@+$'/:IVHW
M-GENT+2,>+?@YB6;!E$:(O6;:/;I,D$_6/B@@FS264<%0(H#XRIMU58X@8YC
M'$37,)J> <0']MJ;4KFC[CH< 6L0XP^#ALBNW;Z(NVR3I%NV<D;8'AZ95T&Y
MT%4B*_KX.<3(NU34 IK@)DRB:XA4^ L0<]J;4KGSRSQ+>9?CDX6\@;I-)?2[
M(9)HD9EN)/\ $L:?6+')$19E*9>14/\ K=),$RW-<J?:@-ME!@+$'/;#A4'S
M2N?-+*Q%XW.%,KY"4#2.9+)-504;OD\-Q9-PGNI$0)90KT#[Y$$B$*-QL4A0
M"U@M P#B#GM3:C<W5NBM;-<=W#!/ ^&9TNR28%_8SOOIBF-/ <J?> YQ;NF1
M6N< ;$'>Y;E#J@ T\ X@&1[4VI7-S':%Q]QQB\'[]^VDWVBLD\?,16!HY<87
MC"BA"KMSMU0-:2W! Z*RA+" @ &$;=8,!8@Y[5.U*YNK<KDXR>$1 '0-M%Y%
M$7:::*W-X5C!"+)IH)M$BK$"0^^D0:)%3)<;@4H=6G@+$//;I0>:5S9V.CP+
MFL#TA/#KC+19G!8'F\0W=.%'KQ&.@8-JFY>J)I('>. 1EB"NY,@@0F^81,)2
M@ B-J' %_'*YNE!YI7-#^6Y;_P"$OT1]BVHWI7%^K58]G-_<[Z:%.U.Y>K=Q
M*?"8:(^Q;47TJB?MS C4[.K_ .=QGD5AYIW'GENCZ$\)AHC[%M1?2J*^U,A3
M9U?W.XSR*#YIW)FENXE'A+]$?8MJ-Z5Q?JU4;.;^YWTT*-J=R]6[B3PE^B/L
M6U&]*XOU:ILYO[G?30FU.Y>K=Q*?"8:)>Q;47TJB?5BIV=7_ ,[C/(K;4[CZ
MMW$H\)?HCRCB^HO9_:N*^U- %-G5_<[C/(JGS3N3-+=#T('28Z(7V8QJ&(]B
M,BAMY,R-1LZO[,[C]2D>:=R_M2W<2GPF&B?4QC4<.QWJB?5BIV=7]SOIH0^:
M5R<Q_$GA,-$^KC&HP^+%1/JQ39U?_.X_4@\TKC'[#^)1X2[1#V+:B^E45ZM4
MV=7_ ,[C/(FU.Y>8[B4^$OT1#DQ;47TJB?MS(TV=7_SN,\BD>:=R9Y;N)/"8
M:(CRXMJ+Z51/VID*;.K_ .=QGD4'S3N3-+=Q*/"8:(>Q?47TLBO5N]1LZO[G
M?30HVIW+U;N)/"7Z(^Q;4;TKB_5JFSF_N=]-";4[EZMW$GA,-$NIB^HP?\E1
M/VYBIV=7_P [C/(IVIW'#^6Z/H3PF&B?L9U']*HGU8J-G-_<[Z:%&U*Y.8_B
M4>$RT1$;>M;4;Q>]<1]J:O39U?W.X_4IVIW)"R6[B4^$OT1]BVHWI7%^K5-G
M-_<[Z:%&U.Y>K=Q)X2_1'V+:C>E<7ZM4V<W]SOIH3:G<O5NXD\)?HC[%M1O2
MN+]6J;.;^YWTT)M3N7JW<2GPF&B/L6U%]*HK[<R-3LZO[G<?J4CS3N3/+=Q*
MINDLT5$!$N+:BC?D 8R(W?'#OSR51WEU?<#TS@9><1]2@^:-SG^6QP=FR+L#
M2_CPT8U+RZ-PQ%#(\:DY@3HQ;K(VC!I&O'M@%*/!TWD'/-.W7G4@.4I3GL4!
MWA !XZ\<+7G=]/K 1:-R*Y:Z,=79?$[Y<N@[?*^WRG P%L V$H" [.J%P ;#
M<-E=< ($#E7>! @$9%>BE*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1%!KV&W+1$+>P7Y:(NN=3<2?9C$X\QCW*#5:(S[!
M,L5,X344*LTQ3)XZ<>-$^;\XY=-V9B)F-VH'$!'91%V$43CNWOMMU+;!Z^P+
M#;EHBN83!:U^K?9>B*0Y ORVHBJ837V7M;K7HBI<1L C5'Y6_B"@^Z>!?*7&
MN%^&+5?K]ZHNWBA/1(AY C7.84_^RRS]\+J&-3#"\P#)JG[5^<8H'#:8U[6$
MMNU$I@O8P"%A P7V5]*.GS'-+'$:O .1?*C6,#@\#VE<H 7DZ@  7VV H[Q0
M"]P+NF$1"UN4>N-8V.U+&PT!9'$N.L28E0!0#D .6_(&P;W$0&UPWAY;<O5K
M+\Q,A"R' .18W,:XQ='25(A<=[D&XF 0$=AAL!C!MV&, 6'L5A-IUB!'@636
M=JZL;$V[=IMHB(W$1N([1O?J=CDK(V:]H@(:!R*NE5MNF((<IC%*8P[3"4 $
M  1ZP  6\2LCJB:^E.L1H'(KZK65;7-]X$+X5S QO?+F *(_PG3$-T-ZPE<-
M]O(/)>NF%CYM:XOEES++8D?48+MTRHFNIFNA%Q%L O46 +H\K$-FV5)Y2CD2
MZLV,A*1BY"QT>D8P$A>:;*HK=U"4P@<^Z0P;A1 37,42[KQ?K9LMM*!\M'(1
MFSF.7)QKC RX]1TSHS+J<YB3K;EA) MW N)H(X:3&Y[GUWZ^4IN1+CBC?G$8
MU=JFK%B8SQ)9,XE6Y@7("43<MK7V5NUHO9LV6*8$,)]K/9 _2Q8:?NM['%[A
M8NU5C</"/?1%)'*7!5$T>],@FL^'N;>CV@J&<M%T4^ZG/=Q5^U Y"  EV %<
M9+=B+I]1QBW<@!GW8+D9DJXQ(Z00CP^M<8-#:,%;KG]=&4*N@<R'<218U--!
M=FG'HJQYWKE2*WFBZS\XE4W$U2@!BEV%(*QLGS5\AY:YHU19QVZ!9P[RP?+W
M$1$5 !/!8LL:PT:;361,Y.7GI&%;H0@P,FV3424=.17;'GB 1LB"1B]SJ'31
M5.)B@).< A[@6KLG7U/E"9*;JDG(1HCG&8D9<RR4TFY&U1ES'B;)AE%ENY8M
MP80>A!3'!WDV5+*N6(%;IBP*T:LI!PN=&ZCHS,3.$F1 (J J%1342,(B;? 4
MPM.FWS*:UQ;GMT9E$Z7<WS+FRX"5"S3R+J*<;QS:9DF\$[</89N]50CGCM(B
M;AXU1-S9':B1"@"/=6Z*A2<I"F !V@-<E23JI\L=/+_,.^;"N&JQ2M>>@=[%
MN9;;<?(Y>UY*WM2?S#I*X[I9?/XAR*>4.0!#]+<*KTKF^R99B.%9@^21[_$.
M11VI VV('Z4"AY=MM2#-F6LED#A*G6D\_B'(E[\@^4'VJ:E1S#I*JY\H"Q_$
M.1+CV/N:G5GBW4.DK%TLOK.(<BM<W7ZH!YT.4>0.3E&K?-S.K/'RJ.EE\_B'
M(HYS8 [Q;#M ;!80'D$.N T^;F]6>-96ND%L2^W@'(F^(\@AL&PV !V];Q:"
M?43/<81!0]\D9'\0Y$WC=</N0J=:LYI5.DE<_B'(F\;KA]R%-:LYI3I)7/XA
MR)O&ZX?<A36K.:4Z25S^(<B;QNN'W(4UJSFITDKG\0Y% "8/S7DA>FM5\TIT
MDKG\0Y%.\;KA]R%-:LYI3I)7/XAR)O&ZX?<A36K.:4Z25S^(<B;QNN'W(>93
M6K.:4Z25S^(<B7,'*/\ ._RJ:U9S2G22N?Q#D3>-UP^Y"FM6<TITDKG\0Y%&
MZ(CO6 1Z^[UJ:U7S2G22N?Q#D4W.'*-OYG^536K.:4Z25S^(<B;QNN'W(4UJ
MSFE.DE<_B'(F\;KA]R%-:LYI3I)7/XAR*O5OVM^ON!?R;4UJSFE.DE<_B'(K
M;QNN'W(4UJSFE.DE<_B'(F\;KA]R%-:LYI3I)7/XAR)O&ZX?<A36K.:4Z25S
M^(<B;QNN'W(>94&?42_?83%1TDKG\0Y$N/*(AY !Y=JQS:JH?++9<HEY%@M3
MIY+!K/.NT9H0CH$5=%%TNZ:I,B.%7BZZ";-)H10SE1T"R8MP:@B'.G=\^8O-
M%+8=X;WK3K#(--_KYC9)WP/M6[<A<ZK,R@8]CCGB3]9*_3?P\M]4&6D^(M]7
M72;K-$XU+NXX%_7*;2W[7HRJ@B8%YA)L( X.7M1/V;C7S5?ID2ZUXH/Y6N;<
MH-N;>.5?7%Q3*QU"SY\QF]&W-#,-Q=Y$$1 1'KCY%:QA9#<7+2G.<TEVZ4*)
MK[;VMUK5"R*P\@VY;41043#>]^I;9:B*HB>XVO:_6_E416+>VWEOUK412:]A
MMRT1"WL%^6B*#7MLY;]:]$4AR!?EM1%-$5 $V]U;7'J>1MHB&$U]E[6ZUZ(K
MT14$3;W5M<.IY.VB*]$2B)1%!KV&W+1%!;VV\M^M:B*U$5!$V]U;7#J>3MHB
MO1%6YMZVVWB=CK^+1$,)@M:_5OLO1%!1-?;>UNM:B*]$5"B:^V]K=:U$5Z(O
MF#77BWTJX<WN'Q^IC34$KG/)!"&Q<V(:<YCG+20GG:P(,8 [S%XB2;LYN0.!
MC-VJIB++)IG.4HE*(T1=7J](]PNLIO,H*8R'+\>6PCWPTI*1G]/LOBX*4D=)
MF361U'@<9FUXKO;D&1X@R>$4>,$%!=$*-P(-AM!U_P!EI(4%P"[)+QD:$&*W
M-ZZ'&^YU9EM%",B0TTM+)Y]!8NXS268KPZ$>I(I1[+$VXR!GG-BW%J8IP-80
MJ6ASC B"C676Q.D:X;%\;=SS%WJ+(R;;+TL'1T\::69Y[ZTA/+XQZ]T3,=-W
M,$WRA6(4PJ\MW:9 K<&0;PF X@0;%A B+2FLMS?](5POLW^$-6^:2$Q'9W X
M1D[;*H3%\DD\.Q."U+DC0FGTCJ/DC>,%A@2.73A#-&@2 IGYXA@4 EA&L?YO
M,*:P7VT01,4IA+NB)0$2B-]T1#:%PV#:K<.565J(L1B[H7Y?*K#.+FZNJ(^V
M$/NG@7SCQ58MD.=:#:@XCB<6K,Y%-Q[!&,C$5$4572J4Q&N3D(HY410 001.
M;:8-A:YC#]1*H[^9/FD!C7 G> 75<4T\^NP^^1):2YP@.$Y%XB_(SXG?@GE/
M3;'_ %4KVXXPN*/\WZ:5X(,"7]U9T%/D9<3OP3RGIOC_ *IUC.,[D!@'Q3P+
M?O5NT%3\C+B=^">4]-X#U3K)+QA<3XZTW5^G"G@6_>K=H*CY&7$[\$\IZ;0'
MJG5GXON%K8MG G<^A3P+?O5NT%/D9<3OP3RGIOC_ *IU@\:7+ST\"W[U;M!4
M_(RXG#"4!THE"V$!OWVQX>3_ )6"M@8ON'Y<LZ8:Q^FZI=@>_'3-?HW:"L.C
M/1*ZDYWG$YF^NT@;3[$&TVK(LL2A'+"3S?* 9F!=%('2:B\3 -'*B8%(=0ZK
MBXC8A//5T6^L9ZIZ"[7Y[#PKT/#N#9T^2WYV#7V@M(M$.5=WO=%<%!O'%:\+
MG$ ]DY%$KQ\+">E48B#26D'S-Y&NGDEBT2^4FF ,T^>YA%1F=14 0662^^UQ
M<O%^(Y3 Z:YH8<AC'D@NQ3/+R["7&:W6)]$/K6D8Z5Z8N7;Y)QP@\6[=LU=(
M(,')I%B*[QNJN[;*KO$%6Q$VY^<: JW!,YRG;JE%0R0[!R#&]_:P/2M)^F^M
M=GEO<C&.8YA#3GW.*VU:@FE&FO?!TR6X0>+))!H,<W462G8ER9Q)/#,^Z6S(
MB;4&SMO'@Y,05@6*0ZZ>Z'WLP*U#<9WZ']()K=8[UGUK.[R\PX6=';"&XM6^
MT3TT29N'[+AGU^*[A)F.CLEQV:R,XRR<?,NHY!A-XZK!0\NA.HHHN'BJJ8[@
M)%;64.GO%$=<XWOS6.LYN5:I\K\)FV#XK11>F&D,TU8/8_A)XMNY)%NT>H+*
MS$.V2,P=2+]H9Z7GRI&,0C5H5<J8@"YP4 NX':&.;CK$#1 /: L[/+3#K&PI
MV.U8[N?0M8UT@TI7**IN$CBV;I)][1<"[F85%9(CY2(1<;C80YQVO'J2@G.F
MB*@BW;JJ!M*!!N,;W^\P=,9#Z;ZRM\M[D'[#M;Z;RY;EW#KICBDH"37AOU^R
MC&C1,$_#(L>S*+<&%[,QS=VM#!%.&#=X1Y#N5Q(Y5/N($*01$P*?>@'&=^:D
M1, *N?+FY"(&79!;A'\.FA4[#SLO"Z*:^ G%PS69BUI^<!FQFD%II&'<BB6,
MCYB6YMB0ZCHP)-'"RK9NH9-,W:;^ XWQ <DU:Y\L;AA9+(6V#P\Z5ME717?#
MCQ!ND&KMZ@20@<@2<,G3=/N]9JY9H2D?&S2J<@V8 <IC-DR)'623.!3&K(,8
M7X0'&:(P5=F]Q"SHB2#N^I;EE_#9HCCQX%Q#Z,ZVYDQD<;=S,HW@<@<#.Q<D
MS%VDO!)-WD"A"*N&[E!,ISN'S7G"+%,B56PA5FXPO[]F<!].%6'ESAT63&%N
M]ZUQQCHGHK*K(,XOAJXI%W;J1F8Q$SF:B&4<BO#/T(U4\C*+?K9H@HZ.>QR<
M\7=3 P"8#A1^,K_8V/3 J=G&&9GLL82Y:AOH+I4<B1W7"WQ1) NY9-$3-<GQ
MUXF<ZY1%XNIOJM%&K-D(;#*E(=8!#=)<;!A\;X@ZU#Y8X>A_*=]/0MT#AQTB
M-C+V='AYXA E6^1*8^VQ?UU1:[U0I8!.5)+R;E-MW&QAU)$YF7.D.H '(8V\
M'G:CQI?Q_;5=F^%]PK13O#CIC"RCV-5X>-;LA5;HP"22N*Y;W0BWEI>(82"Z
M+YS*0T9'IQ4>Z=*-^>:.7BH"W-OI)B)0$<:7[SU9OEKA\VAA+,QR+3L]!M*#
M)*&E^&#B<CUVBJ#5^#3(()X@+U59LFY&(33.1](1R!E5E2J&3(<44RCN *I
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M1]0[BY% _2JM' Y>#S57XS\/]1ZC87B+K)'&GC^CZAW%R*?K5.C@AMX/-50
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MW;B(6,(B.$T=&3'H9<?PJXGS0(15NZGEBE%Z]%,@"!4A>.12)<NY][(*MDA
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MSH&[>$F0+UQAI( Y1#8/<UC6$H@-JD7W=Y,/F96E5^5J^K>LW>6;OL@YHP7
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M?)4-DR _I6,#7\"WL"@!0+;8   !<>0.3;RT #0 ,@6=-PO6\L?-J44@4 Y
MHBFB)1%7=+UO+&B)N%ZWECYM$4B "%A^W1%&X7K>6/FT1-PO6\L?-HBFP6MU
M*(HW"];RQ\VB*0* ;0#[-$4T1*(H$H#M$/LT11N%ZWECYM$5J(H$ 'EHB 4
MV@'V:(IHBKN%ZWECYM$3=+UO+&B*U$2B*! !Y:(HW"];RQ\VB*0  Y*(HW"]
M;RQ\VB)N%ZWECYM$5J(E$707$;'M)C"L:AI!,Z\;,:LZ21<FU*X<MBO8YYGT
M&D[8N%&BR"YFCM+M%2 < 4((E'8(T1:SY-NB&T1T\A;B(B-E90H7$;C8H2(
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M<YN<:KE $UVX@<O(;=\8O^YJ_#E:ZCO"67L#X-=Z8 KV2XL1W9B2F$VA<#.
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M>L/D#36;NA(%2 #O$V?F@^W5M9HI7 D165X)J! 1R+X;?&$-55-@B7UYI7V
M.SN]#DW@$NWDV[*ZO*&M7O;DL%N;(NT3B)="PNRP-F?+N+TWQ_4.#@X)E 2F
MG>-S_-C-%?R+TAR2D@,N!$FI2.T]URV1BDRF A0-O")2B4X 40'9FW+73YH?
M+F^P-PA<:R^J*2P,=+BX[RV/'LE@X5Y&*.<:2D6L=DJ\TKW6=FJ^7C3QIV!(
MM0'+([-1-LL/=1 43,43%+<!#EWG4%0VE?)))>6PBJMO&FZ03]4=&TQ(7*WF
MH.GCI0[D-+(]%\?NQ7G>^2HM0,=VBLQ'O<5N@Q*1,J:B2I *4@&5$4R$ MAX
M?N>N!$'.U0-/I6WW_=W,MX%HI[.L/?L6S>&TW80S@LRC)R*H/3O$7[=.4?2!
M8XS4B!2-FBZ#P6IQ)N?>$NVO8*V>YZT@>V181Q9?0J=[448ZHRK5O-0,%< [
M54TN:24DXDC/ ?O7R302,3)-R)Q2+:#8148DBVYDW,J%3 Q3&*(B8UQ&>Z*R
M(B\V#3O_ $W5C=?5"PZI9$\"Q^O_ $\YP"KZ31+E(KU-1$_?)5!5-H+ETX!L
M4R1>8$I47 I&NFIO\V6]0;HK3D>80^A623?=WN=[4LD0W%JV^HVF9#,RKZ-0
MR_,KN7!SI34BDL[(=-X5-NY.)S@+9NJZ(9,"  @"1>J6G<];"!>=:&7[8+.^
M^+OU3"5; YEP\<KQI3%4H,V%M#S*16Y"9*+Q<SX")22KQ<#H 0B!@>-5S-U!
M$@F$I2B A:G=%;K:VN8;BX_O6CA[MO N9GU$TV<*E*KI!&][N[3N4&B$N<CQ
M(IDGV\T2>F;J.>XRJ+I&$MS% $=TUA !JW=E7)<USW%PL69EYTLUA8QL#!=+
M',FH<RJ(%*FJ8YR)EWAYHIE5!*CO'#>.")1 @"(B-B[;<E=@RRV "T-7 &R8
MX[I5!V<NS;;;LV\EO%N-5@=Q(A!V!<=@=<=@;=@;?%I [B1"=?L6$>Q<;!?Q
M1I I%/,OXP]7Q*0.XD0IL(;!"P\EO'M]FD"D0HY>3;2!138>L-(%2HJ8'<**
M;#UJB!W$2P]8:0*)8>L-(%$L/6&D"B6'K#2!1+#UAI HFW^39R;1J0WVAK P
M!6.8UY;!D=9?;O IIQJ7DFK\7F6(2;G&,7Q=9(,KG!1%9I,,CG!17%$VXAS3
MQQ($+<PCL;%#G;@<"5T+'UX7>)'0.8'32"!N@[J]6\MKKO)U0)NLYK 03$$"
M *_077B:^ADHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?$''=Q
M[Z$]'YI6TU2UMD)-?OW(*P>%85C+5"1R_-Y]- '*L?"LW"[5LBW9MOOKITLH
M1%L2PFN)BE'E[CP_>N(KP91W8TDY]RW)'05QUY7E0W;)Z6LSQAG-F5>?G WT
M^/#!QGZM1>A[C$\VT.U(R==PVP5GG*T-,8YF3](JBA8)CD4,JB5ED3A%,3(M
M5T"E7,42$5%2Q1[/BGROQ1A>4V\;Q Z!OO!L38; 2" <IS"Q<5=&)[KO*;\M
M(UA-,8:PADM^I>Y/?N+0=-&#V4CVLA(F4[W,'+QLW>OBI 7G.XVBJI'#D4S#
MVVZ41*.P:Z#]B[,+1$9%N0.FIESM2N4!<IE*=1N"R8KD(;=W3G1 W.%*;?"P
MB%AN'7HBTR<M%*R*\.E)QZDLV1*Y<Q:;UL>1;MS[H$779%4%RDB??"QS% HW
M#;MHBUJBJ:)#*K*$23(%SJ*'*0A0N 7,<P@4H7'JT18A<MA;@Y!PAW,9,%2N
M.=3Y@R1K;J@*[W-BF;>"PWL-Z69\BAT8695\R<3?$M!<.>.1S]RP&>R+(#NF
M^.8^DL5OW6JT(D=R\?.MQ46<<T!8@&.!#F.8P%*%]H<QA^X9M\UW0,(:TG*5
MUC$V)9>'Z(SW#6>!PKYOT'Z0IGJ9F\7@^;XDRQ!QD#L(^"E8Z35?L5I!7]AL
M7Z+ILW6;J/3]HFH0QR >Q3 &\%=EOW LZY9/S#7!\+3] NJ8=\RZ:^:@4[VZ
MKM%J^_7>=XM'32N-O<ABVLX@Q)++LEURH"VCEA<%0<.UU0*T9I+F:*@0RAPW
M^;-;:%= :XN)CF,%ZH7-< YN0A;J\RB :HF4&<B0$J2B^Z609G.9%%IW>LJ1
M,%M\Z:3'[^82@-DNWMN[:LH6U0F<XS/-4W4?DD(^2< Y!$R#]J *%:$%5P=$
M#J)J+E01'?4.4-PA2B(VL-0;1!%OR,DS>-$G<>]:/&:I.<1=-5T7399,+#SB
M;A!0Z1D[ (7 1#;42&Q?T+LF;?5)TP4TKIWF("_/IQ(].FTTXU4R#3_1;2:)
MU#Q_#YEW!2N8Y+DCJ%;3LC'N#-I N.-8YB[-WO;N4E$2N%C")SDW@()1KUFX
M/*VIO.C-=,F"5KM#FBS/PPT+QO$7FS3W97FC9+)U9D";?L7J)P?\;.GO%KHC
M+:P0":V**8JNY8:@8W-+-UEL.DF$>$HX,L_0,5%]#K1P]T(.@*3?2 P"4#%$
M*Z!?F'ZG#M<:6H!@^):<Q ,+/M7H^',0R<14'S4H0+8 C?(BOI['=1\2R0Z0
M1>3P;[G$Q4 J3Y%)3=YU\B0.87YI8%#GCU[DMOEYDUPL B/#KL"Y,GDN.*I@
MJE/PBB0LSR(*)RK$Z8QZ:@HJ/@.5<2BS(L&X*OG -L$;T1:=GDL.]GG6/MIB
M+=2C2.2DG,8U=H.'K5HLOS*#EPDD<YD45AMN[]A$1V7#;1%R.B)1$HBZ1U\;
M2ZV(0#N%@)?)G4'J7IGD;B&@46[B8<Q<!F<1*2JC%LY<M$G"K5@W45W!4*)@
M((!MHBH&MBP@ ^\WKB%PO8<*8 (=@0'(>4*(I]^M;X&]</:7'^Z*B)[]:WP-
MZX>TN/\ =%1$]^M;X&]</:7'^Z*B+*WUC5>.F;,VD>LS0KMVW:F=/<08(-&P
M+J F+ATJ$^<Y&R&]O*&*4PE( C8;5!(:#'<5'YOQ!=><6VEN4:U://L)PH(W
MORZGH)XD:6>F8,@0CG9UG &<$0<F!40 -P-SMJY;#U6RZZIM0_W0X$C>B+.)
M=6QC<[[YH.@9[YR<,"/M7EGX.GB)_P"H0>)E"_VXBO5#YB7/U)7C6RN^^M/$
MI\'3Q$]? Q[ Y0OZDTVAW/U*;*[[ZWZE'@Z>(G_J&'Z7*%OMQ(5.T.YC_2XD
MV5WWUO&$\'3Q%];!@#KCE"MO^:NK4;0[GZE-E=]]:I\'1Q$_GL$]M"WJ33:'
M<_4ILKOOK?J4>#JXB0,6YL#'M@Y<I6L =?9$[;!62=YB7,6V23H61OE??DBI
M#NEXUKM"NB$(US"3U'XBLB1E>YIAQ+P>F^$R"A&#Q1JJ*[,V1Y0J1NL8JYP+
MNMVQ$@+<1.IRA72[[QD:@F;0#4EPLX89OI!>@W/@"4"#>9#YV??&;B79+K2^
M,(U8HL^ ^??2[X".I!0)K*6<'%) \=%>1JJDB,<Y=R: I)@*R("T<BJ HF,A
M=2N#D8NQ ]NK*F%@' (KFY^ ,-2G:YEA[CQ?]5AC\"Q5T[D^[.CEU.18$=L@
MB!/D:H.UFRSATS=+/B*R0H(&4%L"B9"'W2(G#GQ3WB"?-XKQ*/Z_&%A\#89Z
MA94,"Q<\B[15Z.W4;N%EWO:(N$LK65=/I)P=JE)%CG /P;'8QI#F(*ZADBF,
MF)Q$A=\P/%>)>OXPG@?#74?6M;,:5XL:*=.XG@9R%M+P\U%M<@@)*?R-ZX?P
M,R\C6R,WB#R.4.WE#-$$W9G9%2()H$:W,<O.$$[Q7B7K^,*!@;#74<2P1&$X
M+,-HMVAT>6I[<LDD@]$[O)SLC$9*OWR+U84GCY%P7F6:"*Q6YD2KGYT"BF0@
MD4,\5XEC_/XPLS,$8;#;) 6=OI_A3M!50>CTU09BD2.45([R4Y'1N[%XM)TF
MR;)R0G>JL4WZJX\V82F2:J"H*:GWL8\5XFZ_C"R>"<-]0%RS+]$\%QF;3)'<
M$F09EB(1L([)+8[E[].94E96+:.7L5ZWY%RT=%+"2*YTW#HQN;(1,P;O.&$@
M2,5XEC_/,.%0<$8;(MD""U3;1S1[((*;E(7@XS%B9I#LY6"-DDG+$1EUEYEO
M%.$>]S*1<2G=<>U46>E1334<JH-QW2 *J7.3XKQ+FG'2%KG ^&,U.MK)HI@S
M1=P@[X),IDDV[YV@20B9^011>1[<7ZK-RU8RTJTD422+=F43'6*DHBLNFF9,
MPF'=CQ7B7K^,)X'PSV=;SE^A^E$8OCC_ !CA*R+,(I]CCU_D+!A(9%'3C28:
MF= K IN)9=C&\\V=($ O=!T#/ 6$R B*9B'DXKQ,/ZYTA/ V&8?R%L3+332Z
M743;Q_ =J415>1F&7=TI/"QAV18E^5D#B4?.)8#)I/3 <Z0MTW('(4JA!/?9
M'BO$IL$_C"GP-ACL\=*RH:3Z=<VS.]X#,_,=VX9L@5B\O(X324<<X,@[5:N9
M=HX8L6:R0@F82F4.(@.Z7MK3XJQ+UYTA1X'PQV=;@71#3H,;D)$W!-E 3G?Q
M:$B<<2REVLKW*;'TY D_*OTWZ:"$8K.@JQ*9+?W=S>.<AC 48\5XEZ\Z0G@;
M#/4#0MLF-%,+A)AY'(\&DSE+=-#'D&LCC>03*3,LQ)1+1Q(KKNIJ0;M'42SD
MEW#8YF9EG" (E%1,!4((3XKQ-U_&$\#89Z@15H[2/ 46@C.\".=D<LC,FDBY
M890FNV=/3.$&SUU#(FFBN',2D)E%B*J"02H@3> !$VY Q7B7//.D)X&PSE^7
M7T'I]PD</>8XO%9#.Z /\!E9 70N<4R&;D%9B*(BY<(("^-'2Z[.[I% JI=P
MQNU4#;>AQ9B7KRK,P/AK6B*<+G/R(>&3X,F?IO/>J55\68EZ\K/X(PWU 5/D
M/<,?P8L_3B>]4:GQ9B3KRH\#X<ZD:%<."#AD +>]DS]-Y[U2J/%F)>O*GP1A
MSJ!H3Y$/#)\&3/TWGO5*GBS$O7E/!&&^H"?(AX9/@R9^F\]ZI4\68EZ\IX(P
MWU 3Y$/#)\&3/TWGO5*GBS$O7E/!&&^H"?(AX9/@R9^F\]ZI4\68EZ\IX(PW
MU 3Y$/#)\&3/TWGO5*GBS$O7E/!&&^H"J?@?X9S%LGIFQ ;@([\K.F*-AN%P
M[X]0UA\:I&+\2LB1/-HAE4' ^'B062@UP,8KOS ]/,8TUQYCB>&1#.#@8\ZA
MFS%HFI:ZIQ.JJNLH<Z[ITL8W;JJ',<U@N(UURLJ+TKYW3U$V)C;R+L5#=U)=
M\OHY$ %S^I6ZE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$51#> P<
MEP$+\MMG+6)O\P\*G,ORE?2;N%?6?5##^'[7;3O'I_-\-TC9YSC>HL+CK-[*
MR.--,F5@WS#-%(MD19TXBA-%J-GBR9#&:_>CFL01KW/R9OR[+OKJB[ZMXDUM
M2Z7T<TF ;JZVM;FR@KI>+Z.KJI4HTP)#0Z/IA#[5^<SHL^%+7'B+XTM!T]/<
M3RN/@M.]4,,U SO4)6)D6,!A>/8A-M)]ZH]F5D4VQ)6438]R-6H&%=PJL( 6
MP&$/6?-2_P"[KLN&?==75MK;SGRH2W@AVK:">"P%=-P]=EX-O*6Z<#T8)CH*
M_H\9QI(RSN?/E1<@F(*6:XF^Q>*6C'!DT6:KI[WP+**IHK$*]414$ *0V[N\
MH"!K"'QG(>.CF31G)7LP>)4G<"ZR<<-.3C(,IQ#5&6'('#M-#()=$'40=S .
MI5%]-L&:+5P[5.+N.1[B;%56NS*<%DU 52)650N63_#\I/Y/ELRIE[YC&Y;(
MQTHY81XRK-XW5C\?+"$:)O6DTW3%D==--T8 2(8RJ1 ,)@"B+9S\,RR@-6ZV
MI&3N68,':$F+U=\]>R;QVXDUU5CJ.911DFR4,_3.*!FZIB*LD!243 #%,1<=
M+PE/2LG4:KJSE,A'+/6RJ#.2255:M&;<B(D2;LV<FP:D>,E4=UJKNBFF@.XH
MFJ(;U08PLRI&%IR+I[C^X>\WU0B<-R_!8Q:?D<.3EH^2@6)0,_6B955DY%_'
M(G.4'+EHJT$JB0")CD/<H7"U=TP?>E)0U?\ JR -]>;8\N.LO2E_T@)*^$^&
M3A<U7RS53$I6:Q3(,4QG%L@CIR<E\AC'42)PAW*3]*/8)/B(KN7CQ=$I=XA1
M(0@B83=2N\XIQ-=CJ,R:5S2YPS%>:X8P9><J\6SZAI#6G/O+VJR/0W%\OS!Y
MF4JZDS+2$5CT.^B2*,#1#YKC$JXEXT'"*T8J\%,R[HY5DBKE25*/;%N #7B(
MB2XG.5]),@);&C,T!<11X5=/FRJ)FKB9:)D<R3M<K9XU*J_4D>Y@*D\7/'*.
M 0CRLTN8Y@Z!P*F5(YCH *8V4K2H<).G+.-D&C1Q,E=O&I$49%R[2<+,%4F\
MB@59L!6Z"A4UQD3&<)%4*1?= #;+WJ\P83O%01$0W5VCIUILEIWA:&*=^',\
ML9S./9&6=M6C$[QWD,F_F'PI,H]-%HT03=2!@233* %3*'*-&S=69)G'-!:U
M9+,RD-.,X@OQ4<3_ $>/$]HUK%EV-Q>D^>ZA8E)Y1+N<.S7#,<E,DC)N(D9)
M=PS*Z4BV[@\=*MR."I+IK 2RH"8HF+MKZIPCC+#$ZZVLO28ULZ7+ @ZPQ'"O
MEO%6"K[F7W.F2&.,DS8B&Y8OT&]$WP3Y_H/P[:H,-9F;K&LFUVD$',CB(K[L
MCC>+D@'4(U2>K-A!-GD3HCY=0Q2&,+8.; >VN >*>8%_RK_O1CJ<ZU-(:YC3
MPNBO:O+VY:ZY[MF,KQ!\Q[2. -A]:]!\@X6M.9\\<D96>BFC%JR; PBI8Y&K
MH8YP\=-GKX[Y%^]>R9COU2JN#K<ZLF<2F$2[*Z(O2(GHSN+3R'"7IA(DD2*(
MR;;OF[;NUCLGJ;<R)FMP20:E!F*9&(#VPMC@HW.81WR'#94+&N>Z=:(8GIE.
M2,YCZTF=5]$EA4FSQ9HJBSCPDEY<Z1%4F*#YT<\@Y44 [E9<R13\VGNI%(0I
M%W+1$HB41:9UYP/.\OYOSG4\]^AZ_8HBLE^#)^#\Z'+R^/V:(K_DZ(GY.B)^
M3HBTSKSA/P/X9/S_ )WSW5[/6[-JQS,@X55V;A6B6\Z3\#U?]T_"!YS^J?G?
M'K([W%9_N^A:K^QZ+43^QZ(J&ZG['IH5FJ0_WC[5-"%6_L>BJJ*\@?L?QN7S
MH\E6F>Z?M457\P9,F?*B_G!_!>>_->=\X/X/L_G^Q6L[^4,GV+:E^]].-;>K
MR#^Q?S'+YWD#\'_[O^>[&]6Q,]QJQT_\Y^3)]JP.//!^Q_/.N3D_8JGG?ZGU
M^SNUB6WF4AYQ/\!RAR?@/P9?V+V>MV-VF?.K?LH/X='\!YU;_=?PA/V-^A_&
M]F@]*@K$O^$/^Q_PAOPOB_F?T?Y_L;U3FSK(WWM*NK^ /^Q//!YWS_YC\%_5
M>MV+4"C=6F7_  :'[!\^WY>3\.A^#_JO6J%9WNE:YS_]WY7/[)_">>)_/?GO
MT%J@9?0L8R'(G]/_ /9_V,KR_LO\(7SW]0ZW9W:D>E4S+$Y\Z3]@_@TO/^<\
M\ER_U'K=BFE6.4K3G_#%_M;RH^<Y?.J<OZ#\3^@M0(<JR,O.(?L/\ WY>7^G
M><_JWV^<IFSIG"U"7(/X/D'EY//E\_\ U3\_0Y5#<ZP+_LUE^Q?/%_!_A?S?
MX3L?;M09<Z9LV57;\BG[$_91^7S_ .&'\'V?M43.<BW@//)_I2<GG>4_+]KL
M4S9\JM^TM14J4HB41*(E$2B)1$HB!U?Y.K57Y%AG^YZ4#SP>*'V:UC[XRK5;
ME6KK>6PE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$4=6L8]\Y/I!2
MMCG?P)?V#^#=?L_\!^QU/PO_ +M^,[%JL?>;[V?)E6.;_+.3TK@N#_VLD_\
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8S+<!_"!R<@^+R57,J_L+)4*B41*(O__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
